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ABSTRACT 
Breast cancer is the most commonly diagnosed cancer in women worldwide. In the UK, 
there is 1 in 8 of women that have a risk of being diagnosed with breast cancer in a 
lifetime. Clinically, the common treatment using for breast cancer therapy are 
combinations of surgery, radiotherapy, endocrinal (hormonal) therapy and 
chemotherapy.  The DNA damaging agent epirubicin has been shown to be an effective 
chemotherapeutic drug for breast cancer treatment. Nevertheless, there are more than 
90% of patients with metastatic cancer that found to be resistant to the drug.  
FOXM1 is a transcription factor that has been reported to be responsible for a 
resistance to various chemotherapeutics, including epirubicin. Accumulating evidence 
has revealed that FOXM1 is regulated by modifications at the post-translational levels. 
In this study, I show that FOXM1 can also be regulated by SUMOylation and 
ubiquitination. In response to epirubicin treatment, FOXM1 is modified primarily by 
SUMO1, and not SUMO2/3, in breast cancer cells. The SUMOylation of FOXM1 is 
targeted by RNF168 and leads to its ubiquitination, nuclear exportation and degradation 
through the proteasome degradation pathway. Unfortunately, the study about OTUB1 
about its property in deubiquitinating ubiquitinated FOXM1 does not show the significant 
results. Collectively, this thesis identifies and characterises the role of SUMOylation, 
ubiquitination and RNF168 in modulating FOXM1 expression and activity, by promoting 
its degradation. My data suggest that these proteins and PTMs might be interesting 
targets for the development of novel therapeutic strategies for breast cancer treatment 
and for overcoming conventional chemotherapeutic drug resistance.  
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RNFs  - RING-type zinc finger proteins 
ROS  - Reactive oxygen species 
RPA  - Replication protein A 
RPM   - Round per minute 
RT-qPCR  - Reverse transcriptase quantitative polymerase chain reacton 
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SAC  - Spindle assembly checkpoint complex 
SCF  - Skp1-Cullin1 F-box 
SCGE  - Single Cell Gel Electrophoresis assay 
SDS   - Sodium dodecyl sulfate 
SDS-PAGE  - Sodium dodecyl sulfate - Polyacrylamide gel electrophoresis 
SERMs  - Selective ER modulators  
SIM  - SUMO interacting motif 
SKP1/2 - S-phase kinase-associated protein1/2 
SMC  - Structural maintenance of chromosome 
S-phase - Synthesis phase 
SRB   - Sulphorhodamine-B assay 
SSA   - Single strand annealing 
SSB  - Single strand break 
SSBR  - Single strand break repair 
ssDNA - Single-stranded DNA 
SUMO  - Small ubiquitin-related modifier or small ubiquitin-like modifier 
TAD  - Transactivation domain 
TBS-T  - Tris-buffered saline with tween 
TCA   - Trichloroacetic acid 
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TEMED - N,N,N',N'-Tetramethylethylenediamine 
TOPllα - Topoisomerase llα 
TSG  - Tumour suppressor gene  
Ub   - Ubiquitin 
UbL  - Ubiquitin-like protein 
VEGF  - Vascular endothelial growth factor 
VEGFR - Vascular endothelial growth factor receptor 
WIN  - Winged helix 
XLF  - XRCC4-like factor 
XRCC4 - X-ray repair cross-complementing protein 4 
53BP1 - p53-bonding protein1 
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INTRODUCTION 
 
 
 
 
 
31 
 
1.1 Cancer 
Cancer is a disease caused by uncontrolled cell growth. There are eight biological 
capabilities which have been declared associated with the multistep development of 
cancer (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). These include 
the ability for cells to replicate indefinitely, invade and metastasis to distance organs, 
maintain signalling for cell proliferation, escape from surveillance of growth suppressors, 
reprogramming of energy metabolism, angiogenesis inducible, evading immune 
destruction, and prevent cell death (Figure 1.1). In general, cancer can be differentiated 
into two types, defined by the cellular or tissue type: carcinoma is a cancer developed 
from epithelial cells and sarcoma is a cancer of the connective tissue.  
Cancer is one of the leading causes of death. In 2010, it was estimated that there are 
over 12 million new cancer cases every year, with more than 7 million people dying from 
cancer (Ferlay et al., 2010). More recent data from WHO revealed that, in 2012, there 
were 14.1 million cancer cases diagnosed, with 8.2 million people dying from cancer 
(WHO, 2012). The most common malignancies world-wide are lung, breast and 
colorectal cancers (Ferlay et al., 2010).  
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Figure 1.1 Schematic diagrams of cancer hallmarks and enabling characteristics. 
A. The six out of eight essential properties required for cancer development. B. The 
eight cancer hallmarks (two emerging hallmarks were added later in 2011) with two 
enabling characteristics that have a role in driving cancer progression. (Hanahan and 
Weinberg, 2000; Hanahan and Weinberg, 2011).  
 
A 
B 
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1.2 Oncogenes and Tumour suppressor genes 
The development of cancer can be attributed to genes being altered in a defective 
manner. The two types of genes that are related to cancer genetics are oncogenes and 
tumour suppressor genes. The first evidence that showed a genetic alteration could 
result in cancer was obtained in the study in Burkitt's lymphoma, where it was shown 
that the mutation of MYC oncogene can induce cancer initiation (Croce, 2008).   
1.2.1 Oncogenes 
Proto-oncogenes are genes that have the potential of becoming oncogenes when they 
attain a gained-of-function or when their activity is increased inappropriately. This 
results in cancer development (Bishop, 1991). Proto-oncogenes are believed to have 
been mutated by point mutation, amplification or rearrangement (Todd and Wong, 
1999). Oncogenes encode proteins called oncoproteins which are classified into 6 
groups: apoptosis regulators, signal transducers, growth factors (GF), growth factor 
receptors (GFR), chromatin remodelers, and, transcription factors (TF) (Croce, 2008).  
J Michael Bishop and Harold Vermus were the first to find a cellular oncogene (c-onc) 
and were awarded a Nobel Prize for that (Vogt, 1997). There are three possible 
mechanisms for oncogene activation; these include gene amplification, mutation and 
chromosomal rearrangement. For example, HER2/neu (human epidermal growth 
receptor 2) is one of the important oncogenes, which was found to be overexpressed in 
around 25% of breast cancers. In breast cancer, the activation and amplification of the 
HER2/neu oncogene leads to a poor prognosis. (Croce, 2008). Another example of an 
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oncogene is RAS oncogene, which is activated through a point mutation. The RAS 
proteins play a crucial role in many important pathways that help to sustain normal cell 
proliferation (Downward, 2003). There are 3 members of the RAS family, of which 
mutational activation is always found in human tumours: KRAS, NRAS and HRAS 
(Croce, 2008; Downward, 2003; Rodenhuis, 1992). These 3 members of the RAS family 
have approximately 85% amino acid sequence identity. Around 20% of all tumours have 
been found to contain an activating mutation in one of these RAS genes (Downward, 
2003). Interestingly, each RAS gene mutation is common between different types of 
cancer. KRAS mutations are normally found in adeno-carcinomas of lung cancers, 
colorectal cancers, and pancreatic cancers.  Alternatively, the NRAS mutation is 
commonly found in a subset of acute leukemias and myelodysplastic syndromes, 
whereas mutations of HRAS are very rare, presenting in less than 1% of a total RAS 
mutations in tumours (Downward, 2003; Rodenhuis, 1992). An example of a gene 
presenting the last type of oncogene activation, a chromosomal rearrangement, is the c-
MYC gene. In general, c-MYC is expressed during embryogenesis and is also found in 
highly proliferative tissues like the skin epidermis and gut (Pelengaris et al., 2002). 
Translocation de-regulation of c-MYC is the most general activation mechanism in 
cancers of B and T cells, while c-MYC gene fusion is common in soft-tissue sarcomas 
(Croce, 2008). 
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1.2.2 Tumour Suppressor genes 
Tumour suppressor genes (anti-oncogenes) are genes that encode proteins that 
prevent cells from becoming cancerous. It is believed that, in some cases, they can act 
by negatively regulating cell proliferation. Mutation or deletion of a tumour suppressor 
gene leads to a loss of its function, potentially resulting in cancer development (Lai et 
al., 2012; Osborne et al., 2004). The first study that revealed the existence of tumour 
suppressor genes was done in 1971 (Knudson, 1971). During the study on 
retinoblastoma, Knudson stated that the hereditary and the nonhereditary form of 
retinoblastoma are, somehow, linked together. He raised the “two hit hypothesis” to 
clarify the relationship between the two forms of retinoblastoma. In detail, his hypothesis 
was that retinoblastoma is a cancer that is caused by 2 mutational events. In the 
hereditary form, which is a common form of retinoblastoma, one mutation (the first hit) is 
inherited through the germinal cells in the dominant hereditary form. Subsequently, the 
second hit is developed in somatic cells, inducing the initiation of the disease. In 
contrast, the nonhereditary form is caused by a double mutation in somatic cells. These 
lead to the bilateral forms of retinoblastoma (Knudson, 1971; Payne and Kemp, 2005). 
In 1986, a study was performed to confirm that the mutation of the retinoblastoma gene, 
Rb, is a major course of retinoblastoma. This confirms Knudson’s theory about the 
tumour suppressor gene (Friend et al., 1986). 
Another well-known tumour suppressor gene is TP53, which encodes a protein called 
p53. The p53 protein is a transcription factor that has an important role in many cellular 
processes, such as cell cycle control, apoptosis and stress signalling (Dai and Gu, 
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2010). It is also described as "the guardian of the genome" because it is involved with 
the conservation of the genome stability by preventing the insurgence of mutations (Dai 
and Gu, 2010; Matlashewski et al., 1984). Around 20% to 35% of breast cancers have 
shown to carry a mutation of p53 (Lacroix et al., 2006).  
Other interesting tumour suppressor genes important for breast cancer and ovarian 
cancer are BRCA1 and BRCA2. These genes encode proteins called breast cancer 
susceptibility protein 1 and 2, respectively. These proteins take part in two fundamental 
cellular processes: DNA damage repair and transcriptional regulation (Welcsh and King, 
2001). Clinically, breast or ovarian cancer patients presenting a mutation in either 
BRCA1 or BRCA2 have a poor prognosis. In conclusion, a mutation in tumour 
suppressor genes together with the activation of oncogenes can promote the 
insurgence and progression of cancer, by promoting cell proliferation, cell cycle 
progression and the evasion of apoptosis (Todd and Wong, 1999).  
 
1.3 Breast Cancer 
Breast cancer is the most common cancer in women. Over one million patients are 
diagnosed every year, and the rate is increasing in all regions worldwide (Ferlay et al., 
2010; Kamangar et al., 2006). Breast cancer usually is derived from epithelial tissue of 
the duct or lobule (glands). The most common breast cancer is the ductal carcinoma, a 
cancer of the mammary duct in the breast. This type of breast cancer can also be 
classified in to 2 sub-types: the ductal carcinoma in situ (DCIS), also known as a well-
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defined border cancer with no invasiveness, and the invasive ductal carcinoma (IDS) 
(Anand, 2007). Breast cancer can also affect males, but this is a rare condition with only 
1% of possibility (White et al., 2011). This study was mainly performed on MCF-7 cells, 
which are derived from a woman who suffered from breast cancer. Hence, the word 
“breast cancer” in this study will only be referring to the breast cancer in women.   
The most common treatments for breast cancer are endocrine therapy, radiotherapy 
and chemotherapy. Radiotherapy is used locally to stop the cancer growth or to reduce 
the size of the tumour mass, while chemotherapy and endocrinal therapy are commonly 
used for a systemic treatment. Around 70% of patients with breast cancer are oestrogen 
receptor (ER) positive. In this type of breast cancer, the cell growth is controlled by ERα, 
a member of the Nuclear Receptor (NR) superfamily of transcription factors. ERα 
promotes FOXM1 transcription and leads to an upregulation of cell proliferation 
(Karadedou, 2006; Millour et al., 2010).  Despite ER positive breast cancer can be 
treated with anti-oestrogen therapy (hormonal therapy), one-third of the patients will still 
not respond to the treatment (Karadedou, 2006). For the patients who have ER negative 
breast cancer or who have had a relapse from the endocrine therapy, the systemic 
chemotherapy is the only treatment option.  
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1.4 Clinical management of breast cancer 
Chemotherapy resistance is the cause for 90% of treatment failure in breast cancer 
patients with metastasis (Longley and Johnston, 2005). In general, treatments for breast 
cancer patients are administered according to etiologic and pathological factors, such 
as patient age, histological grade and size of the tumour mass, nodal status and some 
receptors, like HER2 or ER/PR (Guarneri and Conte, 2004). Clinically, breast cancer is 
a heterogeneous disease. According to a previous study by Anderson and Matsuno, it 
can be differentiated according to an expression of hormonal receptors (positive or 
negative; +/-). Moreover, the ER/PR positive group has 2 subtypes which are luminal A 
and luminal B (Anderson and Matsuno, 2006).   
The luminal subtype can be classified in to 2 subtypes: luminal A (ER+, PR+ and HER2- 
with a low proliferative rate), and luminal B (ER+, PR+, and HER2+ with a high 
proliferative rate). Other types of breast cancer are the ER- with HER2+ (Anderson and 
Matsuno, 2006; Perou, 2011) and the triple negative breast cancer (ER-, PR- and 
HER2-). Triple negative tumours are classified as a basal-like breast cancer because 
they express cytokeratin 5, 6 and 17. The cytokeratin expression is commonly found in 
basal epithelial tissues, such as the skin and airways (Perou, 2011). The clinical 
management of breast cancers depends on a medical diagnostic. Treatment is normally 
a combination of various clinical procedures, such as surgery and radiotherapy. In 
metastatic breast cancer, the most important therapies are the systemic therapies, 
which include endocrinal (hormonal) therapy, molecular targeted therapy and 
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chemotherapy. Systemic therapies also help get rid of circulating tumour cells in the 
blood vessels and in the lymphatic system. 
1.4.1 Endocrine (hormonal) therapy 
Endocrine therapy or hormonal therapy is the treatment for patients with oestrogen 
receptor positive breast cancer. Oestrogen has an important role in various 
physiological processes. Oestrogen action is primarily mediated by two oestrogen 
receptors, ERα and ERβ (Ali and Coombes, 2002; Burns and Korach, 2012; Deroo and 
Korach, 2006). In normal breasts, about 15% - 25% of epithelial cells are ER+ (Ali and 
Coombes, 2002). Despite the fact that the role of oestrogen in promoting breast cancer 
is undefined, the majority of primary breast cancers (around 70% – 80%) have been 
found to express ERα at a high level. This evidence confirms that ERα has a crucial role 
in cancer development (Ali et al., 2011). Consequently, ERα has become one of the 
effective targets in breast cancer treatment. There are many ways of inhibiting the effect 
of oestrogen in breast cancer with ER+. Selective ER modulators (SERMs), including 
tamoxifen, are a common treatment for ER+ breast cancer. This type of treatment 
results in cancer regression, in approximately 30% of breast cancer cases (Ali and 
Coombes, 2002). Tamoxifen is a non-steroidal triphenylethylene agent that binds to 
ERα and antagonises its activity (Ali et al., 2011).  Another anti-oestrogen drug that can 
be used for breast cancer treatment is raloxifene and faslodex (Ali et al., 2011; 
Chlebowski, 2014; Ingle et al., 2013). When comparing tamoxifen with raloxifene, 
tamoxifen has been found to have a higher efficiently than raloxifene and faslodex, but 
with a greater side effect of endometrial cancer risk than the other two (Ali et al., 2011; 
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Chlebowski, 2014; Howell et al., 2004). Faslodex is a selective oestrogen receptor 
down-regulator (SERD) that sometimes is called Fulvestrant according to its trade 
name. 
1.4.2 Molecular targeted therapy 
Clear understanding of the molecular events in the development of cancer aids the 
identification of new anti-cancer therapy targets. Molecular targeted therapy is a therapy 
that focuses on a specific molecule that is involved with a crucial mechanism in cancers, 
such as cell invasion and metastasis, cell death, cell cycle control or angiogenesis 
(Alvarez et al., 2010). In breast cancer, the first two examples of approved molecular 
targeted agents against the human epidermal growth factor receptor 2 (HER2) are 
lapatinib and trastuzumab (Alvarez et al., 2010; Sanchez-Munoz et al., 2009). 
Trastuzumab is commonly known as Herceptin, following its trade name. HER2 is a 
surface receptor tyrosine kinase (TK) that was found to be overexpressed in one third of 
breast cancers (Moasser, 2007). Another interesting molecular target for the treatment 
of breast cancer is the vascular endothelial growth factor (VEGF), which can be 
targeted by an agent called bevacizumab (Alvarez et al., 2010). In addition, poly ADP-
ribose polymerase (PARP) inhibitors can be used as a combinational therapy together 
with other cancer therapy. This combination might promote the efficiency of the main 
therapy. PARP is a crucial mediator of base excision repair (BER) mechanism, 
necessary for a single strand break (SSB) repair in cells. The loss of PARP activity 
results in an accumulation of DNA SSB. These can be converted into DNA double 
strand break (DSB) by cellular replication and/or transcription machinery (Patel et al., 
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2011). Taken together, increasing the cancer therapy options helps oncologists and 
doctors find and improve treatments for patients (Sanchez-Munoz et al., 2009). 
1.4.3 Taxanes 
Taxanes are one of the well-known chemotherapy agents for breast cancer treatment. 
Taxanes are products of plants of the Taxus genus. Clinically, there are two available 
taxanes (Markman, 2003) that are commonly used for cancer treatment: paclitaxel 
(Taxol) and docetaxel (Taxotere). These are microtubule-stabilising agents that have a 
role in interfering with spindle microtubule dynamics causing cell cycle arrest and 
subsequent cell death (McGrogan et al., 2008). The result from preclinical studies 
revealed that docetaxel binds stronger to β-tubulin than paclitaxel, as well as having 
longer intracellular retention time and more potential in inducing cell death 
(Bachegowda et al., 2014). Despite this, both drugs have become commonly used as 
chemotherapeutic agents for treating both early-stage and metastatic breast cancer with 
benefits, in terms of the overall survival (OS) and the disease-free survival (DFS) 
(Bachegowda et al., 2014; McGrogan et al., 2008).  
1.4.4 Anthracyclines 
Anthracyclines are anti-cancer chemotherapeutic drugs with a wide spectrum activity 
against various cancers, with the exception of some cancers, including colon cancer, 
which do not response to them. The main mechanism of action of anthracyclines is the 
DNA intercalation and the inhibition of the Topoisomerase llα (TOPllα) enzyme 
(Khasraw et al., 2012; Zunino and Capranico, 1990). Anthracyclines have been reported 
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to increase events of DNA cleavage by purified Topoisomerase ll (Zunino and 
Capranico, 1990). The first two anthracyclines which were discovered in 1960s are 
daunorubicin and doxorubicin (Weiss, 1992). They were isolated from the pigment 
reducing Streptomyces peucetius (Minotti et al., 2004). Doxorubicin (DOX) differs from 
daunorubicin (DNR) only by a single hydroxyl group (red circles in Figure 1.2). This 
similarity has important effect on the spectrum activity of doxorubicin (hydroxyl-
daunorubicin) and daunorubicin. Doxorubicin is normally used for the treatment of 
breast cancer, aggressive lymphomas, childhood solid tumours, soft tissue sarcomas, 
while daunorubicin is important for acute lymphoblastic or myeloblastic leukemias 
(Minotti et al., 2004).  
Many analogues of doxorubicin and daunorubicin were marketed in various countries, 
one of them being idarubicin (IDA), an analogue of daunorubicin, which is available in 
the US. None of the analogues have stronger efficacy in term of cancer treatment than 
the original two anthracyclines, but there differ in toxicity (Weiss, 1992). Another 
interesting analogue of the original anthracycline is epirubicin, an analogue of 
doxorubicin.  
In 1982, epirubicin was approved to be used for cancer treatment, and more than 2,000 
publications have since characterised its efficacy and safety (Khasraw et al., 2012). 
Because of a small difference in its structure, epirubicin activity differs slightly from that 
of doxorubicin. Interestingly, this difference primarily affects its pharmacokinetics and 
metabolism, thus enhancing its total body clearance and making epirubicin have a 
shorter terminal half-life. Epirubicin has been shown to have less side effects in cancer 
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patients, including cardiotoxicity, when compared with doxorubicin (Minotti et al., 2004). 
Therefore, epirubicin has become a common choice in breast cancer treatment, and is 
commonly combines with some other treatments in adjuvant therapy. 
 
 
Figure 1.2 Analogues of important anthracyclines: doxorubicin, daunorubicin, 
epirubicin and idarubicin.  Red circles indicate the difference between DOX and DNR. 
Yellow stars indicate residues that are the side chain of DNR or IDA terminates with a 
methyl in place of a primary alcohol compared with DOX or EPI. Arrows indicate 
structural modifications in EPI compared with DOX, or in IDA compared with DNR 
(Minotti et al., 2004). 
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1.5 Chemotherapy resistance 
Common therapies for breast cancer are endocrine therapy, molecular targeted therapy 
and chemotherapy (Section 1.3). For breast cancer patients who are oestrogen receptor 
negative (ER-) or HER2 negative (HER2-), such as patients presenting the basal-like 
triple negative breast cancer, or patients who have a relapse from endocrine or 
molecular targeted therapies, conventional chemotherapies remains the limited choice.  
Cancer treatment failure in more than 90% of patients with metastatic cancer is caused 
by resistance to the chemotherapeutic drugs (Lippert et al., 2011; Rivera, 2010). 
Patients with metastatic breast cancer (MBC) are primarily treated with taxane or 
anthracycline containing regimens. However, in a lot of cases, patients are treated with 
these regimens as an adjuvant therapy, leading to an increasing number of patients 
becoming resistant to treatment (Rivera, 2010). Normally, breast cancer patients are 
treated with a combination of multiple drugs to avoid the insurgence of resistance to a 
single agent. The simultaneous resistance to different drugs with different targets and 
chemical structures is known as multidrug resistance (MDR) (Szakacs et al., 2006).  An 
important mechanism of MDR is the overexpression of drug efflux proteins, including 
ATP-binding cassette (ABC) transporters (Szakacs et al., 2006; Zelnak, 2010). ABC 
transporters have a role in protecting cells or tissues from being damaged by extruding 
toxic agents, including chemotherapeutic drugs, out of the cells (Zelnak, 2010).  The 
most studied ABC transporter is the multidrug resistance protein 1 (MDR-1), which is 
also known as permeability-glycoprotein (P-gp). It functions by promoting the efflux of 
chemotherapeutic drugs out of cells, and by reducing the intracellular drug levels 
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(McGrogan et al., 2008). Drug efflux is not the only cause of chemotherapy resistance. 
For instance, resistance to taxanes can arise from the loss of β-ll-tubulin and the 
overexpression of β-lll-tubulin. As taxanes work by binding to β-tubulin, resistance to 
their action can be caused by an altered expression of certain β-tubulin isotypes. 
Alternatively, altered expression of the topoisomerase llα (TOP2A) gene can lead to 
anthracycline resistance (Zelnak, 2010). Finally, an increase in the DNA repair 
mechanisms or the down regulation in apoptotic signalling can also promote the 
insurgence of chemotherapeutic drug resistance.  
 
1.6 Cell cycle 
The cell cycle is a strictly regulated process of cell replication and proliferation. It can be 
divided into four distinct phases as G1, S, G2 and M phases. While the cells are in S 
(synthesis) and M (mitosis) phases, the cellular genome is replicated, and separated 
into the two daughter cells, respectively. Both phases are followed by gap periods: G2 
and G1 phases (Berckmans and De Veylder, 2009). In the presence of specific anti-
mitotic signals or an absence of mitotic signals, cells will exit the cell cycle by entering 
into a quiescent state, which is called G0 (Park and Lee, 2003). The cell cycle is tightly 
regulated, because a small mistake can lead to serious consequences for the 
development of the whole organism, such as cancer initiation (Berckmans and De 
Veylder, 2009). Key proteins for the regulation of the cell cycle are the cyclins and the 
cyclin-dependent kinases (CDKs). CDKs belong to a family of serine/threonine protein 
kinase that require a specific cyclin for their activation at specific points of the cell cycle 
46 
 
(Berckmans and De Veylder, 2009; Vermeulen et al., 2003). To date, nine CDKs have 
been identified, but only five of them have been reported to be active during the cell 
cycle: CDK1 (also known as CDC2), CDK2, CDK4, CDK6 and CDK7 (Vermeulen et al., 
2003). During the cell cycle, the levels of CDKs remain stable, while the protein levels of 
the cyclins change. In this way, cyclins periodically activate CDKs. When CDKs are 
activated, they induce their downstream targets by phosphorylating them at specific 
sites (Park and Lee, 2003; Vermeulen et al., 2003).    
Every phase of the cell cycle has at least one checkpoint, where regulatory proteins can 
promote cell cycle arrest (Lukas et al., 2004). The most interesting inhibitory proteins 
are CDK inhibitors (CKIs), which are inhibitors for the cyclin/CDK complexes. According 
to their structures and their specificity, CKIs have been classified into two families: CDK 
interacting protein/kinase inhibitor protein (Cip/Kip) family and the inhibitor of Cdk4 and 
6 (Ink4) families. The Cip/Kip family members, which are p21Cip1, p27Kip1 and p57Kip2, 
have a wide range of substrate specificity and interfere with the activities of cyclin D-, E-
, A- and B-dependent kinase complexes. Conversely, the Ink4 family members, which 
are p16INK4a, p15INK4b, p18INK4c and p19INK4d only target CDK4 and CDK6 by forming 
stable complexes with them and prevent the binding of the cyclins (Lim and Kaldis, 
2013; Vermeulen et al., 2003).   
The cell cycle can be arrested at G1/S, S and G2/M, M checkpoints to evaluate 
extracellular growth signals, DNA integrity and cell size (Park and Lee, 2003). In late G1 
phase, there is a stage called the “restriction point”, which is controlled by the 
retinoblastoma (Rb) protein, which is a tumour suppressor. This stage has a crucial role 
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in cancer prevention, as alterations in the regulation of the transition from G1 to S phase 
could lead to cells proliferating independently of mitogenic stimuli (Lapenna and 
Giordano, 2009). When the cells enter the cell cycle, CDK4 and CDK6 form an active 
complex with D-type cyclins (D1, D2 and D3) and initiate the phosphorylation of Rb to 
inactivate its function (pRB). This pRB inactivation leads to an increase in transcription 
of a few cell cycle genes, particularly of E-type cyclin (E1 and E2), by the E2F 
transcription factor. In late G1, the CDK2-cyclin E heterodimer reinforces the RB1 
phosphorylation on additional sites, initiating the S-phase and the genes involved 
(Berckmans and De Veylder, 2009; Lapenna and Giordano, 2009; Park and Lee, 2003). 
The E2F transcription factor can also target genes that are involved in the DNA repair 
and chromatin dynamics (Berckmans and De Veylder, 2009). After the cells pass 
through the restriction point, pRb is still in a hyper-phosphorylated form due to the 
sequential kinase activity by CDK2-cyclin A and CDK1-cyclin A to ensure that the cell is 
entering into G2 phase.   
The centrosome cycle starts during DNA replication. The centrosome duplicates in late 
S phase to early G2 phase and the duplicated chromosome makes poles for the mitotic 
spindle (Lapenna and Giordano, 2009). In late G2, CDK1 associates with cyclin A to 
initiate mitosis. However, if there is DNA damage during the G2 phase, the cell cycle will 
be arrested immediately at the G2/M checkpoint to prevent the damaged DNA from 
being carried on to the daughter cells. An important mediator of this checkpoint is the 
major mitosis-promoting of the CDK1-cyclin B kinase activity (Lukas et al., 2004). In 
case of DNA damage, combinations of factors come into account to prevent CDK1-
cyclin B activation. These include ataxia telangiectasia mutated (ATM), ataxia 
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telangiectasia and their downstream effectors RAD3-related protein (ATR), and 
checkpoint kinases CHK1/CHK2. In this case, CDK1 is activated at the G2/M boundary 
to repair the damage lesion (Lapenna and Giordano, 2009; Lukas et al., 2004). Other 
key regulators of the G2/M checkpoint are the mitotic serine/thereonine polo-like kinase 
(PLK) family members: PLK1 and PLK3. They promote the beginning of the M phase 
and can be down-regulated by an ATM-dependent mechanism. The overexpression or 
mutation of PLK1 has been found to be associated with tumorigenesis, and with poor 
prognosis (Schmitt et al., 2007).  In the M phase, the spindle assembly checkpoint 
(SAC) complex ensures that chromatids are correctly attached to the mitotic spindles. 
The SAC complex is regulated by an anaphase-promoting complex/cyclosome (APC/C) 
and its cofactors. To complete the cell division process, an activated CDK1 needs to be 
switched off by the proteolysis of cyclin B via APC/C mediated pathway. SAC deficiency 
is a frequent characteristic of cancer cell lines (Lapenna and Giordano, 2009).  
 
1.7 DNA damage response and repair 
The DNA damage response (DDR) is highly complex. The mechanism includes “sensor” 
proteins that sense the damage lesion, “transducer” proteins that transmit the DNA 
damage signal, and “effector” proteins that receive the signal from transducer proteins 
(Schmitt et al., 2007). There are thousands of DNA damage events occurring in human 
cells every day. This is a consequence of both exogenous and endogenous factors. 
DNA damage can interfere with DNA replication and transcription as it can lead to 
mutations and chromosomal aberrations (Polo and Jackson, 2011). DNA damage 
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signalling and repair responses have a crucial role in the maintenance of the genome 
integrity, as it prevents the transmission of the DNA damage lesions and its 
consequences to daughter cells (Ciccia and Elledge, 2010; Hoeijmakers, 2001; 
Hoeijmakers, 2007). DNA damage can be both single-strand break (SSB) and double-
strand break (DSB).  
SSBs are less cytotoxic when compared with DSBs, but it is the most common type of 
DNA damage. This type of DNA damage has been found to be at a frequency of tens of 
thousands per cells a day. This is the consequence of spontaneous DNA decay and the 
direct attack by intracellular metabolites. Endogenous reactive oxygen species (ROS) 
are also a main cause of SSBs (Caldecott, 2008). In contrast, DSBs are the most 
deleterious forms of DNA damage as there is no intact complementary DNA strand that 
can act as a template during the repair. DSBs can occur in response to various factors, 
such as topoisomerase ll inhibitor agents (such as epirubicin) which stop re-ligation of 
the double-stranded DNA cleavage (Polo and Jackson, 2011).  
1.7.1 DNA double strand break repair 
In order to neutralise the effect of the DNA damage on the cells, DNA damage repair is 
necessary (Figure 1.3). Normally, mismatched DNA bases are fixed by a process called 
mismatch repair (MMR). A minute alteration of DNA bases can be corrected by base 
excision repair (BER), which cuts out the damaged base. More complex lesions, such 
as intrastrand crosslinks and pyrimidine dimers, are repaired by nucleotide excision 
repair (NER), by the removal of the oligonucleotide, that contain the damaged bases 
(Ciccia and Elledge, 2010). SSBs are commonly repaired by a single-strand break 
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repair (SSBR), but DSBs are mainly repaired by either of two mechanisms: non-
homologous end joining (NHEJ) and homologous recombination (HR) (Caldecott, 2008; 
Khanna and Jackson, 2001).  
NHEJ is an effective mechanism that operates during all phases of the cell cycle and 
carries out the ligation of DNA ends with small processing at the end joining site. 
Conversely, HR repair is specific to late S and G2 phases of the cell cycle. HR works by 
using an undamaged homologous sequence as a template for the DNA repair, 
preferably the sister chromatid, and it is believed to be a highly precise DNA repair 
method for DSBs (Kass and Jasin, 2010). In HR, the DNA ends are first resected by a 
nuclease in a 5' to 3' direction. Subsequently, the 3' single-stranded tails, the product of 
the resection, enter the undamaged homologous DNA double helix, and are elongated 
by DNA polymerase. After branch-migration, the resulting DNA crossovers, also known 
as Holliday junctions, are resolved by many processes to produce two undamaged and 
repaired DNA molecules. As a result, HR is an accurate DNA repair mechanism with no 
loss or addition to the DNA sequence.  Alternatively, NHEJ does not require an 
undamaged homologous partner and does not depend on extensive homologies 
between the two recombining ends. During NHEJ repair, sometimes after limited 
degradation at the termini, the two ends are joined together (Jackson, 2009; Khanna 
and Jackson, 2001). Error-prone repair can lead to genome instability through the 
accumulation of chromosomal aberrations and mutations. In addition, hyper-
recombination also leads to genome instability phenotypes, such as gene deletion, 
amplification and loss of heterozygosity (Moynahan and Jasin, 2010).   
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Figure 1.3 DNA damage and repair mechanisms DNA can be damaged by various 
DNA damage agents. Most of the DNA repair processes, including BER, NER, HR, EJ 
and mismatch repair, are responsible for DNA damage lesion removal (Adapted from 
Hoeijmakers 2001). 
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The choice of DSB repair pathway is controlled by many agents, such as the nature of 
the damage lesion and the phase of the cell cycle. Accumulated evidence states that 
while NHEJ works throughout in every cell cycle phase, HR is restricted to late S and 
G2 phases. This is due to the presence of the sister chromatids: in mammalian cells, 
the sister chromatid, which is the template for HR repair, is present only during the S 
and G2 phases of the cell cycle (Rothkamm et al., 2003; Yata et al., 2012). A recent 
study demonstrates that even though NHEJ is modulated throughout the cell cycle, it 
only increase its activity from the G1 to the G2/M (G1 < S < G2/M) phases (Mao et al., 
2008). For HR, it is almost absent during the G1 phase, to then become most active in 
the S phase, and descending in G2/M phase (Mao et al., 2008). In addition, an 
important regulatory step that drives to the choice for the DSB repair pathway is the 
process of DSB resection, which is needed for HR but not NHEJ (Polo and Jackson, 
2011).  
1.7.2 Signalling in DNA damage response 
The DNA damage response (DDR) is a complex signal transduction pathway that can 
sense the presence of damaged lesions and transduce the signal to influence cellular 
responses (Ciccia and Elledge, 2010). DNA repair is closely correlated with the 
regulation of the cell cycle through the activation of orchestrated signalling pathways. 
One of the main aspects of the DNA damage signalling is the induction of cell cycle 
checkpoints which delay or stop cell cycle progression during the persistence of the 
DNA damage, thus preventing the replication of the damaged DNA or the segregation of 
abnormal chromosomes during mitosis. These signalling mechanisms can also lead 
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cells to triggering of programmed cell death (apoptosis) or long-term cell-cycle arrest 
(senescence), particularly when the damage persists (Jackson, 2009). DSB recognition 
and repair requires the action of various proteins that are involved with DNA damage 
response pathways: sensors, transducers, mediators and effectors. The DSB response 
pathway (Figure 1.4) allows the transduction of a signal from a sensor that recognises 
the DSB to its downstream effectors via a transduction cascade (Khanna and Jackson, 
2001).  
DNA damage by anthracyclines, such as epirubicin, causes double strand breaks. 
DSBs are recognised by the MRE11-RAD50-NBS1 (MRN) sensor complex. This 
complex promotes the activation of a transducer kinase ATM (Ataxia Telangiectasia 
Mutated) that phosphorylates members of the complex and prepares the DNA for HR 
(Ciccia and Elledge, 2010; Jackson, 2009). To organise the complex, MRE11 (meiotic 
recombination 11), an exonuclease enzyme, binds directly to NBS1, DNA and RAD50 
(Williams et al., 2007). Specifically, RAD50, a member of a structural maintenance of 
chromosome (SMC) related protein family, contains an ATP-binding cassette (ABC) 
ATPase that interacts with MRE11 and associates with the DNA ends of DSBs. MRE11 
has both endonuclease and exonuclease activities that help stabilising the DNA ends. 
These activities are important for the initial steps of DNA end resection, crucial for the 
initiation of HR mechanisms (Ciccia and Elledge, 2010; Williams et al., 2007).  NBS1, 
the last sub unit of the MRN complex, interacts with MRE11 and contains 
supplementary protein-protein interaction domains that are crucial for DDR. In addition, 
NBS1 also interacts with ATM through its C-terminal region. This promotes the 
recruitment of ATM to the site of damage, where ATM is activated (Ciccia and Elledge, 
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2010). The ATM kinase, as a signal transducer, activates the effector CHK1 and CHK2, 
with the help of mediator proteins, including mediators of the DNA damage checkpoint 
(MDC1), p53-binding protein1 (53BP1) and BRCA1. CHK proteins have a role in 
spreading the signal throughout the nucleus. Ultimate targets of these signalling 
cascades involve cell cycle regulators, DNA repair factors, programmed cell death 
machineries, and transcription factors (Harrison and Haber, 2006; Polo and Jackson, 
2011).  
For example, ATM kinase controls the resection of the DNA ends via C-terminal binding 
protein interacting protein (CtIP), that interacts with BRCA1 and MRN, in a BRCA1-C 
(BRCA1-BARD1 heterodimer, CtIP, MRN and damaged DNA) complex (Ciccia and 
Elledge, 2010). The most extensively studied among DDR proteins is the ssDNA-
binding complex replication protein A (RPA). This protein accumulates at resected 
DSBs in an MRN and CtIP dependent manner. An important regulatory step in DSB 
repair is a resection by the MRN complex. The resulting single-stranded DNA (ssDNA) 
overhangs are then coated by RPA before being substituted by RAD51 (Polo and 
Jackson, 2011). An assembly of RAD51 filaments on RPA-coated ssDNA leads to HR 
repair (Ciccia and Elledge, 2010). The RAD51 nucleofilament and some other HR 
factors mediate the search for homology in the sister chromatid, followed by strand 
invasion into the homologous template (Polo and Jackson, 2011).  
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Figure 1.4 DSB damage and repair signalling. DNA can be damaged by either 
exogenous or endogenous agents, resulting in DNA double strand breaks (DSBs). 
DSBs are sensed by “sensors”, and then the signal is transmitted to the signal 
“transducers” to activate the downstream “effectors” via a transduction cascade. Then 
cells enter into the cell cycle arrest, apoptosis, or DNA repair pathways (Adapted from 
Khanna and Jackson, 2001) 
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DSBs can also be recognised by Ku heterodimers (Ku70 and Ku80 subunits). Ku 
heterodimers are involved with guarding genomic integrity via their ability to bind DSB 
and promoter DNA repair by NHEJ (Walker et al., 2001). The Ku protein binds to broken 
DNA ends, then Ku translocates inwards from the ends making the extreme termini 
accessible to the DNA-dependent protein kinase (DNA-PKcs), which is the catalytic 
subunit, so as to allow the NHEJ to be initiated (Mahaney et al., 2009; Yoo and Dynan, 
1999).  Moreover, binding of Ku to the damaged end of the DNA is also required for the 
recruitment of X-ray repair cross-complementing protein group 4 (XRCC4) (Mari et al., 
2006) and the XRCC4-like factor (XLF) which are also known as Cernunnos (Yano et 
al., 2008). Briefly, after the DNA-PKcs is recruited, other factors, including 
polynucleotide kinase (PNK), nuclease Artemis, Aprataxin, and Aprataxin PNK-like 
factor (APLF), are also recruited to the DNA damage site. Accordingly, XRCC4, with the 
help of stimulatory factor XLF, promotes the ligation of the damaged end (Mahaney et 
al., 2009).   
Poly (ADP-ribose) polymerase (PARP) 1/2 can also detect DSBs. PARP, probably with 
the help of DNA ligase III, works in an alternative pathway of NHEJ (alt-NHEJ) that 
functions as a backup of the classical pathway. Moreover, PARP1 directly competes 
with Ku to bind to the DNA ends to promote HR (Wang et al., 2006). During the DNA 
repair process, PARP1 is required for a rapid accumulation of MRE11 and NBS1 (MRN 
complex) at the DNA damage site, in an MDC1 independent manner (Haince et al., 
2008).   
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1.8 Transcription factor Forkhead box M1 (FOXM1) 
The transcription factors forkhead box (FOX) genes encode for a family of evolutionarily 
conserved transcriptional regulators that were named after the Drosophila melanogaster 
fork head gene (fkh) (Hannenhalli and Kaestner, 2009; Weigel et al., 1989). The fkh 
gene is expressed in the early stages of embryo development. A fkh mutation leads to 
defects to the embryo head during embryogenesis (Weigel et al., 1989). The FOX 
proteins are defined by a common DNA-binding domain (DBD), of about 100 amino 
acids in length, called the forkhead box or winged helix domain (Myatt and Lam, 2007). 
This domain consists of three α-helices, three β-sheets, and two large loops, also 
known as ‘wing’ regions that flank the third beta-sheet (Jackson et al., 2010). More than 
50 FOX genes have been identified in humans, which can be further classified into 19 
subfamilies. The DBD is very well conserved across families and species (Jackson et 
al., 2010). The FOX proteins play a central role in various cellular processes not only 
during embryogenesis and development, but also in adult organisms (Benayoun et al., 
2011). Interestingly, various FOX families, including FOXA, FOXC, FOXM, FOXO, and 
FOXP, have been found to be linked to cancer genesis and progression (Myatt and 
Lam, 2007). In this study, I would mainly focus on the role of FOXM1 in breast cancer.  
The FOXM1 (Forkhead box M1) protein is one of the transcription factors that have a 
crucial role in many biological processes, such as cell cycle progression, cell 
proliferation, angiogenesis, apoptosis, tissue homeostasis, and DNA damage repair 
(Figure 1.5). FOXM1 has been found to be overexpressed in various types of cancer, 
including breast cancer. FOXM1 was previously known as Trident, hepatocyte nuclear 
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factor 3/forkhead homolog 11 (HFH11), M-phase phosphoprotein 2 (MPP2) and Winged 
helix (WIN), forkhead drosophila homolog-like 16 (FKHL16) (Koo et al., 2012). The 
human and mouse FOXM1 share 79% homology. In humans, the FOXM1 gene is 
located on the chromosome 12 band p13, composing of 10 exons of which two are 
alternatively spliced (Korver et al., 1997a). Alternative splicing of exon A1 (Va) and A2 
(Vlla) are present in the human FOXM1 gene (Figure 1.6) providing up to 3 distinct 
FOXM1 variants: FOXM1a, FOXM1b and FOXM1c (Koo et al., 2012; Yao et al., 1997). 
FOXM1a contains both alternative exons, Va and VIIa. Presence of those inserts in the 
C-terminal transactivation domain (TAD) leads to an entirely inactive form of FOXM1. 
However, this TAD disruption may cause FOXM1a to be a dominant negative form 
because the TAD activity in DNA binding of this variant is still functional (Koo et al., 
2012; Laoukili et al., 2007; Ye et al., 1997). In contrast, FOXM1b and FOXM1c are 
transcriptionally active. FOXM1c contains only exon Va at C-terminal of DBD, while 
FOXM1b contains none of the alternative exons. Both FOXM1b and FOXM1c can 
promote the expression of target genes in an isoform-specific manner (Koo et al., 2012). 
They act as transactivators through the binding to a conventional FOXM1 consensus 
site: TAAACA (Korver et al., 1997b). 
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Figure 1.5 FOXM1 plays crucial roles in various cellular processes. FOXM1 is a 
member of transcription factor families that have a crucial role in many biological 
processes, such as cell cycle progression, cell proliferation, angiogenesis, apoptosis, 
tissue homeostasis, DNA damage repair, and chemotherapeutic drug resistance 
(Adapted from Koo et al., 2012).  
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Figure 1.6 Schematic of known alternative splice variants and 3 protein regions of 
human FOXM1. A. Axon A1 and A2 are the two out of the ten exons. These two exons 
are alternatively spliced in FOXM1 gene. In C-terminal of DBD, there is exon A1 that 
encodes 15 amino acids. In C-terminal transactivation domain (TAD), there is exon A2 
that encode 38 amino acids. Alternative splicing of these two exons resulted in three 
different isoforms of FOXM1: FOXM1a, FOXM1b and FOXM1c. The FOXM1 protein 
contains three regions: an N-terminal autorepressor domain (NRD), a conserved 
forkhead DNA Binding domain (FKH) and a transactivation domain (TAD) (adapted from 
Koo et al., 2012; Laoukili et al., 2007). 
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1.8.1 FOXM1 is important for cell proliferation and cell cycle control 
FOXM1 has been found to be expressed in all embryonic tissues and many of the 
rapidly proliferating cells. In adults, FOXM1 is expressed at high levels in the thymus 
and testis, and at moderate levels in the lungs and intestine. All of these tissues have a 
rapid proliferation rate (Laoukili et al., 2007). Interestingly, in a study of the Foxm1-/- 
mice, loss of the Foxm1 gene is embryonic lethality. Foxm1-/- embryos were found to be 
dead in the uterus due to pulmonary defects and liver development abnormalities 
(Korver et al., 1998; Krupczak-Hollis et al., 2004).  
FOXM1 encourages cell proliferation by promoting cell cycle progression. FOXM1 
expression is essential for G1/S and G2/M phases of the cell cycle and also for the 
mitotic spindle integrity. FOXM1 deficiency is involved with the decrease in Plk1, Aurora 
B kinase, cyclin A2 and B1 protein levels (Kim et al., 2006; Krupczak-Hollis et al., 2004). 
During the G1/S phase of the cell cycle, FOXM1 regulates CDK subunit 1 (CKS1), S 
phase kinase-associated protein 2 (SKP2), kinase interacting with Stathmin (KIS), and 
c-Jun N-terminal kinase 1 (JNK1), by acting as a transcriptional activator (Petrovic et al., 
2008; Wang et al., 2005; Wang et al., 2008). FOXM1 is also required for the 
transcription of SKP2 and CKS1, which are specific subunits of the Skp1-Cullin 1-F-box 
(SCF) ubiquitin ligase complex. This complex targets cyclin-dependent kinase inhibitor 
(CDKI) proteins, p21Cip1 and p27Kip1, for degradation during the G1/S transition, resulting 
in cell cycle progression to the S phase and in mitosis (Wang et al., 2005).  
FOXM1 activity can also be controlled by phosphorylation and dephosphorylation 
(Figure 1.7). FOXM1 phosphorylation is increased as cells progress from the G1 to S 
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and G2 phases, and then FOXM1 is dephosphorylated when the cells exit mitosis 
(Chen et al., 2009; Fu et al., 2008). Briefly, In the G1/S phase, FOXM1 phosphorylation 
is initiated by CDK2-cyclin E complex, while in the G2/M phase it is mediated by CDK1-
cyclin B1 (Major et al., 2004).  CDK2-cyclin E and CDK2-cyclin A complexes are also 
important for phosphorylation of FOXM1 in the G2/M phase (Laoukili et al., 2007).   
Interestingly, a new conserved CDK1-dependent phosphorylation site (Ser-251) in 
FOXM1 has been shown to be importance of its activation. Mutation of Ser-251 inhibits 
FOXM1 phosphorylation and results in a decrease in its transcriptional activity (Chen et 
al., 2009). It has already been confirmed that FOXM1 activation by phosphorylation can 
enhance the activity of many mitotic regulators, including Plk1 (Fu et al., 2008), Cyclin 
B1 (Leung et al., 2001), survivin, centromere protein A (CENPA), centromere protein B 
(CENPB), and Aurora B kinase (Wang et al., 2005). In order to exit cellular mitosis, 
FOXM1 is degraded through the proteasome degradation pathway by the Anaphase-
Promoting Complex, also known as cyclosome, (APC/C). This pathway is regulated by 
Cdh1 (known co-factor for APC/C). The APC/C-Cdh1 complex binds directly to both D- 
and KEN-box motifs that are located on the N-terminus of FOXM1 (Laoukili et al., 2008). 
In conclusion, all evidence confirms that FOXM1, and its post-translational modifications 
are necessary for cell cycle progression. 
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Figure 1.7 Schematic diagram of FOXM1 regulation during the cell cycle. Protein 
and mRNA levels of FOXM1 are upregulated in late G1 phase, FOXM1 activity is 
subjected to different levels of regulation. Increasing FOXM1 activity in G2/M phase is 
related to its hyperphosphorylation. This suggests that phosphorylation has a crucial 
role in activating FOXM1 (Kwok, 2010; Laoukili et al., 2007; Murakami et al., 2010). 
 
 
 
 
 
 
 
 
64 
 
1.8.2 FOXM1 in DNA repair and chromosome integrity maintenance 
Various findings have revealed the importance of FOXM1 in maintaining genomic 
integrity. Loss of FOXM1 or FOXM1 overexpression can lead to chromosomal 
abnormalities (Laoukili et al., 2005; Wonsey and Follettie, 2005). As is widely known, 
FOXM1 is necessary for the timely mitotic entry. In addition, the centromere protein F 
(CENP-F, mitosin), a kinetochore binding protein, is also a direct target of FOXM1. 
CENP-F is part of the mitotic checkpoint (Laoukili et al., 2005). A study revealed that 
FOXM1 also has a crucial role in the regulation of various genes that are important for 
chromosome segregation and mitosis, including CENP-A, KIF20A and Nek2. FOXM1 
defects have been confirmed to lead to mitotic spindle defects, delays in mitosis and 
mitotic catastrophe (Wonsey and Follettie, 2005).  
There is evidence that the activity of FOXM1 is suppressed at the DNA damage check 
point. FOXM1 has been shown to be repressed by p53, which is important in cell cycle 
delay and G2/M checkpoint, in response to DSBs. Induction of p53 by DNA-damage 
leads to the downregulation of FOXM1 (Barsotti and Prives, 2009; Pandit et al., 2009). 
In contrast, another report showed that FOXM1 remains active during the DNA damage 
response, in the G2 arrest. FOXM1 activates the expression of its downstream targets, 
including PLK1, Cyclin A and Cyclin B, which are crucial for cell cycle re-entry from G2 
arrest and checkpoint recovery (Alvarez-Fernandez et al., 2010).  
In a previous study from our lab, FOXM1 has been reported to be involved in DNA 
damage repair, following epirubicin treatment. FOXM1 is downregulated after epirubicin 
treatment in wild-type breast cancer cells but not in epirubicin resistant cells. The study 
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found that FOXM1, activated by ATM and E2F1, promotes cell survival in epirubicin 
resistant breast cancer cells (Millour et al., 2011). Consistently, FOXM1 interacts with 
NFκB in the presence of chemotherapeutic drugs, to protect the cells from DNA 
damage. Moreover, FOXM1 also regulates the expression of HR repair genes, including 
EXO1, PLK4 and RFC4 (Park et al., 2012). 
1.8.3 FOXM1 and cancer 
FOXM1 is a transcription factor that plays a crucial role in a wide spectrum of cellular 
processes, such as cell proliferation, DNA damage repair, apoptosis, and cell cycle 
progression. Moreover, overexpression of FOXM1 is commonly found in a multitude of 
cancers, including breast cancer (Koo et al., 2012; Wonsey and Follettie, 2005). 
One of the most important processes for tumorigenesis and cancer progression is 
angiogenesis (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). The 
vascular endothelial growth factor (VEGF) family is important for tumour angiogenesis 
and the VEGF ligand binds to tyrosine kinase receptor (VEGFR) to promote its 
activation through dimerisation and phosphorylation (Shibuya and Claesson-Welsh, 
2006). Indeed, VEGF is a direct transcriptional target of FOXM1 and this is mediated 
through two FOXM1 binding sites in the VEGF promoter. Mutation of these binding sites 
significantly reduces the ability of FOXM1 to induce activity of the VEGF promoter. In 
agreement, overexpression of FOXM1 leads to the promotion of angiogenesis in glioma 
cells (Zhang et al., 2008). A study in pancreatic cancer cells also showed that the 
inhibition of FOXM1 expression reduces the expression of matrix metalloproteinase-2 
(MMP-2), MMP-9, and VEGF, resulting in the inhibition of cellular migration, invasion 
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and angiogenesis (Wang et al., 2007). A study in gastric cancer revealed that FOXM1 
has a role in tumorigenesis by inhibiting cellular senescence. FOXM1 depletion leads to 
the down regulation of c-MYC and Skp2, together with the accumulation of CDK 
inhibitor p27kip1. Moreover, FOXM1 knock down can also inhibit telomerase, an enzyme 
that participates in cell immortality (Zeng et al., 2009). In addition, Foxm1-/- MEFs 
revealed a high level of β-galactosidase, p19ARF, and p16INK4A proteins, which are 
hallmarks of premature cellular senescence (Wang et al., 2005). FOXM1 has been 
proved to help preventing cancer cells from undergoing stress-induced premature 
senescence. Overexpression of FOXM1 suppresses cellular senescence and the 
expression of p53 and p21 (Li et al., 2008). 
FOXM1 is widely known to be one of the key regulators of the G1/S and G2/M 
transition, and of the mitotic progression. Consistent with this, FOXM1 also regulates 
the expression level of various genes, including cyclin B, aurora kinases, PLK1, and 
survivin.  (Koo et al., 2012). Foxm1-/- MEFs and FOXM1 depleted human osteosarcoma 
cells show a mitotic blockage and accumulation of CDKI proteins, including p21Cip1 and 
p27Kip1 (Wang et al., 2005). Additionally, the protein and mRNA levels of FOXM1 and 
Bmi-1, its downstream target, are at the maximum levels at G2/M phase. It has been 
confirmed that FOXM1 regulates Bmi-1 expression through c-Myc. These three proteins 
are major regulators of tumourigenesis (Li et al., 2008).  
Interestingly, some cancer cells and stem cells share identical properties, such as self-
renewal ability, immortality and sustained proliferative capacity (Koo et al., 2012). 
Recently, FOXM1 has been revealed to have a crucial role in regulating cancer initiation 
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by provoking stem cell-like self-renewal properties in cancer cells. This study, using a 
functional 3D organotypic epithelial tissue regeneration system, showed that FOXM1 
overexpression disturbs epithelial differentiation, promotes hyperproliferative characters, 
leading the cells to acquire similar properties that can be observed in human epithelial 
hyperplasia (Gemenetzidis et al., 2010). A study of embryonic development revealed 
that FOXM1, induced by retinoic acid (RA), is suppressed during differentiation of 
pluripotent P19 embryonic carcinoma cells at the early stage. This downregulation of 
FOXM1 is consistent with a lower expression of stem cell pluripotency genes, including 
Oct4 and Nanog (Xie et al., 2010). In addition, a study in mouse embryos also showed 
that increasing Foxm1 activity induces the proliferation of respiratory epithelium and 
promotes the growth of lung tumours (Wang et al., 2010). Together these findings 
confirm that FOXM1 has an important role in cancer development.  
1.8.4 FOXM1 and chemotherapy resistance 
Conventional chemotherapy is a common systemic treatment for patients with cancer. 
Chemotherapy helps to prevent cancer cells from proliferation and undergoing 
metastasis. FOXM1 has been found to have an important role for development of 
chemotherapeutic drug resistance. In breast cancer, FOXM1 is related to the resistance 
to various therapies including endocrine therapy (Millour et al., 2010), cisplatin (Kwok, 
2010), Trastuzumab (also known as Herceptin), paclitaxel (Carr et al., 2010), and also 
anthracyclines (Halasi and Gartel, 2012; Millour et al., 2011; Monteiro et al., 2013; Park 
et al., 2012).  
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Hormonal therapy, also known as endocrine therapy, is the preferred option for most of 
breast cancer patients with ERα positive tumours. Normally, these patients are treated 
with anti-oestrogen agents, such as tamoxifen, that promote G1/S cell cycle arrest and 
apoptosis (Koo et al., 2012). However, ERα positive breast cancer patients present 
inconsistent unstable clinical outcomes in response to endocrinal therapy. A 
considerable number of patients at a metastatic stage is found to be resistance to the 
treatment (Ali and Coombes, 2002). Expression of ERα in breast carcinoma cells is 
physiologically regulated by FOXM1 (Madureira et al., 2006). Conversely, ERα is also 
found to regulate FOXM1 expression via an oestrogen response element (ERE) located 
within the proximal promoter region of FOXM1. This feedback mechanism might be 
responsible for an association between the mRNA levels of FOXM1 and ERα, which 
has been observed in breast cancer patient samples (Millour et al., 2010).  A genome 
view study, using a cDNA microarray, revealed that FOXM1 is one of the oestrogen 
responsive genes in breast cancer cells (Cicatiello et al., 2004). Notably, tamoxifen 
treatment has been shown to repress FOXM1 in sensitive breast cancer cell lines, but 
not in resistant cell lines (Millour et al., 2010). All together, these studies indicate that 
high expression levels of FOXM1 are correlated to an endocrine therapy resistance in 
breast cancer.  
Cisplatin, also known as cis-platinum or cis-diaminedichloroplatinum (II)/CDDP, is a 
platinum-based compound that has a high potential for cancer treatment (Koo et al., 
2012). Cisplatin functions by forming DNA adducts (can be called as platinum–DNA 
adducts), intrastrand and interstrand, and thereby activating various signal-transduction 
pathways, such as DNA-damage repair, cell cycle arrest, and apoptosis (Kelland, 2007). 
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Recent studies have also revealed that FOXM1 expression is involved with cisplatin 
resistance (Kwok, 2010; Wang et al., 2013). In breast cancer, cisplatin resistant cell 
lines exhibit elevated FOXM1 in both protein and mRNA levels, when compared with 
sensitive breast cancer cell lines. Furthermore, an increase in FOXM1 expression is 
also correlated with an elevated expression of its downstream targets in the DNA repair 
pathway, including BRCA2 and XRCC1 (Kwok, 2010).  
Another common drug for molecular targeted therapy is gefitinib, a small molecule 
tyrosine kinase inhibitor (TKI) for EGFR (Carter et al., 2009; van Erp et al., 2009). These 
molecular targeted therapy agents, including trastuzumab and gefitinib, mediate 
cytotoxic function in the cells via Forkhead box O3 (FOXO3a) activation, which is 
directly linked to FOXM1 signalling pathways (Koo et al., 2012). Although the treatment 
with trastuzumab is effective, only 30% of patients have found to be responsive to the 
treatment, because of the rapid development of resistance (Burris, 2000; Wilken and 
Maihle, 2010). FOXM1 is a downstream target of HER2 and has a tight correlation 
between their expressions (Bektas et al., 2008). In addition, gefitinib has also been 
found to have an indirect effect on FOXM1 suppression via FOXO3a activation in 
sensitive breast cancer cell lines. Moreover, overexpression of exogenous FOXM1 or a 
constitutively active FOXM1 (NH2-terminal truncated form: ΔN-FOXM1) can promote 
gefitinib resistance (McGovern et al., 2009). 
Commonly used chemotherapy drugs are taxanes and anthracyclines. Taxanes 
polymerise tubulin and induce apoptosis by disturbing microtubule dynamics that are 
required for cell mitosis (McGrogan et al., 2008). In breast cancer, FOXM1 
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overexpression confers resistance to paclitaxel (sometimes known as taxol) by altering 
the dynamics of the microtubules to prevent cancer cell death. FOXM1 depletion by a 
small interfering RNA (siRNA) or an alternate reading frame (ARF) derived peptide 
inhibitor helps to resensitise the cancer cells to paclitaxel (Carr et al., 2010). In recent 
studies, FOXM1 expression has also been found to be related with the cellular response 
to anthracyclines, including doxorubicin and epirubicin (Halasi and Gartel, 2012; Millour 
et al., 2011; Park et al., 2012). Both taxanes and anthracyclines are important 
therapeutic agents for breast cancer patients with metastasis (Zelnak, 2010). While 
taxanes work as microtubule dynamic interrupter, anthracyclines have a role in DNA 
intercalation and induction of DSBs (Minotti et al., 2004)). In breast cancer cell lines, 
FOXM1 is found to be overexpressed in epirubicin resistance breast cancer cells, 
compared with sensitive cells. Depletion of FOXM1 promotes the sensitivity of breast 
cancer cells to epirubicin treatment (Millour et al., 2011; Monteiro et al., 2013). The 
regulation of FOXM1 by epirubicin is mediated by the activation of the DNA damage-
transducer kinase ATM that promotes the expression of E2F transcription factor. This 
factor regulates FOXM1 via E2F-sites, which are located within the proximal promoter 
region of FOXM1. Moreover, FOXM1 has been indicated to be responsible for the DNA 
damage repair mechanisms and cell survival in response to epirubicin treatment (Millour 
et al., 2011). Depletion of FOXM1 in MDA-MB-231 cells (triple negative breast cancer 
cells) known chemotherapy resistant cells, leads to a higher sensitivity to doxorubicin. 
Using the same model, FOXM1-dependent resistance is found to be mediated by 
exonuclease 1 (EXO1), replication factor C4 (RFC4), and PLK4 (Park et al., 2012). 
Despite the fact that FOXM1 is required for DNA repair by HR via BRIP1 regulation, 
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overexpression of FOXM1 can promote cells viability, DNA repair and abrogate DSBs 
after treatment with epirubicin (Monteiro et al., 2013). Collectively, it can be implied that 
FOXM1 might be an interesting target to resensitise therapeutic resistance breast 
cancer cells (Carr et al., 2010).  
 
1.9 Ubiquitination and SUMOylation 
One important feature of DDR proteins is their mobilisation and local accumulation at a 
damaged lesion, which eventually results in the formation of discrete foci. Protein 
assembly at DNA damage sites is tightly controlled and achieved by post-translational 
modifications (PTM) of proteins. These modifications encourage the assembly or 
disassembly of DDR factors or control their times of residence at DNA breaks (Polo and 
Jackson, 2011). Most of the PTMs by ubiquitination are normally involved with protein 
targeting for proteolytic degradation via proteasome pathways, but some ubiquitination 
can also be controlled by protein localisation or its activity. Moreover, there are several 
ubiquitin-like proteins (UbLs) that have the capacity to target other proteins and regulate 
their functions. One of the most important UbLs is a small ubiquitin-related modifier 
(SUMO) that has been shown to covalently bind to various targeted proteins and play a 
crucial part in a huge number of cellular mechanisms, including genome maintenance, 
signal transduction, and gene expression (Gill, 2004).  
Ubiquitin is a globular 76-amino-acid protein. It is highly conserved and is found to be 
different in only three amino acids between humans and yeast (Weissman, 2001). 
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Ubiquitin normally forms a covalent bond with targeted proteins at the lysine side chains 
of those proteins (Muller et al., 2001). Ubiquitination is mediated by the concerted action 
and sequential activity of E1-E2-E3 enzymatic cascade (Figure 1.8), which are 
activating (E1), conjugating (E2), and ligating (E3) enzymes, respectively (Bergink and 
Jentsch, 2009; Gill, 2004; Grabbe et al., 2011). Ubiquitination varies according to the 
lysine residues where they form in the chain (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 
or Lys63) or the amino-terminal methionine (Met1) of the ubiquitin monomer (Grabbe et 
al., 2011). The most common ubiquitin chains in cellular responses are the Lys 48 
(K48)-linked ubiquitin chains and the Lys 63 (K63)-linked ubiquitin chains. While K48 
chains usually act as markers for proteasomal degradation of the targeted protein, K63 
chains are normally a marker for non-degradation and often orchestrate assembly of a 
protein complex in cellular signalling pathways (Nakada et al., 2010). Despite the fact 
that ubiquitination has a role in many cellular processes, including cell cycle and DNA 
damage repair response, it can also play a part in regulating cancer progression 
(Hoeller et al., 2006).  
SUMO (previously known as sentrin), a member of UBL proteins, can be found in all 
eukaryotes and, like ubiquitin, it is highly conserved from yeast to humans (Muller et al., 
2001). In the ubiquitination enzymatic cascade, E3 ligase normally provides substrate 
specificity by specific substrate-binding sites or, sometimes, a combination of E3 and 
E2. In contrast, SUMOylation has a surprisingly simpler cascade than ubiquitination 
(Figure 1.8). There are many different E2 and even more E3 enzymes in ubiquitination, 
but SUMOylation only involves an E1, a single E2 (which is Ubc9) and only a few E3 
enzymes (Bergink and Jentsch, 2009). 
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In budding yeasts (Saccharomyces cerevisiae), there is only one type of SUMO, which 
is called Smt3. In contrast, there are four isoforms of SUMO that can be found in 
vertebrates including human: SUMO1, SUMO2, SUMO3 and SUMO4 (Martin et al., 
2007). SUMO2 and SUMO3 differ from each other merely by only three amino at N-
terminal residues (sometimes called as SUMO2/3), and are found to be functionally 
redundant (Jackson and Durocher, 2013). SUMO1 is around 11.6 kDa, contains 101 
amino acids. SUMO1 has been found to share ~18% homology with ubiquitin. The 3D 
structures of SUMO1, SUMO2/3 and ubiquitin are very similar to each other, but not 
SUMO4. Expression of SUMO4 is limited to the kidney and spleen. Nevertheless, the 
understanding of SUMO4 has yet to be established. It remains unclear whether SUMO4 
might be simply be a pseudogene or whether it might bind non-covalently, and not be a 
part of PTM (Martin et al., 2007). Unlike ubiquitination, SUMOylation does not target 
proteins for proteasome-mediated degradation, but it takes a crucial part in regulating 
function of a targeted protein, including protein-protein interactions and the DNA 
damage repair responses (Bergink and Jentsch, 2009; Park-Sarge and Sarge, 2009).     
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Figure 1.8 Comparison of ubiquitin and SUMO1 in the structure and pathways. 
Ubiquitin (Ub) and SUMO (S) are small modifiers that form covalent bonds with targeted 
proteins. Both modifications are reversible. These ubiquitination and SUMOylation can 
be by a single modifier (monoubiquitination or monoSUMOylation) or multiple modifiers 
to form specific chains (polyubiquitylation or polySUMOylation). The amounts of 
enzymes in Saccharomyces cerevisiae and in human are respectively shown in 
brackets. UBPs are ubiquitin-specific proteases, and ULPs are ubiquitin-like protein 
(SUMO)-specific proteases (Adapted from Bergink and Jentsch, 2009; Gill, 2004). 
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PTMs by SUMOylation have been reported to be important regulators of transcription. 
SUMOylation has various effects over the targeted proteins, but most of the 
SUMOylation events have been found to act as transcriptional repressors (Ouyang et 
al., 2009). A study in Helicoverpa armigera (cotton bollworm) revealed that a 
modification by SUMOylation has an important role in the suppression of the 
transcriptional activity of the forkhead transcriptional factor box A (FOXA), which is 
associated with a downregulation of the transcriptional downstream target of FOXA, 
such as DH-PBAN gene (Bao et al., 2011). Furthermore, SUMOylation of FOXL2, a 
transcription factor essential for ovarian development and maintenance, also leads to 
the inhibition of its transactivation ability (Georges et al., 2011): this FOXL2 
SUMOylation can be found in both humans and mice (Marongiu et al., 2010). Recently, 
FOXC1 and FOXC2, which are important transcription factors in development and 
physiology, have been found to be targeted by SUMO. This modification results in the 
downregulation of the transcriptional activity of FOXC1/C2. SUMOylation deficient 
mutants FOXC1/C2 have a higher transcriptional activity when compared with the wild-
type forms (Danciu et al., 2012). These studies indicate that this novel PTM, 
SUMOylation, has become an important reversible regulator for controlling the 
transcriptional activity of various transcription factors.  
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1.10 RING-type ubiquitin E3 ligase 
Ubiquitin E3 ligases are involved with ubiquitinating enzymatic cascades by recognising 
targeted proteins (ubiquitin substrates) and mediating the ubiquitin transfer from 
conjugating (E2) enzymes to the target proteins (Deshaies and Joazeiro, 2009). There 
are two major classes of E3 ligases (Figure 1.9): HECT (homologous to the E6AP 
carboxyl terminus) and RING (Really interesting new gene) domain containing E3 
ligases (Metzger et al., 2012). The key feature of the HECT domain which contains the 
ligase, also called HECT-type E3, is a conserved cysteine residue. This residue forms 
an intermediate covalent thio-ester bond with the C-terminus of ubiquitin, before 
catalysing its transfer (Di Fiore et al., 2003; Rotin and Kumar, 2009). In contrast, RING-
type E3 does not form a thio-ester bond with the ubiquitin residue like HECT-type E3. 
Instead, it brings the ubiquitin-E2 complex and its substrates (targeted proteins) into 
close proximity to transfer the ubiquitin residue directly from the conjugating E2 enzyme 
to the substrate (Di Fiore et al., 2003; Metzger et al., 2012; Ozkan et al., 2005).    
The role of the RING-type E3 ligases is commonly specified by the RING domain which 
interacts with the ubiquitin-E2 complex to discharge the ubiquitin cargo from an E2 
enzyme (Deshaies and Joazeiro, 2009). RING-type E3 family is composed of three 
distinct groups (Figure 1.10); singles subunit, dimeric and multisubunit. Single subunit 
E3s, such as, parkin and RNF168, have one RING finger (RF) subunit that is 
surrounded by a protein-interacting motif. The RF subunit of the dimeric group and/or its 
surrounding regions acts as dimerisation sites to enhance the activity of E3. The dimeric 
group can be divided into two sub-groups which are homodimers (such as RNF4 and 
77 
 
RNF8) and heterodimers (such as BRCA1). The most complex RING-type E3s are 
multiple subunit E3s, such as, the culling RNG ligase (CRL) superfamily complex. This 
complex consists of the S phase kinase-associated protein 1 (SKP1)–cullin 1 (CUL1)–F-
box protein (SCF) and CRL2 E3 families), the anaphase promoting complex/cyclosome 
(APC/C) and the Fanconi anaemia (FANC). RING-type E3 enzymes control the 
specificity of substrate recognition by PTMs, including phosphorylation, glycosylation 
and SUMOylation (Lipkowitz and Weissman, 2011). 
One of the most well-known RING-type E3 is RNF4. It has been reported to be involved 
with the DNA damage repair pathway. It is also an important DDR protein that is 
involved with HR repair in response to genotoxic stress (Yin et al., 2012).  RNF4 (also 
known as SLX5, SNURF or RES4-26) is a dimeric RING-type E3 ligase that normally 
targets SUMOylated proteins to be ubiquitinated. RNF4 can be recruited to DSB lesions 
with a RING domain, a SUMO interacting motif (SIM) and a combination of  some DNA 
repair proteins, including MRN sensor complex, MDC1 (DNA damage checkpoint 1), 
RNF8 and BRCA1 (Galanty et al., 2012; Yin et al., 2012). In order to target SUMOylated 
proteins, RNF4 engages the substrate proteins through its SIMs while the RING domain 
acts as a dimerisation domain and has a role in catalysing the ubiquitin transfer to the 
substrate. The stability of the ubiquitin-E2 complex is regulated by this RING domain 
dimerisation of RNF4 (Liew et al., 2010). Depletion of RNF4 results in defects of DSB 
repair and cell cycle arrest, caused by the impairment of ubiquitin adduct formation at 
the DSB sites (Galanty et al., 2012). The role of RNF4 in DDR in mammals is poorly 
understood because Rnf4 null mice normally die in the early stages of embryogenesis 
(Vyas et al., 2013). In addition to RNF4, RNF168 is also found to play an important role 
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in response to DSBs (Bartocci and Denchi, 2013; Morris et al., 2009). In some studies, 
the RNF168 pathway has been reported to cross-talk with RNF8 in order to promote the 
formation of ubiquitin chains (Bartocci and Denchi, 2013). At the DSB lesion, RNF8 is 
chained to the damage site through its forkhead-associated (FHA) domain which targets 
the phosphorylated forms of MDC1. RNF8 recognises UBC13, a ubiquitin E2 
conjugating enzyme, through a RING-dependent interaction. Ubiquitination of the 
substrate protein by RNF8 leads to the recruitment of RNF168 to the damaged site to 
further amplify ubiquitin signal (Zhang et al., 2013). RNF168 contains a motif which 
interacts with the ubiquitin (MIU) domain.  It can interact directly with the ubiquitin chain 
that is initially formed by RNF8 (Ohta et al., 2011). In addition, Ubiquitin chains play a 
crucial role in the recruitment and accumulation of various repair proteins, including 
ATM, BRCA1 and 53BP1 (Doil et al., 2009; Zhang et al., 2013). RNF168 activities at the 
damage site are not restricted to the amplification of the signal, but also to help sustain 
BRCA1 at the damaged site to promote DNA repair (Morris et al., 2009). 
 
79 
 
 
Figure 1.9 Schematic of ubiquitin pathway and the different mechanism of 
ubiquitin transferby E3 ligases. In the beginning of the ubiquitin pathway, ubiquitin 
residue (Ub) is activated by ATP at the carboxyl terminus and conjugated, with a thio-
ester bone, to active sites of an activating enzyme (E1). Then Ub is transferred to an 
active site of a conjugating enzyme (E2). Finally, two main groups of E3 ligases (HECT 
and RING type) have different ways to transfer Ub to the substrate: HECT-type E3 has 
a conserved cysteine residue that can directly form a thio-ester bond to Ub and transfer 
it to the substrate, while RING-type E3 acts as scaffolds by facilitating the interaction of 
Ub-E2 complex and the substrate before transferring Ub to the substrate without 
forming a bond with Ub (Adapted from Di Fiore et al., 2003).  
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Figure 1.10 the diagram of three distinct groups of E3 ligase. RING-type E3s can 
be differentiates into 3 groups according to their RF subunit (shown in red colour with a 
square shape) which are single RF subunit, dimeric RF subunit and multi-subunit RF. 
RING-type E3 controls a specificity of substrate recognition by PTMs, including 
phosphorylation, glycosylation and SUMOylation (Adapted from  Lipkowitz and 
Weissman, 2011).  
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1.11 OTUB1 
It is widely known that ubiquitination plays a crucial part in the regulation of a broad 
spectrum of cellular responses, including proteasome degradation, transcription and 
DDR. DUB is an enzyme that is important for balancing these processes by modulating 
ubiquitin signalling (Wiener et al., 2013). OTUB1 is a product of the OTUB1 gene, a 
member of the OTU (ovarian tumour) superfamily of predicted cysteine proteases. 
Some well-known members of this superfamily have been established as important 
regulators in various signalling cascades including inflammation and cancer signalling 
pathways (Mevissen et al., 2013), such as ubiquitin-editing enzyme A20 (also known as 
Tumour Necrosis Factor Alpha-Induced Protein 3 or TNFAIP3) and OTUD family 
members that are known as a negative feedback regulation of NF-κB signalling and 
tumour suppressor  in Hodgkin lymphomas and primary mediastinal lymphomas 
(Malynn and Ma, 2009; Mevissen et al., 2013; Vereecke et al., 2009), OTULIN that 
prevents inappropriate pro-inflammatory signal (Fiil et al., 2013; Keusekotten et al., 
2013),  and ZRANB1 (also known as TRABID) that was discovered to have a role as a 
regulator of cytoskeleton and cell migration (Bai et al., 2011).  
Ubiquitin aldehyde binding 1 (OTUB1), or also known as OTU deubiquitinase is a  
deubiquitination enzyme (DUB) that has a role in a reverse process of ubiquitination, 
blocking the transfer of ubiquitin residues. The regulation of OTUB1 by PTMs remains 
unclear. Only one study has reported that OTUB1 is monoubiquitinated. This 
modification is mediated by UbcH5 E2 enzyme and is critical for the function of OTUB1 
as a deubiquitinating enzyme (Li et al., 2014).   
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OTUB1 is believed to interfere with DNA repair by inhibiting ubiquitination which is one 
of the most important signals in DDR (Figure 1.11). In normal cells, OTUB1 separates 
UBC13, an E2 conjugating enzyme, from the ubiquitination process by binding to it. In 
the presence of DNA damage, OTUB1 separates from UBC13, and lets it participates in 
the ubiquitination, together with the help of an E3 ligase, in DNA damage signalling 
(Rose and Schlieker, 2010). OTUB1 has also been shown to be able to bind to the E2s 
of UBE2D and UBE2E families (Nakada et al., 2010; Sowa et al., 2009). OTUB1 can 
also suppress the RNF168-dependent ubiquitination pathway (Nakada et al., 2010). 
Interestingly, OTUB1 can inhibit the ubiquitination of both K48-linked (Wiener et al., 
2013) and K63-linked ubiquitin chains (Nakada et al., 2010).  
 The function of OTUB1 in cancer development has not yet been thoroughly 
established. In fact, a recent study has revealed that OTUB1 might play a crucial role in 
colon cancer development and metastasis. OTUB1 expression levels in colon cancer 
tissues have been found to be 3.15-fold higher than in the corresponding non-
cancerous tissues (Liu et al., 2014). However, the role of OTUB1 in breast cancer has 
never been studied. OTUB1 has been reported to regulate various DDR proteins that 
have a role in cancer progression and metastasis, including ERα (Stanisic et al., 2009), 
RNF8, BRCA1 (Nakada et al., 2010), and p53 (Li et al., 2014; Sun et al., 2012).  
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Figure 1.11 The blocking of ubiquitin transfer. Normally, OTUB1 isolates UBC13, an 
E2 conjugating enzyme, from ubiquitin loading, interfering with the formation of the 
ubiquitin chain. This is different from other deubiquitinating enzymes that commonly 
work by detaching ubiquitin residue from the substrate protein. In the presence of DNA 
damage, such as the damage from ionising radiation, OTUB1 disengages from UBC13, 
allowing it to form ubiquitin chains, in this case, a K63-linked chain, in the presence of 
an E3 enzyme (RNF168), to be a DNA damage signal (Adapted from Rose and 
Schlieker, 2010).     
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1.12 Thesis Aims 
Chemotherapy resistance is the main obstacle in the treatment of breast cancer, 
especially for the patients who cannot be treated with hormonal therapy or other 
targeted treatments. Anthracyclines, including epirubicin, are effective first-line 
chemotherapeutic agents for breast cancer treatment. However, more than 90% of 
patients with metastatic cancer are found to be resistant to chemotherapeutic 
treatments (Lippert et al., 2011). FOXM1 is a transcription factor that is a key regulator 
of various cellular processes, including DNA damage repair response. FOXM1 
overexpression has been reported to be involved with tumourigenesis and cancer 
progression, including in breast cancer (Koo et al., 2012). Moreover, FOXM1 is also 
involved with the resistance to various treatments, for example, endocrinal therapy 
(Millour et al., 2010), cisplatin (Kwok, 2010), Paclitaxel (Carr et al., 2010), and, most 
recently, epirubicin (Khongkow et al., 2013; Millour et al., 2011; Monteiro et al., 2013). 
Previous studies show that FOXM1 is primarily regulated by PTMs in response to 
treatment with chemotherapeutic drugs. This normal control is deregulated in drug 
resistant cancer cells. Crucial to the understanding of the regulation of FOXM1 is the 
post-translational regulation of FOXM1, which has yet to be clearly understood. FOXM1 
has already been reported to be regulated by reversible phosphorylation throughout the 
cell cycle (Koo et al., 2012). In this thesis, I aim to study the role of SUMOylation and 
ubiquitination in terms of FOXM1 regulation, in response to epirubicin treatment. 
In addition, E3 ligases are important for the ubiquitination of FOXM1, as ubiquitination is 
mediated by the concerted actions and sequential activity of E1-E2-E3 enzymatic 
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cascade (Bergink and Jentsch, 2009; Grabbe et al., 2011). The well-known E3 ligases 
that have been reported to be involved with DDR are RNF4, RNF8 and also RNF168 
(Chapter 1.10). Understanding the interactions between these RNFs and FOXM1 might 
lead to a more thorough understanding of how FOXM1 can be regulated and how this 
control is deregulated in resistant breast cancer. This can be re-sensitised to 
chemotherapeutic agents. Moreover, OTUB1, a deubiquitination enzyme, has been 
reported to regulate various cancer related proteins, including, p53 (Li et al., 2014; Sun 
et al., 2012), and ERα (Stanisic et al., 2009). Interestingly, FOXM1 has previously been 
shown to be regulated by ER (Horimoto et al., 2011; Karadedou, 2006; Millour et al., 
2011) and p53 (Qu et al., 2013). Taken together these data, I hypothesised that FOXM1 
expression is regulated by PTMs in response to chemotherapeutic drug treatment. I  
also aimed to investigate the role of RNFs and OTUB1 in the regulation of FOXM1. If 
these proteins and their post-translation regulation were to have a strong impact over 
FOXM1 expression, they might become novel potential targets for treatment of breast 
cancer and for overcoming drug resistance.  
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1. Cell lines and cell culture 
The human breast cancer cell line, MCF-7 (Michigan Cancer Foundation – 7), was 
acquired from the Cell culture service of Cancer Research UK (London, UK). This cell 
line originated from the American Type Culture Collection (ATCC).  
MCF-7 EpiR cells are breast carcinoma cells which are epirubicin resistant. MCF-7 EpiR 
cells are non-clonal MCF-7 derivatives, generated in the laboratory. They are produced 
by culturing in medium supplemented with stepwise increases in amounts of epirubicin 
(Medac, Hamburg, Germany). The epirubicin concentration in the medium was 
increased until it reached a concentration of 10µM. The resistant cells were all 
maintained in medium supplemented with 10µM epirubicin. 
MCF-7 EpiR OTUB1 stable cell line was generated from MCF-7 EpiR cells transfected 
with pcDNA3-OTUB1 plasmid. Transfected cells were selected by using 1mg/ml of 
neomycin (G418) (Sigma-Aldrich, UK). Single cells were isolated using 96-well plate 
serial dilution before screening by Western Blotting and qPCR. 
Mouse embryonic fibroblasts (MEFs) wild type (Foxm1+/+) and Foxm1 knock-out 
(Foxm1-/-) cells were isolated from wild-type and Foxm1 nullizygous mouse embryos, as 
previously described (Laoukili et al., 2005). MEFs were used for investigating the role of 
FOXM1 as a model for FOXM1 null cells, compared to wt MEFs cells. Both types of 
MEFs were a gift from Professor René Medema, The Netherlands Cancer Institute, The 
Netherlands.  
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All cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-
Aldrich, UK) supplemented with 1% penicillin/streptomycin and 2 mmol/L L-glutamine 
(PSG, Sigma-Aldrich, UK), and 10% foetal calf serum (FCS, First (UK) Link Ltd., UK). 
Before being added to the media, PSG were filtered using a sterile 0.20 µm filter 
(Sartorius Stedim Biotech, UK). Cell lines were cultured at 37C with 10% CO2. For 
MCF7-EpiR cells, 10µM epirubicin was added to the medium (DMEM with FCS and 
PSG) maintaining the cells epirubicin resistance. 
2.1.1. Sub-culturing and long-term maintenance 
Cells were split when at ~60 - 70% confluence.  After washing with phosphate buffered 
saline (PBS) twice, cells were then trypsinised using 1x trypsin in EDTA solution 
(Sigma-Aldrich, UK). Trypsinisation was stopped by adding twice the volume of 
complete medium, before the cells were spun down at 300x g for 4 min to remove the 
trypsin. Cells were then resuspended in fresh complete medium and seeded as required 
in new flasks or dishes.  
 For long-term maintenance, cells were trypsinised and washed with PBS. Cells were 
spun down at 300x g for 4 min to remove supernatant, and then resuspended in 1 ml of 
90% (v/v) FCS and 10% (v/v) dimethyl sulphoxide (DMSO, Sigma-Aldrich, UK). The cell 
suspension was added to cryogenic vials (Corning, UK) and placed into a freezing 
container (Mr. Frosty, VWR International, Lutterworth, UK) and frozen in -80°C freezer. 
To defrost cells, cryogenic vials were taken from the freezer and placed in a 37°C water 
bath until defrosted. The cell suspension was then mixed with complete medium and 
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spun down at 200x g for 2 min to collect the cells. The supernatant was discarded, and 
the cell pellet resuspended with complete medium in flasks or dishes. 
2.1.2. Drug and treatment 
Epirubicin Hydrochloride [2 mg/ml (3400 μM) in 0.9% Sodium chloride, Medac, 
Germany] is an anthracycline drug used for cancer chemotherapy (hereafter referred to 
as epirubicin). Epirubicin, obtained from Imperial College Healthcare (UK), was used at 
1 µM for treating MCF-7 cells and MEFs.   
Cycloheximide (CHX, Sigma-Aldrich, UK) is a compound that inhibits protein synthesis. 
Proteins degraded by an ubiquitin-proteasome pathway are found to be decreased after 
CHX treatment. CHX powder is soluble in 100% ethanol. The stock solution was 
reconstituted at a concentration of 100 mg/ml. The cells were treated at the final 
concentration of 100 µg/ml.  
2.1.3. Single cells clone by serial dilution method 
To generate a stable cell line, cells were transfected with an expression vector with 
resistance to antibiotics. Selective antibiotics were used for selecting transfected cells 
from cells without DNA inserted. Single clones were isolated using a 96-well plate serial 
dilution (Corning, UK). During the process of cloning, cells were always cultured with the 
appropriate selective agent. The transfection efficiency was checked by using a western 
blotting and qPCR. 
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2.2. Molecular plasmids and transformation 
The pcDNA3-FOXM1 plasmid was cloned by Dr. Jimmy Kwok (previous PhD student in 
the laboratory). The pmCherry-FOXM1 plasmid was a gift from Dr. Cornelia Man (The 
Hong Kong Polytechnic University, Hong Kong). The pcDNA3-BRCA1 plasmid was a 
gift from Dr.Jenny Quinn (Queen’s University, Belfast). The pBOS-RNF4, pBOS-RNF4 
CS1 mutation and pcDNA3-RNF4 plasmids were from Professor Jan Brosens 
(Reproductive Health, University of Warwick, UK). The pcDNA3-OTUB1, pcDNA3-
RNF168 plasmids were kind gifts from Dr. Daniel Durocher (The Lunenfeld-Tanenbaum 
Research Institute Mount Sinai Hospital Joseph & Wolf Lebovic Health Complex, 
Canada). The HA-ubiquitin, FOXM1-Ubc9 and FOXM1 (5XK>R)-Ubc9 fusion, PGL2-
CyclinB1 promoter and PGL2-Cyclin B1 mutant promoter, eGFP-FOXM1 wt and eGFP-
FOXM1 5xK>R mutant plasmids were constructed by Dr. Stephen Myatt (previous 
postdoc in the laboratory). The tRFP-SUMO1 plasmid was a kind gift from Dr Simon 
Ameer-Beg (Guy’s hospital campus, King’s College London, UK).  
All plasmids were amplified in One Shot® TOP10 Chemically Competent E. coli 
(Invitrogen, UK) and plasmid DNA extracted using a QIAGEN plasmid MAXI kit 
(QIAGEN, UK) according to the manufacturer protocol.    
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2.3. Transfections 
2.3.1. FuGENE 6 transfection 
FuGENE 6 transfection reagent (Promega UK) was used for transfecting plasmid DNA 
to MCF-7 cells. First, cells were seeded to approximately 60% confluency on the next 
day. The ratio for Transfection of FuGENE 6: plasmid DNA was 3:1 according to 
manufacturer recommendation and the previous titration. Briefly, according to the 
manufacturer protocol, FuGENE 6 was diluted by DMEM serum free medium and 
incubated for 5 min. Plasmid DNA was then added to the FuGENE-DMEM dilution and 
left for another 15 min to incubate before gently adding to the cells. At least 24 h 
incubation at 37ºC with 10% CO2 was required prior to the drug treatment or other 
experiment procedures.       
2.3.2. XtremeGENE HP transfection 
In order to increase the efficiency of the Transfection, XtremeGENE HP reagent (Roche 
Diagnostics, UK) was used to transfect the eGFP-FOXM1 (wt and 5X K>R) plasmids to 
MCF-7 cells for using in confocal microscopy experiments. Cells were seeded to be 
approximately 60% confluent on the following day. The manufacturer protocol was 
followed; the ratio of XtremeGENE HP to plasmid DNA at 3:1 was used. Certain amount 
of plasmid DNA was diluted in DMEM serum free or Opti-MEM I Reduced Serum Media 
(Life technologies, UK) before XtremeGENE HP was added. The complex mixture was 
left for incubation for 15 min, and then added directly dropwise to the cells. Before 
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further experiment was carried out, the cells were incubated at 37ºC with 10% CO2 for 
no less than 24 h. 
2.3.3. Oligofectamine transfection 
In order to knock down genes for functional analysis, small interfering RNAs (siRNAs, 
Dharmacon, Epsom, UK) specific to the gene of interest were transfected into the cells 
using Oligofectamine reagent (Invitrogen, Life technologies, UK). At the first day, cells 
were seeded to be 70% confluenton the following day. The Oligofectamine mixture was 
prepared by adding oligofectamine to Opti-MEM and being incubated for 10 min. Then, 
the dilution of siRNA (50nM final concentration) in Opti-MEM and 1x siRNA buffer 
(Thermo scientific, UK) was added to the first mixture and left to incubate for 25 min. 
Following incubation, Opti-MEM was added until the manufacturer recommended 
volume was reached. The cells were washed with PBS after complete medium was 
removed. The mixture was then added to the cells dropwise and returned to the 
incubator at 37ºC with 10% CO2 for 4 h to 6 h before the addition of the complete 
media. The cells were placed back for further incubation for at least 24 h prior to 
experiments being carried out.  
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2.4. Protein preparation 
2.4.1. Protein lysate extraction 
Cells were harvested using trypsinisation and spun down at 300x g for 4 min to collect 
the cell pellets. The cell pellets were washed with PBS and transferred to 1.5 ml 
eppendorf tubes before being spun down for 4 min at 300x g. Cleaned cell pellets were 
then lysed with lysis buffer (50 mM Tris-HCl pH 7.8, 150 mM NaCl, 2 mM 
Ethylenediaminetetraacetic acid (EDTA), 1mM Dithiothreitol (DTT), 1% (v/v) Nonidet P-
40, 1 mM Phenylmethylsulfonyl fluoride (PMSF), 1 mM Sodium fluoride (NaF), 1 mM 
Sodium ortho-vanadate (Na3VO4) and 100 mM N-Ethylmaleimide (NEM), and a 
“complete” protease inhibitor cocktail (Roche Diagnostics, UK). Once the pellets were 
lysed, they were placed on ice for 20 min and placed on vortex every 10 min. The whole 
lysate (supernatant) was collected by centrifugation at 14000x g at 4°C for 10 min.  
The concentrations of the protein lysates were determined using the Bio-Rad Dc Protein 
Assay kit (Bio-Rad, UK). Following the manufacturer protocol, the protein concentration 
was determined by microtitre plate reader (Sunrise, Tecan, Reading, UK) at 700 nm 
wavelength,. Protein lysates were kept in a -80ºC freezer until further require. 
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2.4.2. Nuclear and cytoplasmic protein fractionation 
Sub-cellular protein fractionation is a method for studying nuclear-cytoplasmic 
localisation of proteins. In this study, fractionation was performed according to the 
manufacture protocol using NER-PER Nuclear and Cytoplasmic Extraction kit (Thermo 
Scientific, UK).  Cells were harvested by trypsinisation. Cell pellets were resuspended in 
200 µl of chilled CER I solution, containing complete protease inhibitor then vortexed at 
a high speed for 15 sec and incubated for a further 10 min on ice. After that, 11 μl of 
chilled CER II solution was added before vortexing for another 5 s and incubation on ice 
for 1min. The supernatant (cytoplasmic fraction) was then collected by centrifugation at 
13,000 xg 4°C for 5 min. The supernatant was transferred to a new pre-chilled 
eppendorf. The insoluble fraction was washed once with PBS (optional) before being 
lysed by chilled NER solution with complete protease inhibitor. The samples were then 
vortexed for 15 sec and incubated for 45 min (vortex every 10 min). Supernatant 
(nuclear fraction) was collected by centrifugation at 13,000 x g 4°C for 10 min. Both 
cytoplasmic and nuclear fractions were stored at -80°C until further use.      
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2.5. Western blotting 
Protein expression was investigated using western blotting. Proteins were separated 
according to their molecular weights by Sodium Dodecyl Sulphate-Polyacrylamide gel 
electrophoresis (SDS-PAGE). The proteins were then transferred to nitrocellulose 
membranes for immunoblotting and visualisation.  
2.5.1. SDS-PAGE and nitrocellulose membrane transferring 
SDS-PAGE consists of two parts: a stacking gel (upper part) and a resolving gel (lower 
part). The percentages of resolving gel (varying an amount of bis-acrylamide solution, 
Table 2.1) were adjusted depending on the size of the protein of interest. For example, 
the smaller the protein, the higher the percentage of bis-acrylamide solution would be 
used to make the SDS-PAGE gels. The polymerisation of the gel was catalysed by 
ammonium persulphate (APS) and tetramethylethylenediamine (TEMED).  
Protein lysate was prepared by mixing 25 µg of lysate with 2x SDS loading dye [2% 
(w/v) SDS, 350 mM DTT, 62.5 mM Tris buffer pH 6.8, 25% (v/v) glycerol and 0.001% 
(w/v) bromphenol blue]. Protein samples were denatured at 100°C for 5 min. Samples 
were loaded into the gel, Novex charp protein standard (Invitrogen, UK) served as a 
marked for determining molecular sizes.  
Proteins were separated by molecular weight in running buffer [0.1% (w/v) sodium 
dodecyl sulphate, 25 mM Tris, 190 mM glycine] at 90 V using a Bio-Rad Mini-
PROTEAN system (Bio-Rad, Hempstead, UK). The proteins on the gel were then 
transferred to Protran nitrocellulose membrane (Whatman International, Kent, UK) using 
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a Bio-Rad Trans-Blot cell wet transfer system (Bio-Rad, Hempstead, UK) in transfer 
buffer (25 mM Tris, 190 mM glycine and 20% Ethanol) at 90 V for 90 min on ice. 
Table 2.1 Ingredients of the different percentages of SDS-PAGE gels.  
 
Resolving gel stacking 
 
5% 7% 10% 12% 14% gel 
ddH2O (ml) 5.68 5.02 4.02 3.35 2.68 3.67 
1.5M Tris pH 8.8 (ml) 2.5 2.5 2.5 2.5 2.5 - 
1.5M Tris pH 6.8 (ml) - - - - - 0.42 
30% Acrylamide/ 
1.67 2.33 3.33 4 4.67 0.83 0.8% Bis Mix 
(37.5:1) (ml) 
10% SDS (μl) 100 100 100 100 100 50 
25% APS (μl) 40 40 40 40 40 20 
TEMED (μl) 10 10 10 10 10 10 
TOTAL (ml) 10 10 10 10 10 5 
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2.5.2. Antibodies 
The antibodies that were used in this study are following;  
Table 2.2 Lists of antibodies that were used in western blot 
 Antibody Company species Catalog No. 
Cyclin B1 Santa cruz Rabbit sc-752 
ERK Santa cruz Rabbit sc-292838 
Flag M2 Sigma-Aldrich Mouse F1804 
FOXM1 (C-20) Santa cruz Rabbit sc-17783 
GFP(B-2) Santa cruz Mouse sc-9996 
Lamin B Abcam Mouse 119D5 
OTUB1 Sigma-Aldrich Rabbit O9889-200UL 
PARP Cell signalling Rabbit #9542 
RFP Abcam Rabbit ab62341 
RNF168 R&D Systems Sheep AF7217 
RNF168 Home made Rabbit - 
RNF4 Novus Biologicals Mouse H00006047-A01 
RNF8 Abcam Rabbit ab4183 
SUMO1 Santa cruz Rabbit sc-5308 
β-tubulin  Santa cruz Rabbit sc-9104 
γH2Ax  Cell signalling Rabbit #9718 
Rabbit HRP Dako Goat P0448 
Mouse HRP Dako Goat P0447 
Sheep HRP Dako Rabbit P0163 
NOTE: RNF168 (Home-made) was a generous gift from Dr. Raimundo Freire , Hospital 
Universitario de Canarias, Spain. 
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2.5.3. Immunoblotting 
After removing nitrocellulose membranes from the transfer tank, protein transfer was 
confirmed by staining the membranes with Ponceau S (Sigma-Aldrich, UK). The red 
stain from Ponceau S was washed out by Tris-buffered saline with tween (TBS-T, 20 
mM Tris pH 7.6, 136 mM NaCl, 0.01% (v/v) tween). Having removed the stain, the 
membranes were blocked with 5% (w/v) BSA (BSA, Sigma) in TBS-T for 30 – 45 min. 
Membranes were incubated with primary antibodies in 5% BSA-TBS-T and 0.02% (v/v) 
azide overnight, shaking at 4°C.  
On the following day, the membranes were washed with TBS-T for 15 min 4times. The 
membranes were then incubated with secondary antibody conjugated with horseradish 
peroxidase (HRP) (Dako, Ely, UK) in TBS-T (1:5000 dilution) for 30 min, following this, 
the membranes were again washed 4 times (15 min per each wash). Once washed, 
Enhanced chemiluminescence detection system (ECL,Perkin Elmer, UK) was added to 
enable visualisation. Luminescence signal was detected using Amersham Hyperfilm 
ECL (GE Healthcare, UK) before being developed with a SRX-101A X-ray developer 
(Konica Minolta, Tokyo, Japan) or an Optimax 2010 X-Ray film processor (IGP, Essex, 
UK).            
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 2.6. Co-immunoprecipitation assay (co-IP) 
Cells were seeded and treated as usual, and then harvested using trypsinisation. Total 
protein lysate was prepared with lysis buffer as previously described. The protein 
concentrations were measured. The lysate was then pre-cleaned using Dynabeads (Life 
Technologies, UK) according to primary antibodies to be used for the IP experiments 
(protein A for rabbit antibody and protein G for mouse antibody). The mixes were 
rotated for 2 h at 4°C. After the pre-clean process, the Dynabeads were removed from 
the lysate using DynaMag magnetic stand (Life Technologies, UK). The lysates were 
then separated into 3 equal volumes (input, igG control and pull-down; ratio of each 
condition was 1:20:20). The input was mixed with 2x SDS loading dye, like the normal 
western blot process, before boiling at 100°C for 5 min and kept at -20°C until further 
use.  
For other conditions, lysate samples were incubated with a rabbit or mouse IgG 
negative control (Dako, UK) or specific primary antibodies on a rotator for 2 h at 4°C. 
After that, lysate was removed and the Dynabeads were washed 3 times with PBS. At 
the third wash, the Dynabeads were changed into a new eppendorf to avoid non-
specific adhesion to the old eppendorf. Proteins were eluted from the Dynabeads using 
2x SDS loading dye and boiled at 100°C for 5 min. Proteins were kept at -20°C until 
required.     
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2.7. Real-time reverse transcription quantitative PCR (RT-qPCR) 
2.7.1. Total RNA isolation and quantification 
Total RNA was extracted from cell pellets by using RNeasy mini kit (Qiagen, UK) 
according to the manufacturer protocol. Cells were briefly resuspended in Buffer RLT as 
recommended in the table 2.3:  
Table 2.3 Volumes of Buffer RLT for lysing cell pellets 
Number of cell pellets  Volume of Buffer RLT (μl) 
<5 x 106  350 
5 x 106 – 1 x 107  600 
Cell suspension was then directly transferred to a QIAshredder spin column which was 
placed into a 2 ml collection tube and centrifuged at 13,000 xg for 2 min to collect the 
flow through. The same volume of 70% ethanol was added to the lysate and mixed well. 
Samples were then transferred to an RNeasy spin column in a 2 ml collection tube and 
spun at ≥8000xg for 15 s, with the flow through discarded. The column membrane was 
then washed with 700 μl of Buffer RW1 and centrifuged for 15 s at ≥8000xg before 
washed for another 2 times with Buffer RPE. To ensure that no ethanol (from Buffer 
RPE) was left, the empty tube was spun down at 13,000 xg for a further minute 
(optional). For elution, the column was placed into a new 1.5 ml collection tube and 
eluted with 30–50 μl of RNasefree water. The eluted RNA concentration was measured 
using a NanoDrop ND-1000 (Thermo Scientific, UK) and the sample stored at -80°C 
until needed for further experiments. 
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2.7.2. cDNA synthesis 
Complementary DNA (cDNA) was synthesised from 1 μg of total RNA. Reverse 
transcription was performed using Superscript lll first strand cDNA synthesis (Life 
technologies, UK). 1μl of 50μM oligo(dT)20 Primer (Life technologies, UK) and 1μl of 
10mM dNTPs (Life technologies, UK) were added to RNA. The volume of the mix was 
adjusted with Ambion DEPC-treated water (RNase-free water, Life technologies, UK) up 
to 13 μl. The mixture was incubated at 65ºC for 5 min before being cooled down at 4ºC 
for 4 min. One μl of reverse transcriptase Superscript III (200U/μl), 1μl of 0.1M DTT, 1μl 
of RNsaeOUT recombinant RNase inhibitor and 1x first-stand buffer (All are from Life 
technologies, UK ) were added to the first mixture. The mixture was incubated at 25°C 
for 5 min, then at 50°C for 60 min, and 70°C for 15 min (in the thermo cycler). The 
cDNA-containing mixture was diluted at the ratio of 1:4 with Ambion DEPC-treated 
water and kept at -20°C until qPCR analysis.   
2.7.3. Primers design and optimisation 
In this study, all primers were designed using Primer Express 3.0 software (Applied 
Biosystems, UK). This software produced an amplicon between 100 – 200 bp, 
according to the gene sequences from Pubmed (National Center for Biotechnology 
Information: NCBI, USA). Newly designed primers were optimised to find the 
concentration ratio of the primer. The standard curve from each concentration ratio was 
checked for an equation slope (theoretically between -3.3 to -3.8) and R2 (should not be 
lower than 0.98). A list of primers is shown in Table 2.4 (Primers are written 5’ to 3’) 
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Table 2.4 List of gene-specific primers which were used for qPCR 
Gene species Sense Antisense 
L19 Human GCGGAAGGGTACAGCCAAT GCAGCCGGCGCAAA 
L19 Mouse CCCGTCAGCAGATCAGGAA GTCACAGGCTTGCGGATGA 
FOXM1 Human TGCAGCTAGGGATGTGAATCTTC GGAGCCCAGTCCATCAGAACT 
FOXM1 Mouse GCAGAATCGGGTTAAGGTTGAG GACACAGAGTCCTGCCAAGATGT 
OTUB1 Human CAGGCCTGACGGCAACTG AGTGCCTCCAAGTGGGAGAA 
OTUB1 Mouse CGGCCTGATGGCAACTG TGCCTCCAGGTGGGAGAA 
RNF4 Human GTGTAGCATGTCTGCCCTCTGA GCCGTGATGCCCAGAAGA 
RNF8 Human CCCCAAAGAATGACCAAATGATA CAGGACCTGCTAATTCATCCAAA 
RNF168 Human AAGAGCAAATGGTGCCAAAC GGTGTTGGATGCTTTGTGTG 
CCNB1 Human CAGTTATGCAGCACCTGGCTAAG TGTGGTAGAGTGCTGATCTTAGCAT 
BRCA1 Human GCGGACTCCCAGCACAGA GCTTATTCCATTCTTTTCTCTCACACA 
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2.7.4. Quantitative Polymerase chain reaction (qPCR) 
The quantitative polymerase chain reaction (qPCR) was performed using a SYBR-green 
master mix (Applied Biosystem, UK) and run in a 7900HT fast real-time PCR system 
(Applied Biosystem, UK). Per one reaction, 2 µl of cDNA were mixed with 12.5 μl of 
SYBR-green master mix and optimised volumes of primers and made up to 25 µl with 
Ambion DEPC-treated water. The standard curve was produced from the mixture of 5 μl 
cDNA from every sample, and then diluted 1:4 for 4 serial dilutions. DEPC-treated water 
was used as no template control. 7900HT fast Real-time PCR system was set as: 95°C 
for 10 min for enzyme activation and followed by 40 cycles at 95°C for 10 s 
(denaturation) and 60°C for 30 s (primer annealing/extension). Gene expression was 
quantified using a standard curve and normalised to the L19, a non-regulated ribosomal 
housekeeping gene, which served as an internal control. All measurements were in 
triplicate. A dissociation curve was used to confirm an absence of non-specific 
amplicon.  
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2.8. Sulphorhodamine-B assay (SRB) 
Cells were seeded in 96-well plates (~5,000 cells/well) and left to grow at 37°C with 
10% CO2 overnight. On the following day, the cells were treated with the drug of 
interest. To harvest, cells were fixed by adding 100 µl of ice-cold 40% (w/v) 
trichloroacetic acid (TCA, Sigma-Aldrich, UK) to each well and incubated at 4°C for 1 h. 
Plates were rinsed 3 times with slow running water before being stained with 100 µl of 
0.4% (w/v) Sulphorhodamine-B (SRB, Sigma-Aldrich, UK) in 1% (v/v) acetic acid (VWR 
International, UK), followed by incubation for 1 h at room temperature. Following 
incubation, the plates were washed with 1% (v/v) acetic acid and left to be dry 
overnight. For measurement, 100 µl of 10 mM Tris-base (VWR International, UK) was 
used to dissolve SRB from cells in a shaker for 30 min. Optical density (OD) was read at 
492 nm using a microtitre plate reader (Sunrise, Tecan, Reading, UK). Results were 
normalised to untreated or control wells. This assay was used for measuring protein 
content, the difference between each condition was assumed to be equivalent to a 
difference of the number of cells.   
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2.9. Luciferase reporter assay 
Cells were grown in 96-well plates (approximately 5,000 cells/well) and left in an 
incubator at 37°C 10% CO2 overnight. On the following day, using FuGENE 6 
transfection reagent, cells were co-transfected with a Luciferase reporter plasmid, 
Renilla plasmid (pRL-CMV, Promega, UK), transfection efficiency control, and the 
expression plasmid of interest.  
To harvest, after 24 h of transfection, cells were washed with PBS before being lysed 
with 100 µl/well of 1x Steady lite plus reagent (Perkin Elmer, UK) and incubated for 15 
min in a dark environment. Lysates were transferred to a luciferase plate (Perkin Elmer, 
UK) where the emission of Luciferase-derived light can be measured using a 
PHERAstar Plus microplate reader (BMG Labtech, Aylesbury, UK). Then, 25 μl of the 
renilla substrate mix (1% (w/v) coelenterazine (Lux Biotechnology, UK), 0.04 M EDTA, 
0.5 M HEPES pH 7.8) was added to each well and incubated 20 min in the dark. The 
presence of EDTA inhibited the Luciferase enzyme. The luminescence light from Renilla 
was measured using the PHERAstar Plus microplate reader.  
The Luciferase reading was normalised to the renilla reading, well by well. All 
measurements were performed in six replicates. 
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2.10. Immunofluorescent staining (IF) 
Cells were grown on 4-chamber culture slides (BD Biosciences, UK) and transfected or 
treated as usual. Before staining, cells were washed twice with PBS and fixed with 4% 
(v/v) paraformaldehyde (PFA, Sigma-Aldrich, UK) in PBS for 15 min. The fixed cells 
were washed 3 times with PBS and then permeablilised with 0.2% (v/v) Triton X-100 
(Sigma-Aldrich, UK) in PBS for 10min. Cells were then washed another 3 times before 
5% (v/v) goat serum (Sigma-Aldrich, UK) in PBS was added for 30 min to block the non-
specific binding. Next, the cells were incubated in primary antibody diluted in 0.2% (v/v) 
goat serum at 4°C overnight. The excess antibodies were removed by washing with 
PBS 3 times. Once the cells were washed, Secondary antibodies (table 2.5) in PBS 
were added to the cells and the mixtures were left to incubate in the dark for 45 min.  
Stained cells were then washed with PBS 3 times before the chambers were removed 
from the slides. The nucleus of the cells was stained and slides were mounted using 
Vectashield Mounting Medium with 4',6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories, USA) and covered by cover-slips. Slides were sealed using a clear nail 
vanish and kept at 4°C until visualised. Images were taken using a Leica TCS SP5 
confocal microscope (Leica Microsystems, Germany) with 63x objective and LAS-AF 
software.     
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Table 2.5 List of antibodies which were used for IF staining 
Antibodies Colour species company Catalog No. 
SUMO1 (primary) Rabbit Cell Signalling #4930 
FOXM1 (primary) mouse MyBiosource MBS120349 
RNF168 (primary) Rabbit Home Made - 
Alexa Fluor 488 anti Rabbit Green goat Lift Technologies A-21070 
Alexa Fluor 555 anti Rabbit Green goat Lift Technologies A-21428 
Alexa Fluor 488 anti mouse Red goat Lift Technologies A-10680 
Alexa Fluor 555 anti mouse Red goat Lift Technologies A-21422 
 
2.11. Fluorescence lifetime imaging microscopy and Fluorescence 
Resonance Energy Transfer (FLIM-FRET) 
Cells were seeded in 96-well plate overnight. The next day, cells were co-transfected 
with FRET donor and acceptor using XtremeGENE HP transfection (Roche Diagnostics, 
UK). After 24 h of transfection, cells were treated with epirubicin at various time points. 
To harvest, cells were washed and immersed in Hanks' Balanced Salt solution supplied 
with glucose and L-glutamine. FLIM-FRET measurement was done by Douglas Kelly, a 
PhD student in a Photonics Group, Department of Physics, Imperial College London, 
South Kensington Campus, London, UK, using an automated 96-well plate reading 
FLIM microscope Olympus IX81-ZDC (Olympus, UK) as previously described (Alibhai et 
al., 2013). Images were acquired with 40x long working distance air objective with an 
NA of 0.6 using Olympus LUCPLFLN 40X objective lens (Olympus, UK). Data were 
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analysed using FLIMfit software which was developed by the photonics group (Imperial 
College London, UK)  
2.12. COMET Assay (Single cell gel electrophoresis, SCGE) 
Microscopy slides with double frosted 45º ground edges (Thermo Scientific, UK) were 
emerged in 1% (w/v) normal melting point agarose (NMA, Promega, UK) in H2O to 
prepare the pre-coated first layer. These slides were kept in 4ºC until further use. 
Cell pellets were re-suspended in 0.7% (w/v) of low melting point agarose (LMA, 
Promega, UK) in PBS at 37°C and spread homogenously on pre-coated glass slides. 
Slide with cells were then coated with 0.7% (w/v) LMA and immersed into ice-cold lysis 
buffer (2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris, 10% (v/v) DMSO, 1% (v/v) Triton X-
100, 1% (v/v) sodium sarcosinate, 250mM NaOH pH10, and N-lauroylsarcosine) for 1 h. 
The coating was done for one more layer. After being lysed, slides were placed in an 
electrophoresis tank filled with alkaline electrophoresis buffer (1 mM Na2EDTA, 150 mM 
NaOH pH 12.8). The electric current was adjusted between 250 and 300 mA. 
Electrophoresis was performed on ice at 25 V for 15 min in the dark. Slides were 
immediately subjected to neutralised buffer (400 mM Tris pH 7.5) twice for 5 min. The 
nuclei were stained with DAPI. The slides were covered with cover slips. Individual cells 
was visualised using a Nikon Eclipse E400 Upright Microscope (Nikon, Japan) 
connected with a digital CCD camera ORCA-03G C8484-03G02 (Hamamatsu, Japan). 
DNA double strand breaks were analysed using the COMET assay IV software 
(Perceptive Instruments, UK).      
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CHAPTER 3 
FOXM1 AND ITS MODIFICATION BY 
SUMOYLATION IN RESPONSE TO 
CHEMOTHERAPY IN BREAST CANCER 
CELLS 
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3.1 Introduction and Objectives 
Anthracyclines, such as doxorubicin and epirubicin, are typical chemotherapeutic drugs 
for breast cancer therapy. They are members of the Streptomyces peucetius–derived 
antibiotics. The main mechanism of anthracyclines is inhibiting the nuclear 
topoisomerase ll (TOPO ll) enzyme (Nielsen et al., 1996) by restraining its catalytic 
activity (Stearns et al., 2004). Anthracyclines form a complex with DNA by intercalating 
between base pairs. Anthracyclines is the preferred treatment for advanced stage 
breast cancer, especially for hormone receptor (ER/PR) negative counterparts (Palmieri 
et al., 2010). For patients who relapse from other treatments, such as endocrine 
therapy, chemotherapy is the only option.  
Forkhead box protein M1 (FOXM1) is a transcription factor that plays a key role in 
various cell regulation mechanisms such as cell cycle control, cell proliferation, 
apoptosis, DNA damage and repair (Koo et al., 2012). In response to genotoxic drugs, 
FOXM1 mediates drug resistance and enhances DNA repair by controlling DNA repair 
genes including BRIP1 (Monteiro et al., 2013), NBS1 (Khongkow et al., 2013) and 
Rad51 (Zhang et al., 2012). FOXM1 has been found to be upregulated in various 
cancers. In breast cancer, FOXM1 is involved in resistance to various cancer 
treatments, for example, endocrine therapy (Millour et al., 2010), cisplatin (Kwok, 2010), 
paclitaxel (Carr et al., 2010), and, especially, epirubicin (Khongkow et al., 2013; Millour 
et al., 2011; Monteiro et al., 2013).  
FOXM1 has been reported to be controlled by different PTMs. One of these 
modifications is phosphorylation. In an inactive stage, transcriptional and 
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transactivational activity of FOXM1 is suppressed by its own N-terminal autorepressor 
domain (NRD) in G1 and early S phases (Koo et al., 2012). This NRD binds directly to 
its C-terminal transactivation domain (TAD) (Park et al., 2008). Phosphorylation of 
FOXM1 is increased throughout cell cycle progression from G1 to S and G2 phases. 
During G2, FOXM1 is phosphorylated by cyclin A-CDK complexes. This allows FOXM1 
to be free from its autorepression (Laoukili et al., 2008). Additionally, phosphorylation of 
FOXM1 also culminates with its nuclear translocation during G2/M phase (Koo et al., 
2012; Laoukili et al., 2008). At the mitosis exit, FOXM1 is dephosphorylated (Chen et 
al., 2009; Fu et al., 2008). Although many studies report about the phosphorylation of 
FOXM1, other PTMs including SUMOylation and ubiquitination remain poorly 
understood.  
SUMOylation is a reversible PTM by the small ubiquitin-related modifier (SUMO) 
proteins. Although the structure of SUMO is similar to that of ubiquitin, the cellular 
outcomes of SUMOylation can be distinct from ubiquitination. While ubiquitination 
targets a protein for proteolytic breakdown or sub-cellular redistribution, SUMOylation 
takes part in various pathways, including sub-cellular localisation of SUMO-target 
protein such as RanGAP1. Besides regulating its nuclear translocation, SUMOylation of 
RanGAP1 is also required for its recruitment to the mitotic spindle during the mitosis 
(Joseph et al., 2002). In a study with Dictyostelium, SUMOylation is required for the 
nuclear export of MEK1, under starvation conditions (Sobko et al., 2002). SUMOylation 
has also been found to have a role in cell cycle progression. In a study of yeast, 
mutation of SUMO-activating enzyme (E1) and SUMO-conjugating enzyme (E2) results 
in cell cycle arrest at the G2/M phase. In addition, SUMO modifications are necessary 
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for anaphase-promoting complex/cyclosome (APC/C) activity in order to control cell 
cycle progression through SUMOylation-ubiquitination crosstalk (Hay, 2005). Moreover, 
SUMOylation has also been reported to involve in DNA damage response. For 
example, SUMOylation is required for an assembly of promyelocytic leukaemia nuclear 
(PML) bodies to participate in the DNA damage repair (Kerscher et al., 2006). 
SUMOylation of proliferating cell nuclear antigen (PCNA) is also important for RAD6-
dependent DNA repair (Watts, 2006).  
SUMOylation has been reported to have a fundamental role in regulating other forkhead 
proteins such as FOXA1 (Bao et al., 2011; Belaguli et al., 2012) and FOXC1/2 (Danciu 
et al., 2012). Interestingly, SUMOylation of these forkhead proteins leads to an inhibition 
of their function. In this chapter, I hypothesised that FOXM1 might be modified by 
SUMOylation. Therefore, I investigated the effect of SUMOylation on the role of FOXM1 
in response to epirubicin. This should lead to a better understanding of how FOXM1 is 
regulated by post-translational modification, especially SUMOylation and ubiquitination. 
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3.2 Results 
3.2.1 FOXM1 is involved in epirubicin resistance 
FOXM1 is widely known to promote cellular migration and invasion, DNA damage 
repair, and chemotherapeutic drug resistance including epirubicin, an anthracycline 
chemotherapeutic drug (Millour et al., 2011). In order to confirm the importance of 
FOXM1 in epirubicin resistance (Monteiro et al., 2013), previously reported by our 
previous PhD student in the lab (Dr. Lara Monteiro), MCF-7 and MCF-7 EpiR cells were 
treated with 1 μM epirubicin and harvested at different time points (0, 4, 8, 16, 24, and 
48 h) for western blotting analysis. The expression levels of FOXM1, PARP, cyclin B1, 
γH2Ax and β-tubulin were determined. The results showed a decrease in FOXM1 
protein levels after treatment with epirubicin in MCF-7 cells. In contrast, FOXM1 protein 
levels in MCF-7 EpiR cells were stably expressed throughout the time course of 
epirubicin treatment (Figure 3.1A). Cyclin B1 was used as a positive control for the 
activity of FOXM1 as this is a well-established downstream target of FOXM1 (Leung et 
al., 2001). Accordingly, the down-regulation of FOXM1 activity observed in MCF-7 cells 
was also confirmed by a reduction in the expression levels of cyclin B1. Cleaved poly-
ADP ribose polymerase (PARP, arrow) and γH2Ax are known markers of apoptosis and 
DNA damage responses, respectively. MCF-7 cells exhibited an increase in cleaved 
PARP after 24 h of epirubicin treatment and also displayed higher γH2Ax expression 
compared with MCF-7 EpiR cells. 
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FOXM1 mRNA levels were also analysed using qPCR. The mRNA levels correlated 
with the results from western blotting; the expression of FOXM1 decreased after 
treatment with epirubicin in MCF-7 cells. In MCF-7 EpiR cells, FOXM1 mRNA levels 
were also shown to be highly expressed both before and after epirubicin treatment 
(Figure 3.1B). The resistant phenotype of MCF-7 EpiR cells was confirmed using SRB 
assay. The result showed that MCF-7 cells were significantly more sensitive to 
epirubicin compared with MCF-7 EpiR cells especially after treatment with 
concentrations higher than 0.2 μM (Figure 3.2).  
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Figure 3.1 Time course experiment in MCF-7 and MCF-7 EpiR cells. MCF-7 and 
MCF-7 EpiR cells were treated with 1 μM epirubicin and harvested at different indicated 
time points (0, 4, 8, 16, 24 and 48 h). A. Protein lysates were extracted and analysed by 
western blotting. B. The mRNA levels of FOXM1 of each time point was analysed by 
qPCR. Statistical analysis was performed using Student’s t-test. (**, p ≤ 0.001; ***, ≤ 
0.0001 significant; ns, non-significant) 
A 
B 
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Figure 3.2 MCF-7 EpiR cells are more resistant to epirubicin than MCF-7 cells. 
MCF-7 and MCF-7 EpiR cells were treated with various indicated concentrations of 
epirubicin for 24 h. Cell proliferation was measured by SRB assay. The result was 
normalised to the untreated control (0 μM concentration). Results represent the average 
of three independent experiments including 6 replicates ± SD. Statistical analysis was 
performed using Student’s t-test. (**, p ≤ 0.001; ***, ≤ 0.0001 significant; ns, non-
significant) 
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3.2.2 Foxm1-/- MEFs are significantly more sensitive to epirubicin than wt MEFs 
To confirm the role of FOXM1 in epirubicin resistance, I used SRB assay to compare wt 
and Foxm1-/- MEFs. The cells were treated with epirubicin at various concentrations for 
24 h.  The result revealed that Foxm1-/- MEFs were more sensitive to epirubicin 
compared with wt MEFs, especially at high epirubicin concentrations, 0.5 μM to 1 μM 
(Figure 3.3).  To further analyse the importance of FOXM1 in DNA damage, COMET 
assay was performed under an alkaline condition using wt and Foxm1-/- MEFs. Cells 
were treated with 1 μM epirubicin and harvested at 0, 6 and 24 h after treatment.  The 
cell pellets were resuspended in low-melting point agarose (LMA) before being used for 
electrophoresis. The cellular DNA was stained with DAPI. Images were captured using 
40x magnification objective. The percentage of the DNA in tail was quantified using 
COMET IV software. The results showed that at 6 h Foxm1-/- MEFs had a significantly 
higher percentage of DNA in tails (damaged DNA) compared with wt MEFs (Figure 
3.4A). At 24 h, the percentage of the DNA in tails of wt and Foxm1-/- MEFs showed no 
significant difference (Figure 3.4A), but there were fewer Foxm1-/- MEFs, compared with 
wt MEFs (Figure 3.4B). This showed that Foxm1-/- MEFs have fewer surviving cells after 
24 h of epirubicin treatment compared with wt MEFs. In conclusion, the cells with lower 
FOXM1 expression were more sensitive to epirubicin and had more DNA damage than 
the cells with higher FOXM1 expression levels. This data confirms that FOXM1 has an 
important role in mediating epirubicin resistance.  
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Figure 3.3 Foxm1-/- MEFs are more sensitive to epirubicin than wt MEFs. Foxm1-/- 
MEFs and wt MEFs were treated with various indicated concentrations of epirubicin for 
24 h. Cell proliferation was measured by SRB assay. The result was normalised to the 
untreated control (0 μM concentration). Results represent the average of three 
independent experiments including 6 replicates ± SD. Statistical analysis was performed 
using Student’s t-test. (**, p ≤ 0.001; ***, ≤ 0.0001 significant; ns, non-significant) 
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Figure 3.4 Foxm1-/- MEFs show more DNA damage than wt MEFs after epirubicin 
treatment. Foxm1-/- and wt MEFs were treated with 1 μM epirubicin and harvested after 
0, 6 and 24 h of the treatment. The cells were used to perform the COMET assay to 
examine the DNA damage.   A. Images were acquired with a Nikon Eclipse E400 
Upright microscope (40x magnification objective). B. DNA damage was quantified using 
COMET Assay IV software and measured for percentages of DNA in tail. Represented 
data are the average of two independent experiments (**, p ≤ 0.001; ***, ≤ 0.0001 
significant; ns, non-significant). 
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Figure 3.4  (continued) 
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3.2.3 FOXM1 can be modified by Small ubiquitin-related modifier1 (SUMO1) 
Since our previous data shown that FOXM1 plays a critical role in epirubicin resistance, 
investigation of FOXM1 regulation might beneficial in order to overcome 
chemotherapeutic drug resistance. As SUMOylation is also important in DNA damage 
response (Galanty et al., 2009; Morris et al., 2009), I hypothesised that FOXM1 might 
be modified by SUMOylation and this could have a role in the epirubicin-mediated DNA 
damage response.  
In order to test this hypothesis, MCF-7 cells were transfected with 
SUMO1/SUMO2/SUMO3 or empty vector control, together with the wt FOXM1 
expression vector before the total protein lysates were used for western blotting 
analysis. The result showed multiple higher molecular weight bands (poly-SUMOylation) 
in FOXM1-SUMO1 co-expression condition, but this is not the case for the SUMO2, 
SUMO3 (SUMO2/3) or empty vector control (pcDNA3) transfected conditions (Figure 
3.5). This result suggests that FOXM1 is predominantly targeted by SUMO1.  
To confirm the presence of an interaction, MCF-7 cells were transfected with pcDNA3-
Flag-FOXM1 (FOXM1) or pcDNA3-Flag empty vector control (Flag), together with tRFP-
SUMO1. After 24 h of transfection, cells were treated with 1 μM epirubicin and 
harvested at 0, 6, 24 and 48 h after treatment with epirubicin. Immunoprecipitation was 
performed using ANTI-FLAG M2 affinity gel beads to pull down the Flag-tagged protein. 
Input and eluent were analysed by western blotting and probed with various specific 
antibodies (FOXM1, SUMO1, and Flag). Higher molecular weight bands were only 
found in the pcDNA3-Flag-FOXM1 transfected cells and were absent in the pcDNA3-
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Flag empty vector transfected control (Figure 3.6). After 24 and 48 h of epirubicin 
treatment, the bands that correspond to the FOXM1-SUMO1 decreased in response to 
epirubicin treatment. This result further confirms the interaction between FOXM1 and 
SUMO1 and also that epirubicin has an effect on it.  
A covalent interaction between SUMO1 and FOXM1 was identified using Ni2+ pull down 
from His-tagged SUMO1 (His-SUMO1) expressing cells. The experiment was 
performed in collaboration with Dr. Stephen Myatt from our lab. MCF-7 cells were co-
transfected with FOXM1, Ubc9 and His-SUMO1. First, the His-tagged protein was 
pulled down using Ni2+-column under denaturing conditions (8M urea) to prevent de-
SUMOylation and proteolysis.  The expression of FOXM1 was analysed by western 
blotting. The higher molecular weight bands corresponded to SUMOylation of FOXM1 
(Figure 3.7A).  
In addition, an in vitro SUMOylation assay (Enzo Life Sciences, Exeter, UK) was also 
used to confirm the interaction between SUMO1 and FOXM1. From the preliminary 
experiment done by Dr. Stephen Myatt, in vitro SUMOylation assays exhibited FOXM1 
SUMOylation in an ATP-dependent manner (Figure 3.7B). 
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Figure 3.5 FOXM1 interacts with SUMO1 but not SUMO2/3. MCF-7 cells were 
transfected with FOXM1 together with or without SUMO1 or SUMO2 or SUMO3. The 
cells were harvested 24 h after transfected and used for western blotting. The 
immunoblots were probed using antibodies against FOXM1, SUMO1, SUMO2/3 and β-
tubulin (used as a loading control). Multiple higher molecular weight bands were 
observed (higher than FOXM1: 105 KDa). This experiment was performed in 
collaboration with Dr. Stephen Myatt.  
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Transfection:         pcDNA3/SUMO1         pcDNA3-FOXM1/SUMO1   
        
 
 
Figure 3.6 Confirmation of the interaction between FOXM1 and SUMO1 and its 
degradation after epirubicin treatment. MCF-7 cells were transfected with pcDNA3-
Flag-FOXM1 or pcDNA3-Flag empty vector control, and tRFP-SUMO1. The transfected 
cells were treated 1 μM epirubicin and harvested at different indicating time points (0, 6, 
24 and 48 h).  Co-IP was performed using ANTI-FLAG M2 Affinity Gel to pull down the 
Flag-tagged protein. Input represents 1:10 dilution of the pull down. Eluent was 
analysed by western blotting and the expression of FOXM1, SUMO1, and Flag were 
determined.  
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Figure 3.7 FOXM1 interacts with SUMO1 via covalent bond. A. FOXM1, Ubc9 and 
His-tagged SUMO1 were co-expressed. SUMOylated proteins were purified under 
denaturing conditions (8 M urea) using Ni2+ column affinities pull down. Input and His-
tagged protein were analysed by western blotting and probed with antibodies against 
FOXM1. B. His-tagged FOXM1 was induced to be expressed in E. coli using IPTG and 
isolated with Ni2+ column affinity pull down. The extracted lysates from E. coli in the 
presence or absence of IPTG were incubated with Ubc9 and SUMO1 with and without 
Mg2+-ATP in reaction buffer. SUMOylation of FOXM1 was examined using western 
blotting. These two experiments were performed in collaboration with Dr. Stephen 
Myatt. 
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3.2.4 The interaction of FOXM1 and SUMO1 increases after 6 h of epirubicin 
treatment before decreasing after 24 h of the treatment 
Co-immunoprecipitation was used to study the interaction between FOXM1 and 
SUMO1. Input and eluent were analysed by western blotting. Higher molecular weight 
bands (160kDa) were found confirming that FOXM1 forms higher order complexes with 
SUMO1. The results from MCF-7 cells (Figure 3.8A and 3.8C) showed a stronger 
interaction of FOXM1-SUMO1 compared to MCF7 EpiR cells (Figure 3.8B and 3.8D). 
Interestingly, the endogenous FOXM1 levels in MCF-7 cells decreased after epirubicin 
treatment for 24 h (Figure 3.8C). However, the higher molecular weight band for 
FOXM1-SUMO1 complex remained constant. This suggests that there is an increase 
onFOXM1 SUMOylation upon epirubicin treatment in MCF-7 cells.     
To confirm the increase in the interaction between FOXM1 and SUMO1 after epirubicin 
treatment, immunofluorescent staining was performed. MCF-7 and MCF-7 EpiR cells 
were treated with 1 μM epirubicin and harvested at different time points (0, 6, 24 and 48 
h). Cells were then fixed with 4% paraformaldehyde (PFA) and stained with FOXM1 
(Alexa488, shown as green), SUMO1 (Alexa555, shown as red) and DAPI (blue). The 
merged (yellow colour) showed the co-localisation of FOXM1 and SUMO1 (Figure 3.9). 
In accordance to the co-IP results, there was an increase in the FOXM1-SUMO1 
interaction in MCF-7 especially after 6 h of epirubicin treatment, but this was not 
observed in MCF-7 EpiR cells. In contrast, there was a weaker FOXM1-SUMO1 
interaction in MCF-7 EpiR cells compared to MCF-7 cells. After 24 h and 48 h of 1 µM 
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epirubicin treatment, the levels of co-localisation of FOXM1-SUMO1 were decreased in 
MCF-7 cells, but not in MCF-7 EpiR cells.  
In collaboration with the Photonic group (Imperial College London, South Kensington 
Campus), Douglas Kelly (a PhD student) kindly helped me to perform the Fluorescence 
Lifetime Imaging and Förster resonance energy transfer (FLIM-FRET) experiment to 
confirm the interaction between FOXM1 and SUMO1, after epirubicin treatment. MCF-7 
cells were co-transfected with eGFP-FOXM1 (donor) and tRFP-SUMO1 (acceptor). 
FLIM-FRET is used for measuring the exponential decay rate of fluorescent proteins. 
When two proteins are close enough (approximately less than 10 nm), there is energy 
transfer between the two fluorescent proteins. The energy transfer from the donor 
protein (in this case eGFP) to the acceptor protein (in this case tRFP) results in 
decreasing the lifetime of the donor fluorescence (Ishikawa-Ankerhold et al., 2012). 
The FLIM-FRET result exhibited an increase in decay of the eGFP donor signal after 
treatment with epirubicin at 6 and 8 h (Figure 3.10). This result indicates that the 
FOXM1-SUMO1 interaction increased after epirubicin treatment. In contrast, the control 
condition (eGFP-FOXM1 with tRFP empty vector) showed little or no decay of eGFP-
FOXM1 donor. This indicates that the decay of eGFP signals in FOXM1-SUMO1 co-
transfected conditions was due to the FRET from the FOXM1-SUMO1 interaction.  
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Figure 3.8 Co-immunoprecipitation (co-IP) shows an interaction between FOXM1 
and SUMO1. MCF-7 and MCF-7 EpiR cells were treated with 1 μM epirubicin and 
harvested after 0, 6 and 24 h of the treatment. Antibodies against SUMO1 were used to 
perform co-immunoprecipitation and probed for FOXM1, and vice versa. Input 
represents 1:10 dilution of pull down and IgG was used as a negative control. Protein 
eluent from beads and input were analysed using western blotting. Higher molecular 
weight bands confirmed the interaction between FOXM1 and SUMO1 (shown in 
asterisk, *)    
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Figure 3.9 Immunofluorescent staining shows co-localisation of FOXM1 and 
SUMO1. A. MCF-7 and B. MCF-7 EpiR cells were treated with 1 µM epirubicin and 
harvested at 0, 6, 24 and 48 h after the treatment. The treated cells were then fixed with 
4% PFA before being stained with antibodies against FOXM1 (Alexa488, shown as 
green), SUMO1 (Alexa555, shown as red) and DAPI (blue). Images were taken using a 
Leica TCS SP5 confocal microscope (Leica Microsystems, Germany) with 63x objective 
and LAS-AF software. Images are the representative of 3 independent experiments, 
results obtained from at least 10 different fields.  
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Figure 3.9 (continued) 
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Figure 3.10 FLIM-FRET confirms an increase in the interaction of FOXM1-SUMO1 
following epirubicin treatment. FLIM-FRET experiment was performed by Douglas 
Kelly, a collaborator from the photonic group (Imperial College London, South 
Kensington campus, London, UK). MCF-7 cells were co-transfected with eGFP-FOXM1 
and tRFP-SUMO1. The transfected cells were used for performing the FLIM-FRET 
experiment after epirubicin treatment at indicated time points. Fluorescent life time was 
analysed and the graph was plotted using the mean lifetime ± SEM (standard error of 
the means). Statistical analysis was obtained with Tukey’s HSD test compared with 0h 
(*, p < 0.05 significant; ns, non-significant)  
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3.2.5 FOXM1 is SUMOylated at multiple sites 
In order to get better insights into which FOXM1 sites could be potentially SUMOylated, 
I used SUMOplot (http://www.abgent.com/tools, Abgent, UK) and SUMOsp 
(http://sumosp.biocuckoo.org, CUCKOO Workgroup, University of Science & 
Technology of China, China) to predict FOXM1 SUMOylation sites (Figure 3.11A, B). 
The predicted sites were then mutated using the site-direct mutagenesis kit to create 
the FOXM1 5x(K>R) mutant plasmid. This plasmid carried 5 point mutations that 
created SUMO modification sites, by changing the lysine residues into arginine. This 
plasmid was generated by Dr.Stephen Myatt.    
MCF-7 cells were transfected with FOXM1 wt or FOXM1 5x(K>R) plasmids, with or 
without SUMO1/Ubc9. As expected, cells transfected with FOXM1 wt revealed not only 
a band corresponding to SUMOylated FOXM1 in the presence of SUMO1 and Ubc9. In 
contrast, cells transfected with FOXM1 5x(K>R) mutation did not express the band 
corresponding to the SUMOylated FOXM1 (Figure 3.11C). This confirms that FOXM1 
was indeed modified by SUMO1 at multiple sites (K201, K218, K460, K478 and K495).  
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Lysine N     ѱ K X E   C 
201 198 R S I K Q E M 204 
218 215 R Q V K V E E 221 
460 457 Q T I K E E E 463 
478 475 R P I K V E S 481 
495 492 R P I K V E S 495 
          
 
 
 
 
Figure 3.11 FOXM1 is SUMOylated at multiple sites. A. The table shows 5 
consensus sequences (Ψ is a hydrophobic residue; K is a lysine that has conjugated 
with SUMO; x is any amino acid; E is an acidic residue) of predicted SUMO modification 
site from SUMOplot (Abgent, UK) and SUMOsp (CUCKOO Workgroup, University of 
Science & Technology of China, China). B. The schematic shows positions of predicted 
SUMO modification sites from A. (NRD is an N-terminal regulatory domain; FKH is a 
forkhead domain; TAD is a trans-activation domain). C. MCF-7 cells were transfected 
with FOXM1 wt or 5x(K>R) mutant together with Ubc9 and SUMO1, or empty vector 
control. SUMOylation of FOXM1 was determined at higher molecular weight by western 
blotting.  
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3.2.6 SUMOylated FOXM1 is mainly cytoplasmic rather than nuclear 
After confirming that FOXM1 is SUMOylated, I decided to investigate the impact of 
SUMOylation on the sub-cellular localisation of FOXM1. MCF-7 cells were transfected 
with FOXM1 in the presence or absence of SUMO1 and Ubc9. Multi-SUMOylation of 
FOXM1 was found at higher molecular weight band in the cytoplasmic fraction of these 
cells when co-transfected with SUMO1 and Ubc9 (Figure 3.12A).  To further confirm 
this, MCF-7 cells were transfected with FOXM1 (wt)-Ubc9 or FOXM1 5x(K>R)-Ubc9. 
Ubc9-fusion directed SUMOylation system (UFDS) was used in this experiment in order 
to bypass the requirement of SUMO E3 ligase enzymes. It is widely known that the 
SUMOylation pathway requires E1-E2-E3 enzymatic cascade. Ubc9 is exclusively E2 
SUMO-conjugating enzyme, but there are few E3 ligases in this cascade. The SUMO-
E3 ligase for this pathway remains unknown. The UFDS is the best way to study the 
SUMOylation of FOXM1 excluding the interference of the SUMO-E3 ligases (Jakobs et 
al., 2007). As expected, cells with an overexpression of FOXM1 (wt)-Ubc9 showed an 
auto-SUMOylation in the cytoplasmic fraction but not in the FOXM1 5x(K>R)-Ubc9 
transfected cells.  
In addition, there was less FOXM1 in the cytoplasmic fraction of the cells transfected 
with FOXM1 5x(K>R)-Ubc9, compared with the FOXM1 wt-Ubc9 transfected cells 
(Figure 3.12B). Furthermore, confocal microscopy also confirmed that SUMOylation is 
important for cytoplasmic translocation of FOXM1. The GFP tagged-FOXM1 (wt)-Ubc9 
was found in both cytoplasm and nucleus, while eGFP-tagged FOXM1 5x(K>R)-Ubc9 
was present only in the nucleus fraction (Figure 3.12C).  
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Figure 3.12 SUMOylated FOXM1 is predominantly found in the cytoplasm of MCF-
7 cells. A. MCF-7 cells were transfected with FOXM1 together with or without SUMO1 
and Ubc9. Sub-cellular fractionation extraction was performed and the lysates were 
analysed by western blot. Lamin B and β-tubulin were used as loading controls for 
nuclear and cytoplasmic fractions, respectively. B. FOXM1 (wt)-Ubc9 or FOXM1 
(5x(K>R))-Ubc9 were transfected into MCF-7 cells. C. MCF-7 cells were transfected 
with eGFP-FOXM1 (wt)-Ubc9 or eGFP-FOXM1 (5x(K>R))-Ubc9 and stained with DAPI 
(nucleus) and β-tubulin (cytoplasm). Images were taken with a Leica TCS SP5 confocal 
microscope (Leica Microsystems, Germany) with 63x objective and LAS-AF software. 
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To prove that there is a nuclear-cytoplasmic translocation of FOXM1, 
immunofluorescent staining was performed to examine the endogenous levels of 
FOXM1 protein levels in cells treated with leptomycin B (LMB), a nuclear export 
inhibitor, or a vehicle (ethanol). The result confirmed that FOXM1 can only be found in 
the nuclear fraction after LMB treatment. In contrast, FOXM1 was found in both nuclear 
and cytoplasmic fractions in the cells treated with vehicle alone (Figure 3.13). These 
results suggested that there is a nuclear export mechanism for FOXM1 which is 
SUMOylation-dependent. 
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Figure 3.13 Leptomycin B inhibits nuclear export of endogenous FOXM1. MCF-7 
cells were treated with 6 h of 10 ng/ml leptomycin B (LMB) or vehicle (ethanol). After 24 
h of treatment, cells were stained with antibodies against FOXM1 (green), DAPI (blue) 
and β-tubulin (red). Images were taken with a Leica TCS SP5 confocal microscope 
(Leica Microsystems, Germany) with 63x objective and LAS-AF software. 
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3.2.7 SUMOylation promotes the degradation of FOXM1 and this is mediated by 
Cdh1 
Previously, FOXM1 was found to be degraded in a Cdh1 dependent manner during 
cellular mitotic exit (Laoukili et al., 2008). To determine whether this Cdh1-mediated 
effect could be affected by the SUMOylation status of FOXM1, I firstly confirmed the 
effect of overexpression and depletion of Cdh1. To this end, MCF-7 cells were 
transfected with Cdh1 expression vector or pcDNA3 empty vector control. The 
transfected cells were treated with CHX to inhibit protein synthesis. The protein 
expression was examined by western blotting.  The results showed that FOXM1 was 
degraded faster in cells with Cdh1 overexpression when compared to the empty vector 
control (Figure 3.14). In order to silence Cdh1, MCF-7 cells were transfected with 
siCdh1 or NSC siRNA. The result showed that in Cdh1 depleted cells, FOXM1 protein 
degrades slower than the cells transfected with the NSC control (Figure 3.15). In 
conclusion, Cdh1 is found to promote the degradation of FOXM1.  
Since SUMOylation was shown to be important for the nuclear export of FOXM1 (Figure 
3.12 and 3.13), I next investigated the role of SUMO1 in the regulation of FOXM1 
ubiquitination and degradation in Cdh1 dependent manner. MCF-7 cells were 
transfected with FOXM1 with and without Ubc9 and SUMO1 for 24 h before the 
transfected cells were treated with CHX. When SUMO1 and Ubc9 were overexpressed, 
FOXM1 protein was found to degrade faster than in the control cells in the absence of 
SUMO1/Ubc9 (Figure 3.16A). This result suggests that SUMOylation might have an 
important role in accelerating the ubiquitination and degradation of FOXM1.  
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Consequently, I hypothesised that SUMOylation is involved in the degradation of 
FOXM1 through the APC/C-Cdh1 complex. To test this, MCF-7 cells were transfected 
with V5-tagged-FOXM1 wt or V5-tagged-5x(K>R), with increasing levels of a 
constitutively active Cdh1 expression vector (Cdh1(4a)). This experiment was done in 
collaboration with Dr.Stephen Myatt. The results showed that the increasing levels of 
Cdh1 resulted in the presence of the higher molecular weight bands (arrow) in the 
position where the ubiquitination form of FOXM1 was expected. This higher molecular 
weight band can only be found in MCF-7 cells transfected with FOXM1 wt expression 
and not in those transfected with FOXM1 5x(K>R) expression (Figure 3.16B). This 
suggests that the SUMOylation status of FOXM1 might be important for the 
ubiquitination of FOXM1 and this is in a Cdh1 dependent manner.   
To further investigate the effect of SUMOylation on the Cdh1-mediated degradation of 
FOXM1, cells expressing either FOXM1 wt or 5x(K>R) were treated with CHX in the 
presence or absence of Cdh1 overexpression. The cells overexpressing FOXM1 wt and 
Cdh1 revealed a significant higher degradation rate than in the cells lacking Cdh1 
overexpression, or in the 5x(K>R) transfected cells (Figure 3.17).  In contrast, the cells 
transfected with FOXM1 5x(K>R) showed no difference in their degradation rate 
between cells with or without the overexpression of Cdh1. 
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Figure 3.14 Cdh1 overexpression increases the degradation rate of the FOXM1 
protein. A. MCF-7 cells were transfected with Cdh1 or empty vector control. Then, cells 
were treated with 100 µM CHX and harvested at several time points (0, 2, 4, 6 and 8 h). 
Densitometry was used to quantify the FOXM1 levels from western blots using ImageJ. 
β-tubulin was used for normalisation. The asterisk indicates pcDNA3-flag-Cdh1 band. B. 
Quantitative FOXM1 levels were normalised to 0 h CHX treatment. C. Quantitative 
FOXM1 levels were normalised to 2 h CHX treatment 
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Figure 3.15 Cdh1 knockdown stabilises the FOXM1 protein. A. MCF-7 cells were 
transfected with siCdh1 or NSC. Then, cells were treated with 100 µM CHX before 
being harvested at several time points (0, 2, 4, 6 and 8 h). Densitometry was used to 
quantify the FOXM1 levels from western blot using ImageJ. β-tubulin was used for 
normalisation. B. Quantitative FOXM1 levels were normalised to 0 h CHX treatment. C. 
Quantitative FOXM1 levels were normalised to 2 h CHX treatment 
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Figure 3.16 SUMOylation of FOXM1 accelerates the degradation of FOXM1 which 
is mediated by Cdh1. A. FOXM1 was overexpressed in MCF-7 cells with or without 
Ubc9/SUMO1. Transfected cells were treated with 100 µM CHX before being harvested 
at several time points (0, 4, 6 and 8 h). FOXM1 expression was analysed by western 
blot. Densitometry of FOXM1 levels was quantified with Image J and normalised to β-
tubulin. Densitometry was the means ± SEM. Statistical analysis was analysed by 
Student’s t-test. (**, p ≤ 0.001; ***, ≤ 0.0001 significant; ns, non-significant)  B. MCF-7 
cells were transfected with FOXM1 wt or 5x(K>R) mutant, and increasing levels of 
Cdh1. FOXM1 bands were examined by western blotting. The higher molecular weight 
bands were indicated by the arrow. This experiment was performed in collaboration with 
Dr. Stephen Myatt. 
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Figure 3.17 Cdh1 overexpression affects the degradation of FOXM1 wt but not 
FOXM1 5x(K>R) mutant. MCF-7 Cells were transfected with V5-tagged FOXM1 wt or 
5x(K>R) mutant before being treated with 100 µM CHX before being harvested at 
several time points (0, 2, 4, 6 and 8 h). Western blot was used for protein analysis. 
FOXM1 levels were quantified using Image J and normalised to β-tubulin. Densitometry 
represents the means ± SEM. Statistical analysis was performed using Student’s t-test. 
(**, p ≤ 0.001; ***, ≤ 0.0001 significant; ns, non-significant)   
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3.2.8 SUMOylation affects the ubiquitination of FOXM1 
It is widely known that most of the SUMOylation events that occur within a cell leads to 
the crosstalk with the ubiquitination pathway (Bergink and Jentsch, 2009; Hunter and 
Sun, 2008; Praefcke et al., 2012). Therefore, I decided to investigate the role of 
SUMOylation of FOXM1 in its ubiquitination and degradation.  Therefore, MCF-7 cells 
were transfected with FOXM1 wt or 5x(K>R) together with Flag-Cdh1(4a). The 
transfected cells were then used for a co-immunoprecipitation experiment. As expected, 
the ubiquitinated form of FOXM1 - the higher molecular weight - was found only in cells 
transfected with FOXM1 wt, but not in those transfected with the FOXM1 5x(K>R) 
mutant (Figure 3.18A). Interestingly, the study showed that Cdh1 was able to bind to 
both FOXM1 wt and 5x(K>R). This suggests that SUMOylation has no effect on the 
interaction between FOXM1 and APC/Cdh1 complex but affects its subsequent 
ubiquitination.  
In addition, co-expression of HA-ubiquitin (Ub) with V5 tagged-FOXM1 wt or 5x(K>R) 
was performed before the transfected cells were used for co-immunoprecipitation. In 
agreement with the previous data, FOXM1 wt showed a stronger interaction with HA-
ubiquitin, compared with FOXM1 5x(K>R) (Figure 3.18B). Collectively, these data 
shows that ubiquitination of FOXM1 cannot occur without SUMOylation. 
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Figure 3.18 SUMOylation affects FOXM1 ubiquitination. A. MCF-7 cells were co-
transfected with FOXM1 wt or 5x(K>R), and together with Flag-Cdh1. Transfected cells 
were used for  co-IP with a FOXM1 antibody after 24 h of transfection. Precipitated 
protein and total protein lysate (input) were analysed by western blotting. The 
membrane was probed with Flag, FOXM1 and β-tubulin antibodies. B. MCF-7 cells 
were co-transfected with FOXM1 wt or 5x(K>R), with or without HA-ubiquitin. Protein 
lysates were then used for co-IP with V5 antibodies. Ubiquitination of FOXM1 was 
detected using HA antibodies. 
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3.2.9 SUMOylation-deficient form of FOXM1 shows an increased transcriptional 
activity of its downstream targets 
Based on my results, I then proposed that the SUMOylation-deficient FOXM1 (5x(K>R)) 
mutant should have a higher transactivation activity over its downstream targets when 
compared with the wt form of FOXM1. To test this, the transactivation activity of FOXM1 
5x(K>R) was compared with FOXM1 wt, by performing luciferase reporter assay using 
various FOXM1-responsive promoters. The result showed that SUMOylation-deficient 
FOXM1 (5x(K>R)) had a significantly higher transactivation activity over cyclinB1 
(Figure 3.19A), 6x-DNA-binding element (6XDBE) (Figure 3.19C) and GADD45 (Figure 
3.19D) promoters. In contrast, the result from the cyclin B1 mut3 promoter (containing 
mutations at 3 consensus forkhead binding sites) showed no difference between 
FOXM1 wt and 5x(K>R) (Figure 3.19B).  This suggests that FOXM1 regulates its 
downstream targets, such as cyclin B1, through forkhead response elements (FHREs). 
When FOXM1 cannot be SUMOylated, it is more stable and unable to be degraded 
through the proteasome-degradation pathway. This leads to its increasing 
transactivational activity over its downstream targets.  
To confirm the previous results, the luciferase assays were repeated using cyclin B1 
(Figure 3.20A) and 6XDBE (Figure 3.20B) promoters with increasing amounts of 
FOXM1 wt or 5x(K>R) plasmids (0-100ng). This result also confirmed that the 
SUMOylation-deficient FOXM1 has a higher transactivation activity over its downstream 
targets compared to FOXM1 wt. 
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Figure 3.19 SUMOylation of FOXM1 suppresses cyclin B1 transcription. MCF-7 
cells were co transfected with a gradient of (0 - 25 ng) wt FOXM1-Ubc9 or 5x(K>R) 
FOXM1-Ubc9 (DNA concentration was normalised with empty vector control ), and 
luciferase reporters driven by (A) wild-type cyclin B1 promoter, (B) cyclin B1 mut3 
promoter contained three mutant consensuses forkhead binding sites, (C) the FOXM1 
6x-DNA-binding element (6XDBE), or (D) the GADD45 promoter. Luciferase assays 
were then performed following 24 h of transfection. The Luciferase activity was 
measured using PHERAstar Plus microplate reader. Reporter gene activity was 
normalised to the Renilla control activity. Graphs represent the mean of 3 independent 
experiments ±SEM. Statistical analysis was performed using Student’s t-test. (*, p ≤ 
0.05 significant; ns, non-significant)   
 
 
 
A 
D 
B 
C 
148 
 
 
 
Figure 3.20 FOXM1 with 5x(K>R) mutation has higher transactivation activity over 
its downstream target than wild-type. MCF-7 cells were co transfected with gradient 
of (0 - 100 ng) wt FOXM1-Ubc9 or 5x(K>R) FOXM1-Ubc9 (DNA concentration was 
normalised with empty vector control), and luciferase reporters driven by (A) wild-type 
cyclin B1 promoter, (B) the FOXM1 6x-DNA-binding element (6XDBE) promoter. The 
Luciferase activity was measured using PHERAstar Plus microplate reader. Reporter 
gene activity was normalised to the Renilla control activity. Graphs represent the means 
of 3 independent experiments ±SEM. Statistical analysis was performed using Student’s 
t-test. (*, p ≤ 0.05 significant; ns, non-significant)   
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3.2.10 SUMOylation-deficient FOXM1 induces higher epirubicin resistance when 
compared to FOXM1 wt 
FOXM1 has already been well established that it is involved in the promotion of 
epirubicin resistance (Gomes et al., 2013; Halasi and Gartel, 2012; Khongkow et al., 
2013; Millour et al., 2011; Monteiro et al., 2013). Therefore, I next investigated the effect 
of SUMOylation of FOXM1 on epirubicin resistance. MCF-7 cells were transfected with 
FOXM1 wt, FOXM1 5x(K>R) or an empty vector control. The transfected cells were 
treated with various concentrations of epirubicin (0 – 20 µM). Cell proliferation was then 
measured using SRB assay. The result showed that the SUMOylation-deficient FOXM1 
transfected cells showed a significantly higher percentage of cell survival (Figure 
3.21A). The overexpression levels of FOXM1 wt and 5x(K>R) were confirmed by 
western blotting (Figure 3.21B).  
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Figure 3.21 MCF-7 cells overexpressing FOXM1 5x(K>R) mutant are more 
resistant to epirubicin treatment than cells overexpressing FOXM1 wt. MCF-7 cells 
were transfected with FOXM1 wt, 5x(K>R) mutant, or pcDNA3 empty vector control. A. 
24 h after transfection, cells were reseeded to 96-well plates overnight before being 
treated with various concentrations of epirubicin. Cell proliferation was indicated using 
SRB assay. Data represented 6 replicates (mean±SD). Statistical analysis was 
performed using a Student’s t-test (*, p ≤ 0.05 significant; ns, non-significant). The 
statistic compared between FOXM1 wt and FOXM1 5x(K>R) transfected cells. B. The 
protein expression was studied using western blotting. The membrane was probed with 
antibodies against FOXM1, GFP and β-tubulin. The asterisk indicates eGFP-FOXM1 
specific bands.     
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3.3 Discussion and conclusion 
FOXM1 is upregulated in various types of cancer, including primary breast cancer 
(Ahmad et al., 2010 ; Francis et al., 2009; Wonsey and Follettie, 2005). In many studies, 
FOXM1 has been shown to have a crucial role in promoting cancer metastasis (Koo et 
al., 2012; Xue et al., 2014),  cancer invasion and angiogenesis (Wang et al., 2007), 
relapse from endocrine therapy (Millour et al., 2011), as well as resistance to 
chemotherapy (Carr et al., 2010; Khongkow et al., 2013; Kwok, 2010; Monteiro et al., 
2013). In this chapter, I confirm that FOXM1 plays a crucial role in epirubicin resistance. 
When comparing MCF-7 and MCF-7 EpiR cells, FOXM1 is shown to be down-regulated 
by epirubicin treatment in MCF-7, at both protein and mRNA levels. However in MCF-7 
EpiR cells, FOXM1 expression levels are higher. This FOXM1 down-regulation is 
accompanied by a decrease on its downstream target, cyclin B1. Consistent with 
previous studies from our lab, after epirubicin treatment, MCF-7 cells displays higher 
levels of γH2Ax (a marker for DNA double stranded breaks and genomic instability) and 
cleaved PARP (a cell death marker) when compared to MCF-7 EpiR cells (Monteiro et 
al., 2013). This suggests that FOXM1 is responsible for the promotion of epirubicin 
resistance in breast cancer. In order to confirm the involvement of FOXM1 in epirubicin 
resistance, the role of FOXM1 in DNA damage repair and cell survival was studied. 
Foxm1 depleted mouse embryonic fibroblasts (Foxm1 -/- MEFs), (were found to have a 
highly significant lower percentage of cell survival compared to wt MEFs, especially 
when treated with a high epirubicin concentration of epirubicin ( 0.05µM). In regards to 
DNA damage, alkaline COMET assay confirmed that the absence of FOXM1 leads to 
an increase in the DNA damage levels. After 6 h of epirubicin treatment, Foxm1 -/- MEFs 
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showed higher percentages of DNA in tails (damaged DNA) compared to wt MEFs. 
Although quantitative data analysis showed no difference after 24h of epirubicin 
treatment, the figures obtained using confocal microscopy exhibited dramatically lower 
number of cells in Foxm1-/- MEFs compared with wt MEFs. This shows that Foxm1-/- 
MEFs have lower cell survival rates that the wt MEFs. At 24 h of epirubicin treatment, 
the cells capable of repairing the damaged DNA, those with higher FOXM1 levels, have 
already done it while cells unable to repair DNA have probably died at this time point. In 
summary, these data strongly support the previous findings from our lab that FOXM1 
enhances DNA damage repair and plays a key role in increasing epirubicin resistance 
(de Olano et al., 2012; Khongkow et al., 2013; Millour et al., 2011; Monteiro et al., 
2013).  
Understanding the regulation of FOXM1, especially at the post-translational level, is 
crucial to improve current cancer therapy. For example, phosphorylation has been 
reported to regulate FOXM1 (de Olano et al., 2012; Joshi et al., 2013; Millour et al., 
2011). FOXM1 phosphorylation inhibits its own autorepression in the cytoplasm 
(Laoukili et al., 2008) and initiates mitosis by entering the nucleus (Koo et al., 2012; 
Laoukili et al., 2008). Once mitosis is finished, FOXM1 is dephosphorylated (Chen et al., 
2009; Fu et al., 2008). However, PTMs of FOXM1 by ubiquitination and SUMOylation 
remain unclear.  Additionally, it has been reported in many studies that SUMOylation 
plays a role in the inactivation of a variety of transcription factors, including the 
Forkhead related family members FOXA1 (Bao et al., 2011; Belaguli et al., 2012) and 
FOXC1/2 (Danciu et al., 2012). Therefore, I hypothesised that SUMOylation might have 
an impact in the regulation of FOXM1 post-translationally and this might have a 
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functional outcome. To determine whether this was the case, MCF-7 cells were 
transfected with FOXM1, Ubc9 and SUMO1/SUMO2/SUMO3, or empty vector control. 
Protein lysis was performed in the presence of N-ethylmaleimide (NEM). When studying 
SUMO modifications, NEM works as a SUMO conjugated stabiliser by covalently 
changing the sulfhydryl group of SUMO-specific proteases at the catalytic cysteine 
(Babic et al., 2006; Li and Hochstrasser, 1999). The results showed that FOXM1 can 
form an interaction with SUMO1. Furthermore, this interaction was shown to be specific 
between FOXM1 and SUMO1 and not SUMO2/3. This interaction was confirmed by 
immunoprecipitation experiments using ANTI-FLAG M2 affinity gel. SUMO1-FOXM1 
complexes were found at higher molecular weight than the endogenous FOXM1. As 
expected, co-IP results from endogenous proteins also displayed bands similar to the 
band of SUMO1-FOXM1 complexes. Collectively, these results confirm that FOXM1 
forms a complex with SUMO1. In addition, FOXM1 SUMOylation was further confirmed 
using an in vitro SUMOylation assay. The covalent bond between both proteins was 
then identified in order to prove that FOXM1 is modified specifically by SUMO1 and not 
just by a random interaction. His-tagged SUMO1 was transfected into cells together with 
FOXM1 and Ubc9, before the His-tagged proteins were pulled down using Ni2+-column 
affinity pull down under denaturing conditions (Lamsoul et al., 2005; Li et al., 2012; Zilio 
et al., 2013). The bands corresponding to the complex of His-tagged SUMO1 and 
FOXM1 were found at a higher molecular weight (160 kDa). This demonstrates that the 
interaction between SUMO1 and FOXM1 occurs via a covalent linkage.  
Although the endogenous band for FOXM1, observed in input conditions, was 
decreased after 24 h of epirubicin treatment, the SUMO1-FOXM1 complex showed the 
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same expression levels when compared with the untreated control. This suggests that 
epirubicin treatment has an effect on FOXM1 by increasing its SUMOylation status after 
a short time of exposure to epirubicin. The decreasing protein levels of FOXM1 after 24 
h in the input conditions indicate that there might be a degradation of FOXM1 after the 
treatment. In agreement, the results from the immunofluorescent staining revealed an 
increase in the co-localisation between FOXM1 and SUMO1 in MCF-7 cells after 
epirubicin treatment. In contrast, the co-localisation in MCF-7 EpiR cells remained stable 
and at low levels both before and after epirubicin treatment. In MCF-7 EpiR cells the co-
localisation fluorescence intense was lower than in MCF-7 cells. This suggests that 
SUMOylation of FOXM1 increases in response to epirubicin treatment only in sensitive 
breast cancer cells. In epirubicin resistance MCF-7 cells, there is lower level of FOXM1 
when compared with the MCF-7 cells. This in agreement with the stable level of FOXM1 
in MCF-7 EpiR cells after epirubicin treatment. Correspondingly, FLIM-FRET results 
further confirm that in MCF-7 cells SUMOylation levels increase after epirubicin 
treatment. Collectively, the experiment shows that FOXM1 is SUMOylated between 4 to 
6 h of epirubicin treatment, before it starts to be degraded between 16 to 24 h of 
epirubicin treatment. Importantly, this shows that SUMOylation precedes the 
degradation of FOXM1.  
To further examine the role of SUMOylation in the regulation of FOXM1 a mutant 
FOXM1 plasmid was generated harbouring 5 point-mutations at predicted SUMO 
modification sites (5x (K>R)). This plasmid was generated by Dr. Stephen Myatt in our 
lab. The SUMOylated sites were predicted using SUMOplot and SUMOsp. Western blot 
results of MCF-7 cells transfected with the SUMO-deficient FOXM1 plasmid confirmed 
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that this mutant is in fact unable to be SUMOylated.  As it is widely known, FOXM1 is 
active in the nucleus where it regulates the transcription of its downstream targets, while 
the inactive form of FOXM1 is normally located in the cytoplasm. The regulation of 
FOXM1 by SUMOylation was then investigated by transfection MCF-7 cells with 
different forms of FOXM1 to determine their sub-cellular localisation. The nuclear-
cytoplasmic fractionation was performed using Ubc9-fused FOXM1 wt or 5x(K>R) 
transfected cells. The Ubc9-fusion directed SUMOylation system (UFDS) was used in 
order to bypass the requirement of SUMO E3 ligase enzymes (Jakobs et al., 2007). 
Only Ubc9-fused FOXM1 wt transfected cells showed SUMOylation in the cytoplasmic 
fraction, but not in the Ubc9-fused FOXM1 5x(K>R) transfected cells. The results from 
the protein fractionation showed that the SUMOylation of FOXM1 is most likely to occur 
in the cytoplasmic fraction rather than in the nuclear fraction. The results from confocal 
microscopy also confirmed that FOXM1 wt was found both in the nucleus and 
cytoplasm; however, FOXM1 5x(K>R) was only found in the nucleus. This suggested 
that SUMOylation might play a role in the nuclear export mechanism for FOXM1. To 
confirm the nuclear export of FOXM1, LMB was used to inhibit protein export in the cells 
(Jang et al., 2003; Wolff et al., 1997). MCF-7 cells were treated with LMB before the 
immunofluorescent staining has been performed to investigate the sub-cellular 
localisation of the endogenous FOXM1 protein. The immunofluorescent study showed 
that LMB was able to inhibit the nuclear export of FOXM1 to the cytoplasm (Jang et al., 
2003; Wolff et al., 1997). All together, these data confirms that the SUMOylation of 
FOXM1 results in its nuclear exclusion. As mentioned before, cytoplasmic FOXM1 is 
normally associated with an inactive form of the protein that is unable to regulate gene 
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transcription. Therefore, I decided to investigate the effect of SUMOylation on the 
transactivational activity of FOXM1. 
My observations are in agreement with various studies that SUMOylation targets 
various transcription factors to inhibit their functions. Some of these factors include, 
FOXA1 (Bao et al., 2011) and FOXC1/FOXC2 (Danciu et al., 2012). Previous reports 
have already shown that Cdh1 is required for the degradation of FOXM1 (Laoukili et al., 
2008; Park et al., 2008). Accordingly, I also found that the degradation rate of FOXM1 is 
enhanced in cells overexpressing Cdh1, and when the transcription of FOXM1 is 
inhibited by CHX. On the other hand, in the absence of Cdh1, FOXM1 protein is found 
to be more stable. Cdh1 not only works as an adaptor for the interaction between 
FOXM1 and the APC/C complex, but is also reported to be essential for the ubiquitin-
mediated proteolysis of FOXM1 (Li et al., 2012; Park et al., 2008). The FLIM-FRET 
results together with the co-IP data, confirm that SUMOylation occurs in MCF-7 cells in 
response to epirubicin treatment, between 4 to 6 h preceding the degradation of 
FOXM1. 
 Therefore, I hypothesised that SUMOylation is required for the Cdh1-mediated 
degradation of FOXM1. The results from the CHX treatment show that the FOXM1 
degraded faster in the presence of SUMO1/Ubc9 overexpression and epirubicin. 
Moreover, when MCF-7 cells were transfected with FOXM1 wt or 5x(K>R) mutant with 
increasing amounts of Chd1, the higher molecular weight band associated with the 
ubiquitinated form of FOXM1 was only found in the FOXM1 wt transfected cells. This 
157 
 
indicates that ubiquitination-mediated degradation of FOXM1 cannot occur without 
SUMOylation.  
This is consistent with other studies showing that Cdh1 has a crucial role in APC/C-
dependent degradation via the ubiquitin-proteasome pathway (Cataldo et al., 2013; 
Hyun et al., 2013; Li et al., 2012). This further supports the idea that SUMOylation of 
FOXM1 leads to the degradation of FOXM1 via the ubiquitin-proteasome. To confirm 
this, MCF-7 cells were transfected with FOXM1 wt or 5x(K>R) before being treated with 
CHX.  In cells overexpressing Cdh1, there was a markedly increase in the degradation 
rate of FOXM1 wt in comparison with empty vector transfected cells. Interestingly, the 
degradation rate of SUMOylation-deficient FOXM1 was unaffected by overexpression of 
Cdh1, indicating that SUMOylation is required for the Cdh1-mediated degradation of 
FOXM1. 
Furthermore, the co-IP results of ubiquitin also confirm that there is an interaction with 
FOXM1 wt but not with the SUMOylation-deficient FOXM1. Surprisingly, Cdh1 can form 
a complex with FOXM1 5x(K>R). This suggests that SUMOylation is not required for the 
interaction between FOXM1 and Cdh1, but it is crucial for the ubiquitination of FOXM1.  
Additionally, SUMOylation is also found to induce a decrease on the transactivation 
activity of FOXM1 since SUMOylation-deficient FOXM1 has a higher transactivation 
activity on the downstream targets of FOXM1, including cyclin B1 (Leung et al., 2001) 
and 6xForkhead response element (FHRE) promoters (6xDNA binding element: 
6XDBE) (Furuyama et al., 2000; Laoukili et al., 2005). However, this transactivation 
activity is dependent on the FHREs since the cyclin B1 mutant3 (Cyclin B1 with 
158 
 
mutation of FHREs) promoter shows no difference between FOXM1 wt and 5x(K>R). 
Moreover, I also found that FOXM1 5x(K>R) overexpression has a positive effect on the 
cell survival rate when compared to FOXM1 wt. This evidence indicates that 
SUMOylation-deficient FOXM1 enables the cells to overcome the anti-proliferative effect 
of epirubicin more than the FOXM1 wt.   
Taken together, my results confirm the importance of FOXM1 in epirubicin resistance 
and DNA damage response. In addition, I have shown that FOXM1 can be modified 
predominantly by SUMO1 in response to epirubicin treatment. However, it does not 
exclude the involvement of SUMO2/3 in the modification of FOXM1 and its activity. 
Moreover, SUMOylation plays an important role in the FOXM1 Cdh1-mediated 
degradation via the ubiquitin-proteasome pathway. I have also shown that the 
SUMOylation-deficient FOXM1 has a higher transactivation activity on the down-stream 
targets of FOXM1 (cyclin B1 and 6XDBE) and it enhances epirubicin resistance in MCF-
7 cells. Therefore, this study shows that SUMOylation has a crucial role in the regulation 
of FOXM1 in terms of its degradation and inhibition of its function. According to my 
study, SUMOylation is an interesting candidate that drives the molecular switch that 
controls the role of FOXM1 in epirubicin-induced DNA damage response and could 
potentially have future clinical applications. Understanding more about the regulation of 
FOXM1 by SUMOylation might lead to the development of an inhibitor that promotes the 
degradation of FOXM1. Such inhibitor could have a therapeutic use in combination with 
epirubicin in order to disable the resistant-downstream target gene network that is under 
the control of FOXM1.  
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3.4 Future work 
Although SUMOylation is linked with ubiquitination and degradation of FOXM1 by an 
APC-C/Cdh1 complex, SUMOylation does not mediate the interaction of FOXM1 with 
the complex. This suggests that, there might be another protein that acts as a mediator 
between them. According to various studies, SUMO-targeting ubiquitin ligases 
(STUbLs), such as RNF4 and RNF8, have a role in mediating the crosstalk between 
SUMOylation and ubiquitination. To further investigate the regulation of FOXM1, I would 
firstly study the role of E3 ubiquitin ligases such as RNF4, RNF8 and RNF168. These 
RING-type E3 ligases have been reported to mediate the DNA damage response (DDR) 
(Galanty et al., 2012; Mallette et al., 2012; Munoz et al., 2012; Nakada et al., 2010; Yin 
et al., 2012). Then, the regulation of FOXM1 by E3 ligases would be investigated. By 
overexpression and silencing of E3 ligases including RNF4, RNF8, and RNF168, 
FOXM1 expression and degradation would be assessed. Subsequently, I would 
determine the presence of an interaction between FOXM1 and the E3 ligases using co-
IP. Once the interaction has been confirmed, one can use luciferase reporter assays to 
determine the effect of the E3 ligases on the transactivation activity of FOXM1. Finally, I 
will also investigate the importance of SUMOylation in the regulation of FOXM1 by E3 
ligases. Using western blotting analysis, the degradation of FOXM1 wt and 5x(K>R) can 
be determined in the presence of E3 ligases and the interaction between E3 ligases and 
FOXM1 wt and 5x(K>R) would be defined. 
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CHAPTER 4 
THE REGULATION OF FOXM1 BY RING-
TYPE E3 LIGASES: RNF4 AND RNF168 
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4.1 Introduction and Objectives 
Ubiquitin E3 ligase is widely known to be important for recognising ubiquitin substrates, 
in targeted proteins, and mediating ubiquitin transfer from a conjugating (E2) enzyme to 
these proteins (Deshaies and Joazeiro, 2009).  There are two major classes of E3 
ligase: HECT (homologous to the E6AP carboxyl terminus) and RING (Really 
interesting new gene) domain containing E3 ligases. HECT-type E3 works by first 
forming a covalent bond with ubiquitin residues which are transferred from E2 to the 
substrate protein (Metzger et al., 2012). In contrast, RING-type E3 ligases help to bring 
the ubiquitin-E2 complex and the substrate protein into close proximity to discharge the 
ubiquitin residue directly from the E2 enzyme to the substrate protein(Metzger et al., 
2012; Ozkan et al., 2005; Rotin and Kumar, 2009).  
FOXM1 plays a key role in DNA damage response (DDR) and epirubicin resistance in 
breast cancer (Halasi and Gartel, 2012; Koo et al., 2012; Millour et al., 2011; Monteiro 
et al., 2013; Park et al., 2012; Wonsey and Follettie, 2005). In the previous chapter, I 
have found that SUMOylation of FOXM1 leads to its degradation via an APC/Cdh1 
complex (Chapter 3). However, the APC/Cdh1 complex does not mediate this process 
directly. This suggests that there are other E3 ligases that might be involved in this 
proteasome degradation pathway. Previous studies reported that RING-type E3 ligases, 
including RNF4, RNF8, RNA168 and BRCA1, are involved in DDR (Galanty et al., 2012; 
Mallette et al., 2012; Oestergaard et al., 2012; Wu et al., 2010; Yin et al., 2012). The 
role of RING-type E3 ligase is commonly defined by a RING domain that interacts with 
the ubiquitin-E2 complex (Deshaies and Joazeiro, 2009). Mutations on this RING 
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domain of RING-type E3 ligases (by point mutations from a zinc-coordinating cysteine 
residue to a serine residue - CS mutation) lead to a catalytically inactive form of this 
ligase (Ahner et al., 2013; Luo et al., 2012; Tatham et al., 2008). This mutation results in 
the lack of ability of E3 ligase to ubiquitinate its substrate proteins. 
In this study, I intended to investigate one of the potential candidate E3 ligases, RNF4, 
RNF8 and RNF168, that might be involved in the regulation of FOXM1. In my previous 
chapter, I have concluded that it is possible that following SUMOylation, FOXM1 is 
ubiquitinated. This ubiquitination could be mediated by one or more of these E3 ligases 
before the degradation of FOXM1. Therefore, I decided to identify which E3 ligases is 
involved in the degradation of FOXM1. The identification of this E3 ligase could prove 
useful to develop new and improved cancer therapeutics targeting FOXM1 and its role 
in promoting drug resistance. 
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4.2 Results 
4.2.1 Evaluation of the expression levels of RNF4, RNF8 and RNF168 in MCF-7 
and MCF-7 EpiR in response to epirubicin treatment 
E3 ligases including RNF4, RNF8 and RNF168 have been reported to be involved in 
promoting ubiquitination of targeted proteins, leading to their degradation in response to 
genotoxic stresses (Galanty et al., 2012; Mallette et al., 2012; Oestergaard et al., 2012; 
Yin et al., 2012). In order to assess the expression of RNFs in response to epirubicin 
treatment, MCF-7 and MCF-7 EpiR cells were treated with epirubicin at different times 
(0, 4, 8, 16, 24, and 48 h). The protein lysates and mRNA were then extracted from 
these cells. Western blotting and qPCR were used to study the expression levels of 
protein (Figure 4.1) and mRNA (Figure 4.2), respectively. The RNF4 expression levels 
in MCF-7 and MCF-7 EpiR cells were found to correlate with FOXM1. In MCF-7 cells, 
RNF4 and FOXM1 levels decreased after epirubicin treatment but this was not the case 
in MCF-7 EpiR cells. For RNF8, the result showed no significant change in both MCF-7 
and EpiR cells, with and without epirubicin treatment. Interestingly, in MCF-7 cells the 
protein expression levels of RNF168 were found to be more highly expressed than in 
MCF-7 EpiR cells. Moreover, the mRNA levels of RNF 168 in MCF-7 cells were 
significantly increased after epirubicin treatment, especially after 16 h.  
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Figure 4.1 Western blot analysis of FOXM1, RNF4, RNF8 and RNF168 in MCF-7 
and MCF-7 EpiR cells following epirubicin treatment. MCF-7 and MCF-7 EpiR cells 
were treated with 1μM epirubicin for 0, 4, 8, 16, 24 and 48 h. Protein lysate was 
extracted and analysed by western blotting. The membrane was probed with antibodies 
against FOXM1, RNF4, RNF8 and RNF168. β-tubulin served as a loading control. 
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Figure 4.2 RNF4, RNF8 and RNF168 mRNA expression levels in MCF-7 and MCF-7 
EpiR in response to epirubicin treatment. The transcript levels of RNF4, RNF8 and 
RNF168 from MCF-7 and MCF-7 EpiR cells were analysed by qPCR. Statistical analysis 
was performed using Student’s t-test. (*, p ≤ 0.005; **, ≤ 0.001 significant; ns, non-
significant)  
MCF-7  
MCF-7 Epi
R
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4.2.2 The expression levels of RNF4, RNF8 and RNF168 affect FOXM1 protein 
levels 
Next, I examined the relationship between the different RNFs and FOXM1. In order to 
further examine the potential regulation of FOXM1 by RNFs, exogenous RNFs 
expression plasmids were transfected into MCF-7 cells. After 24 h of transfection, the 
cells were harvested and analysed for western blotting. The overexpression results 
showed that FOXM1 protein levels were dramatically upregulated when MCF-7 cells 
were overexpressed with RNF4 (pcDNA3-flag-RNF4), when compared with the empty 
vector control (pcDNA3). In contrast, MCF-7 cells with RNF168 overexpression 
(pcDNA3-flag-RNF168) showed a decrease in the protein levels of FOXM1 when 
compared with the control (pcDNA3). Notably, in the cells transfected with RNF8 
(pcDNA3-HA-RNF8) there was a discrete decrease in the FOXM1 protein levels when 
compared with the control (Figure 4.3). These data might indicate that RNF4 has a role 
in enhancing the expression of FOXM1, while RNF168 has a role in suppressing its 
expression.  Unfortunately, RNF8 was not found to have an effect on FOXM1 protein 
expression, displaying a similar trend as RNF168.  
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Figure 4.3 Effects of RNF4, RNF8 and RNF168 overexpression on FOXM1 in MCF-
7 cells. A. MCF- 7 cells were transfected with RNF4, RNF8, RNF168 or pcDNA3 empty 
vector control. Whole protein lysates were extracted and used for western blotting 
analysis. The immunoblot membranes were probed with antibodies against FOXM1, 
RNF4, RNF8, RNF168, and β-tubulin. Asterisks indicate flag-RNF4, HA-RNF8 and flag-
RNF168, respectively. B. Densitometry of FOXM1 levels were quantified by Image J 
and normalised to β-tubulin.  
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Conversely, I also performed the knock-down experiment to confirm the above results. 
To this end, MCF-7 cells were transfected with specific siRNA against RNFs (siRNF4, 
siRNF8, siRNF168) or the non specific control (NSC). The following day, the cells were 
harvested and analysed by western blotting. In the RNF4 silenced cells, there was a 
down-regulation of FOXM1 protein expression levels, while in the RNF168 knock-down 
cells a slight upregulation of FOXM1 expression was observed when compared with the 
NSC control. Unfortunately, the knock-down of RNF8 did not show to increase the 
levels of FOXM1 (Figure 4.4). These results also confirm the overexpression data in 
which FOXM1 protein levels can be upregulated by RNF4 and suppressed by RNF168. 
However, the effect of RNF8 on FOXM1 protein levels remains unclear.  
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Figure 4.4 Effects of RNF4, RNF8 and RNF168 knock-down on FOXM1 expression 
in MCF-7 cells. A. MCF- 7 cells were transfected with siRNF4, siRNF8, siRNF168, or 
NSC. The immunoblot membranes were probed with antibodies against FOXM1, RNF4, 
RNF8, RNF168, and β-tubulin B. Densitometry of FOXM1 levels were quantified by 
Image J and normalised to β-tubulin  
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4.2.3 Expression levels of RNF4 and RNF168 affect cyclin B1 transcription 
I next examined the effects of the three potential RING-type E3 ligases over the 
transactivation activity of FOXM1. MCF-7 cells were transiently co-transfected with 
increasing amounts of different RING-type E3 expression vectors and a luciferase 
reporter containing the wild-type cyclin B1 promoter. The result showed that RNF4 
promoted the transcription activity of cyclin B1, a downstream transcriptional target of 
FOXM1, while RNF168 repressed its activity. By contrast, RNF8 and BRCA1 
expression had no significant effects over the activity of cyclin B1 promoter (Figure 4.5). 
Collectively, these data suggests that RNF4 and RNF168 might work as upstream 
regulators of FOXM1, while the role of RNF8 remains unclear.   
 
 
 
 
 
 
 
 
171 
 
 
 
Figure 4.5 RNF4 overexpression promotes the transcription of cyclin B1 promoter 
while RNF168 overexpression suppresses its transcription activity. A. MCF-7 cells 
were co-transfected with increasing amounts (0-30ng) of different RING-type E3s, 
including RNF4, RNF8, RNF168 or BRCA1 (DNA concentrations were normalised to 
empty vector control), and luciferase reporters containing the wild-type cyclin B1 
promoter. The Luciferase activity was measured by PHERAstar Plus microplate reader. 
Reporter gene activity was normalised to the Renilla control activity. Graphs represent 
the mean of 3 independent experiments ±SEM Statistical analysis was performed using 
Student’s t-test compared with 0ng of RING-type E3 transfection. (**, p ≤ 0.01 
significant; ***, p ≤ 0.001 significant; ns, non-significant)  
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4.2.4 Overexpression of RNF4 promotes FOXM1 expression while a knock-down 
of RNF4 suppresses FOXM1 expression 
According to the previous results (Section 4.2.2 and 4.2.3), RNF4 has been shown to be 
able to promote FOXM1 expression and its transactivation activity. To further 
investigate the influence of RNF4 expression over FOXM1, MCF-7 cells were 
transfected with pcDNA3-flag empty vector or pcDNA3-flag-RNF4 for 24 h before 
treatment with 1 µM epirubicin. After 24 h of treatment, the cells were harvested for 
western blotting and qPCR analyses. The results, for both protein and mRNA, showed 
an upregulation of FOXM1 in RNF4-overexpressing MCF-7 cells when compared with 
the control, in both the absence and the presence of epirubicin. Interestingly, FOXM1 
expression levels remained elevated even after 24 h of epirubicin treatment (Figure 
4.6). Conversely, MCF-7 cells with a depletion of RNF4 (siRNF4) exhibited a 
downregulation of FOXM1 expression both with and without epirubicin treatment (Figure 
4.7). Taken together, these data indicate that RNF4 might have a role in promoting the 
expression of FOXM1.  
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Figure 4.6 Effects of RNF4 overexpression on FOXM1 in MCF-7 cells in a 
response to epirubicin treatment. MCF- 7 cells were transfected with siRNF4, or the 
NSC control. The cells were harvested after 0, or 24 h of epirubicin treatment. A. The 
cell lysates were analysed by western blotting. The asterisk indicates flag-RNF4. The 
arrow indicates the endogenous levels of RNF4. B. The mRNA from the cells was 
collected and the expression levels of RNF4 and FOXM1 were analysed using qPCR. 
Statistical analysis was performed using Student’s t-test (*, p ≤ 0.05; **, ≤ 0.01 
significant; ns, non-significant).  
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Figure 4.7 Effects of RNF4 knock-down on FOXM1 expression in MCF-7 cells in 
response to epirubicin treatment. MCF- 7 cells were transfected with siRNF4, or the 
NSC control. The cells were harvested after 0, or 24 h of epirubicin treatment. A. The 
cell lysates were analysed by western blotting. B. The mRNA from the cells was 
collected and the expression levels of RNF4 and FOXM1 were analysed using qPCR. 
Statistical analysis was performed using Student’s t-test (*, p ≤ 0.05; **, ≤ 0.01 
significant). 
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4.2.5 RNF4 promotes the growth of MCF-7 cells, but fails to re-sensitise these 
cells to epirubicin treatment 
Various studies reported that FOXM1 promotes epirubicin resistance (Khongkow et al., 
2013; Monteiro et al., 2013). In previous experiment, I found that overexpression of 
RNF4 has a role in increasing the expression levels of FOXM1 (Figure 4.6 and 4.7). I 
therefore hypothesised that RNF4 might also affect the sensitivity of the cells to 
epirubicin. To this end, MCF-7 cells were transfected with pcDNA3-flag-RNF4 (RNF4) 
or pcDNA3-flag empty vector control (pcDNA3) for 24 h before SRB assays were 
performed in the presence of various indicated concentrations of epirubicin (0 µM – 20 
µM). The percentages of the cell survival and cell growth were quantified. Surprisingly, 
the result showed no differences in the percentages of cell survival between RNF4 
overexpressing cells and the control, after 24 h of epirubicin treatment (Figure 4.8A). 
Conversely, I knocked down RNF4 in MCF-7 cells and performed similar SRB assays. 
The results showed that in RNF4 depleted cells there was no difference in the 
percentages of cell survival compared to the NSC (Figure 4.9A). 
Interestingly, although the expression of RNF4 was unable to change the sensitivity of 
MCF-7 cells to epirubicin, it affected the ability of the cells to proliferate. The SRB result 
revealed that, in the absence of epirubicin, the overexpression of RNF4 leads to an 
increase in the growth rate, while the depletion of RNF4 leads to a slower growth rate 
when compared with the corresponding controls (Figure 4.8B and 4.9B). In summary, 
the expression of RNF4 did not affect the sensitivity of MCF-7 cells to epirubicin 
treatment instead it only promoted their cell growth.   
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Figure 4.8 RNF4 overexpression does not affect the sensitivity of MCF-7 cells to 
epirubicin nor cell growth. MCF- 7 cells were transfected with pcDNA3-RNF4 or 
pcDNA3 empty vector control. The cells were then treated with various concentrations 
of epirubicin 24 h before the cell proliferation was analysed by SRB assays. The results 
were normalised to the untreated conditions (0μM concentration). A. The percentages 
of survival and B. the percentages of cell growth were plotted. Results represent the 
average of 6 replicates ± SD. Statistical analysis was performed using Student’s t-test 
(***, ≤ 0.001 significant; ns, non-significant).  
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Figure 4.9 RNF4 knock-down does not affect the sensitivity of MCF-7 cells to 
epirubicin but reduces cell growth. MCF- 7 cells were transfected with siRNF4, or 
NSC. The cells were treated with various concentrations of epirubicin 24 h before the 
cell proliferation was identified by an SRB assay. A. The percentages of cell growth and 
B. the percentages of cell growth were plotted. The result was normalised to an 
untreated condition (0 μM concentration). Results represent the average of 6 replicates 
± SD. Statistical analysis was performed using Student’s t-test (*, p ≤ 0.05; **, ≤ 0.001 
significant; ns, non-significant).  
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4.2.6 RNF4 promotes long-term cell proliferation in MCF-7 cells 
To further study the role of RNF4 on long-term cell proliferation, RNF4 was 
overexpressed or knocked down in MCF-7 cells. The transfected cells were then 
reseeded into 6-well plates with a very low cell number (500 cells/well) for colony 
formation assays. The ability of cells to proliferate was gauged by crystal violet staining 
to define the role of RNF4 in long-term growth control. The result showed that 
overexpression of RNF4 significantly promoted long-term cell proliferation (Figure 4.10). 
Conversely, the RNF4 depleted cells revealed significantly lower rates of the cell 
proliferation when compared with the NSC control (Figure 4.11). Interestingly, both for 
short and long-term growth rates were extremely low when RNF4 was depleted from the 
cells. The SRB assay revealed no growth from RNF4-knocked down MCF-7 cells 
(Figure 4.9B) and less than 1% proliferation in 15 days of a long-term assay. This 
suggests that RNF4 has a crucial role in promoting long-term cell proliferation in MCF-7 
cells.   
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Figure 4.10 RNF4 overexpression showed no effect over long-term cell growth. 
MCF- 7 cells were transfected with pcDNA3-RNF4 or pcDNA3 empty vector control. A. 
The transfected cells were re seeded in 6-well-plate at a very low concentration (500 
cells per well) for clonogenic assay. The cells were harvested every 2 days after 
seeding. B. The percentage of cell proliferation was measured using crystal violet 
staining. Results represent the average of triplicates ± SD. Statistical analysis was 
performed using Student’s t-test (***, ≤ 0.001 significant; ns, non-significant).  
.  
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Figure 4.11 RNF4 knock-down showed a reduction in long-term cell growth. MCF- 
7 cells were transfected with siRNF4, or NSC. A. The transfected cells were reseeded 
in 6-well-plates at a very low concentration (500 cells per well) for clonogenic assay. 
The cells were harvested every 2 days after seeding. B. The percentages of cell 
proliferation were measured using crystal violet staining. Results represent the average 
of triplicates ± SD. Statistical analysis was performed using Student’s t-test (*, p ≤ 0.05 
significant; **, p ≤ 0.01 significant; ***, p ≤ 0.001 significant; ns, non-significant).  
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4.2.7 The regulation of cyclin B1 transcription activity by RNF4 partially depends 
on the RING-domain of RNF4 
Since RNF4 had an effect on the expression of FOXM1, I hypothesised that it might 
also have a role in regulating the transcription of cyclin B1 by modulating the 
transactivation activity of FOXM1. The result from my previous experiment confirmed 
that RNF4 has a role in promoting cyclin B1 promoter, a downstream transcriptional 
target of FOXM1 (Figure 4.5). Therefore, I investigated whether the regulation of cyclin 
B1 transcription activity depends on the forkhead response elements (FHREs). To 
address this, MCF-7 cells were co-transfected with increasing amounts (0 – 30 ng) of 
Flag-RNF4 wt and a luciferase reporters containing a wild-type cyclin B1 promoter or a 
mutant cyclin B1 mut3 promoter containing both the forkhead binding sites mutated. 
DNA concentration were normalised to the pcDNA3 flag empty vector control. The 
reporter gene activity was normalised to the activity of a Renilla control. Surprisingly, the 
result showed an upregulation of a cyclin B1 promoter activity in both wt and mutant3 
transfection (Figure 4.12). This result indicates that the same upregulation of the 
transcriptional activity of cyclin B1 promoter partially relies on the presence of FHREs. 
This also indicates that the induction of cyclin B1 promoter by RNF4 does not require 
FHREs as well as other transcription factor-binding sites. 
I also studied the importance of the RING-domain of RNF4 in promoting the 
transcriptional activity of cyclin B1 promoter. To test that, RNF4 CS mutation was used. 
This is a mutation from cysteine into serine residues in the RING finger domain. It 
destroys the RING domain of RNF4 and abolishes the ability of RNF4 to function 
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properly (Ahner et al., 2013; Luo et al., 2012; Pero et al., 2001). Firstly, MCF-7 cells 
were co-transfected with increasing amounts (0 – 30 ng) of RNF4 wt or RNF4 with CS 
mutations, and the wt cyclin B1 promoter reporter. The following day, luciferase assay 
was performed and the result was normalised to the activity of the Renilla control. 
Remarkably, increasing levels of RNF4 CS mutation transfection showed the same 
levels of cyclin B1 promoter transcriptional activity (Figure 4.13). This indicates that the 
RING-domain of RNF4 might have a crucial role in regulating cyclin B1 transcriptional 
activity as the mutation of RNF4 could not promote the transcriptional activity of cyclin 
B1 promoter.   
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Figure 4.12 The effect of RNF4 over the transcription of cyclin B1 partially 
depends on forkhead response elements (FHREs). MCF-7 cells were co-transfected 
with increasing amount (0 - 30 ng) of flag-RNF4 wt (DNA concentration was normalised 
by empty vector control), and luciferase reporters containing the wild-type cyclin B1 
promoter or cyclin B1 mut3 promoter. The Luciferase activity was measured by 
PHERAstar Plus microplate reader. Reporter gene activity was normalised to the 
Renilla control activity. Graphs represent the mean of 3 independent experiments 
±SEM. Statistical analysis was performed using Student’s t-test (ns, non-significant).  
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Figure 4.13 The RING domain of RNF4 is important for promoting a transcription 
of cyclin B1.  MCF-7 cells were co-transfected with increasing amount (0 - 30 ng) of 
RNF4 wt or RNF4 with (CS1) mutation of RING domain (DNA concentration was 
normalised by empty vector control), and luciferase reporters containing wild-type cyclin 
B1 promoter. The Luciferase activity was measured by PHERAstar Plus microplate 
reader. Reporter gene activity was normalised to the Renilla control activity. Graphs 
represent the mean of 3 independent experiments ±SEM. Statistical analysis was 
performed using Student’s t-test compared between wt and CS1 mutation at the same 
amount of DNA transfection. (***, p ≤ 0.001 significant; ns, non-significant)  
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4.2.8 RNF4 does not delay the degradation rate of FOXM1 in response to 
epirubicin treatment 
Previously, RNF4 was found to promote the expression of FOXM1. Moreover, MCF-7 
cells overexpressing RNF4 showed higher FOXM1 protein levels after 24 h epirubicin 
treatment compared to the pcDNA3-flag empty vector control transfected cells (Figure 
4.3).  I then hypothesised that the overexpression of RNF4 might also delay the 
degradation of FOXM1. In order to test this hypothesis, the degradation rate of FOXM1 
was determined after cycloheximide (CHX) treatment in combination with epirubicin. 
MCF-7 cells were transfected with flag-RNF4 or an empty vector control. The following 
day, the cells were treated with 1 μM epirubicin for 2 h prior to 100 µM cycloheximide 
treatment at indicated time points (0, 1, 2, 4, 6 and 8 h). The cells were harvested for 
the protein extraction. The FOXM1 protein expression was examined by western 
blotting. Unexpectedly, the result revealed no significant difference between the 
degradation rate of FOXM1 in cells with and without overexpression of RNF4 (Figure 
4.14).  
In addition, a similar experiment was performed using MCF-7 cells transfected with 
siRNA smart pool targeting RNF4 (siRNF4) or non-target siRNA control (NSC). This 
result also showed no noticeable differences in the degradation rate of FOXM1 between 
RNF4 depleted cells and the NSC control (Figure 4.15). These data show that RNF4 
does not play a direct role in the degradation of FOXM1.      
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Figure 4.14 Overexpression of RNF4 has no significant effect on the degradation 
of FOXM1. A. MCF-7 cells were transfected with RNF4 or empty vector control 
(pcDNA3). Then, cells were treated with 1 μM epirubicin 2 h prior to 100 μM 
cycloheximide (CHX) treatment at several time points (0, 1, 2, 4, 6 and 8 h). 
Densitometry was used to quantify the FOXM1 level from western blot using imageJ. β-
tubulin was used for normalising. B. Quantitative FOXM1 level was normalised relative 
to 0 h CHX treatment. Graphs represent the mean of 3 independent experiments ±SD. 
Statistical analysis was performed using Student’s t-test compared between pcDNA3 
empty vector and RNF4 overexpression at the same time point (ns, non-significant). 
The asterisk indicates an endogenous RNF4.  
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Figure 4.15 depletion of RNF4 has no significant effect over the degradation of 
FOXM1. A. MCF- 7 cells were transfected with siRNF4 NSC. Then, cells were treated 
with 1 μM epirubicin 2 h prior to 100 μM cycloheximide (CHX) treatment at several time 
points (0, 1, 2, 4, 6 and 8 h). Densitometry was used to quantify the FOXM1 level from 
western blot using imageJ. β-tubulin was used for normalisation. B. Quantitative 
FOXM1 level was normalised relative to 0 h CHX treatment. Graphs represent the mean 
of 3 independent experiments ±SD. Statistical analysis was performed using Student’s 
t-test compared between pcDNA3 empty vector and RNF4 overexpression at the same 
time point. (ns, non-significant)  
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4.2.9 RNF168 suppresses FOXM1 expression   
In contrast to RNF4, RNF168 was found to down regulate the expression of FOXM1 
(Figure 4.3 and 4.4). To further investigate the regulation of FOXM1 by RNF168, MCF-7 
cells were transfected with pcDNA3-flag-RNF168 (RNF168) or pcDNA3-flag empty 
vector control (pcDNA3) before treatment with 1 μM epirubicin and 24 h. The following 
day, cells were harvested for western blotting and qPCR analyses. The western blot 
confirmed that RNF168 overexpression was successful. The result showed the down 
regulation of FOXM1 protein both before and after epirubicin treatment in RNF168 
overexpressed cells, compared with the pcDNA3 transfected control (Figure 4.16A). 
The qPCR result showed a small reduction on the FOXM1 mRNA levels in the absence 
of epirubicin while it showed no differences after 24 h of epirubicin treatment (Figure 
4.16B). This indicates that RNF168 might down-regulate FOXM1 at post translational 
levels.  
Next, I performed the siRNA experiment to confirm the overexpression results. MCF-7 
cells were transfected with siRNF168 and NSC to investigate the effects at protein and 
mRNA levels of FOXM1 in an RNF168 depleted environment. After 24 h of transfection, 
the cells were harvested and analysed by western blotting and qPCR. RNF168 depleted 
MCF-7 cells show a significant higher FOXM1 protein levels in both before and after 24 
h of epirubicin treatment. However FOXM1 mRNA levels were found to be more stable 
in RNF168 silenced cells before and after 24 h of epirubicin treatment (Figure 4.17). 
This indicates that RNF168 depletion might stabilise FOXM1 protein levels, especially in 
the presence of epirubicin.    
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Figure 4.16 Effect of RNF168 overexpression over FOXM1 in MCF-7 cells in a 
response to epirubicin treatment. MCF- 7 cells were transfected with pcDNA3-flag-
RNF168 (RNF168), or the pcDNA3-flag empty vector control (pcDNA3). The asterisk 
indicates pcDNA3-flag-RNF168. The arrow indicates endogenous RNF168. The cells 
were harvested after 0, or 24 h of epirubicin treatment. A. The cell lysates were 
analysed by western blotting. B. The mRNA from the cells was collected and the 
expression levels of RNF168 and FOXM1 were analysed using qPCR. Statistical 
analysis was performed using Student’s t-test. (*,p ≤ 0.05; ns, non-significant).  
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Figure 4.17 Effect of RNF168 knock-down on FOXM1 in MCF-7 cells in a response 
to epirubicin treatment. A. MCF- 7 cells were transfected with siRNF168, or the NSC 
control. The cells were harvested after 0, or 24 h of epirubicin treatment. A. The cell 
lysates were analysed by western blotting. B. The mRNA from the cells was collected 
and the expression levels of RNF168 and FOXM1 were analysed using qPCR. 
Statistical analysis was performed using Student’s t-test. (ns, non-significant). 
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4.2.10 RNF168 sensitises MCF-7 cells to epirubicin treatment 
My previous experiment indicated that RNF168 represses FOXM1 protein expression 
levels. Hence, RNF168 was hypothesised to increase the sensitivity of MCF-7 cells to 
epirubicin treatment. To test this, MCF-7 cells were transfected with pcDNA3-flag-
RNF168 (RNF168) and pcDNA3-flag empty vector control (pcDNA3). The transfected 
cells were subjected to an SRB assay with a range of concentrations of epirubicin 
treatment (0 – 20 µM). The percentages of cell survival were measured and quantified. 
As expected, the result from the RNF168-overexpressed cells exhibited extremely 
significant low percentages of cell survival after treatment with epirubicin for 24 h 
(Figure 4.18A). Conversely, I also performed the siRNA experiment to confirm the effect 
of RNF168 on epirubicin resistance and sensitivity. MCF-7 cells were transfected with 
siRNF168 and NSC before performing an SRB assay with a various concentrations of 
epirubicin (0 – 20 µM). The depletion of RNF168 increased the percentages of cell 
survival in MCF-7 cells (Figure 4.19A). Additionally the result indicated that RNF168 
does not change the growth rate of MCF-7 in the absence of epirubicin (Figure 4.18B 
and 4.19B). All together, the results indicate that RNF168 has a role in increasing the 
sensitivity of MCF-7 cells to epirubicin, but not their cell proliferation capacity. 
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Figure 4.18 RNF168 overexpression promotes sensitivity of MCF-7 cells to 
epirubicin but does not affect cell growth. MCF- 7 cells were transfected with 
pcDNA3-RNF168 or pcDNA3 empty vector control. The cells were treated with various 
concentrations of epirubicin 24 h before the cell proliferation was identified by an SRB 
assay. The result was normalised to the untreated condition (0 μM concentration). A. 
The percentage of cell survival and B. the percentages of cell growth were plotted. 
Results represent the average of 6 replicates ± SD. Statistical analysis was performed 
using Student’s t-test (*, p ≤ 0.05 significant; **, p ≤ 0.01 significant; ***, p ≤ 0.001 
significant; ns, non-significant).  
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Figure 4.19 RNF168 depletion reduces the sensitivity of MCF-7 cells to epirubicin 
but does not affect cell growth. MCF-7 cells were transfected with siRNF168, or NSC. 
The cells were treated with various concentrations of epirubicin for 48 h before the cell 
proliferation was analysed by SRB assay. A. The percentage of cell growth and B. the 
percentages of cell growth were plotted. The result was normalised to the untreated 
condition (0 μM concentration). Results represent the average of 6 replicates ± SD. 
Statistical analysis was performed using Student’s t-test (*, p ≤ 0.05 significant; **, p ≤ 
0.01 significant; ***, p ≤ 0.001 significant; ns, non-significant).  
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4.2.11 RNF168 does not play a crucial role in controlling long-term cell 
proliferation in MCF-7 cells 
To emphasise that RNF168 is not responsible for cell proliferation ability, MCF-7 cells 
expressing flag-RNF168 or pcDNA3 empty vector were used for clonogenic 
experiments. The transfected cells were seeded into 6-well plates with a very low 
number of cells. Cell proliferation was determined using crystal violet staining. 
Consistently, the results showed no significant difference in the percentage of long-term 
cell proliferation (Figure 4.20). Similarly, the result from RNF168 depleted cells also 
showed the same growth rate as the NSC conditions (Figure 4.21). These data are 
consistent with the SRB assay result (Figure 4.18B and 4.19B). It can be assumed that 
RNF168 has no distinguishable effects on both short-term and long-term cell 
proliferation of MCF-7 cells.  
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Figure 4.20 RNF168 overexpression showed no effects over cell growth in long-
term experiment. MCF- 7 cells were transfected with pcDNA3-RNF168 or pcDNA3 
empty vector control. The transfected cells were seeded in 6-well-plate at very low 
concentrations (i.e. 500 cells per well) for clonogenic assays. The cells were harvested 
every 2 days after being seeded. A. The cell proliferation was measured using crystal 
violet staining. B. The percentages of cell proliferation curve were plotted. The result 
represents the average of triplicates ± SD. Statistical analysis was performed using 
Student’s t-test (ns, non-significant). 
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Figure 4.21 RNF168 knock-down showed no effects over cell growth in long-term 
experiment. MCF-7 cells were transfected with siRNF168, or NSC. The transfected 
cells were re seeded in 6-well-plate at a very low concentration (500 cells per well) for 
clonogenic assays. The cells were harvested every 2 days after being seeded. A. The 
cell proliferation was measured using crystal violet staining. B. The percentages of cell 
proliferation curve were plotted. The result represents the average of triplicates ± SD. 
Statistical analysis was performed using Student’s t-test (ns, non-significant). 
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4.2.12 The Forkhead binding sites of cyclin B1 are important for the transcription 
activity regulated by RNF168  
It is widely known that cyclin B1 is a downstream target of FOXM1 (Leung et al., 2001). 
Since I have shown that RNF168 has a role in suppressing cyclin B1 transcriptional 
activity, it was necessary to examine whether RNF168 regulates the transactivation 
activity of FOXM1 over cyclin B1 promoter. To this end, I used the cyclin B1 mut3 
promoter (containing mutations in the three consensus forkhead binding sites) for 
luciferase assays. First, MCF-7 cells were co-transfected with increasing amount (0-
50ng) of pcDNA3-flag-RNF4 wt, and luciferase reporters, wt cyclin B1 promoter or cyclin 
B1 mut3 promoter. The activity of the reporter gene was normalised to the activity of the 
Renilla control. The result showed significantly lower transactivation activity of cyclin B1 
wt promoter compared with that of the cyclin B1 mut3 promoter (Figure 4.22). This 
result provides evidence that the regulation of cyclin B1 transcription by RNF168 
requires the consensus forkhead binding sites. In the case of the wild type forkhead 
binding sites transfection, RNF168 might regulate the cyclin B1 promoter though 
FOXM1 that binds to it. By mutating the forkhead binding sites, FOXM1 could no longer 
bind to the cyclin B1 promoter and this affected the transcription of cyclin B1 promoter 
by RNF168.  
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Figure 4.22 RNF168 overexpression promotes the transactivation activity of the 
cyclin B1 wt promoter but not the cyclin B1 mutant promoter (cyclin B1 mut3). 
MCF-7 cells were co-transfected with increasing amounts (0-50ng) of RNF168 (DNA 
concentration was normalised by empty vector control), and luciferase reporters 
containing wild-type cyclin B1 promoter, or cyclin B1 mut3 promoter containing the three 
mutant consensus forkhead binding sites. Luciferase assay was then performed after 24 
h following transfection. The luciferase activity was measured by PHERAstar Plus 
microplate reader. Reporter gene activity was normalised to the Renilla control activity. 
Graphs represent the mean of 3 independent experiments ±SEM. Statistical analysis 
was performed using Student’s t-test. (*, p ≤ 0.05 significant; **, p ≤ 0.01 significant; ***, 
p ≤ 0.001 significant)   
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4.2.13 RNF168 promotes the degradation of FOXM1 in response to epirubicin 
treatment 
The previous result showed the importance of RNF168 in suppressing FOXM1 protein 
expression levels, especially after epirubicin treatment (Figure 4.16 and 4.17). 
Therefore, an experiment was then performed to determine whether the expression of 
RNF168 promotes the degradation of FOXM1 in the presence of epirubicin. First, MCF-
7 cells were overexpressed with pcDNA3-flag-RNF168 (RNF168) or pcDNA3-flag empty 
vector control (pcDNA3). The cells were treated with 1 μM epirubicin for 2 h before 
being treated with 100 µM CHX. The cells were then harvested at various time points 
indicated (0, 1, 2, 4, 6, 8 h) for western blotting analysis. The degradation rate of 
FOXM1 was determined by densitometry from the western blot. The result displayed a 
dramatically faster degradation rate of FOXM1 in MCF-7 transfected with flag-RNF168, 
when compared with the control (Figure 4.23). A similar experiment was also performed 
in MCF-7 cells transfected with siRNA smart pool targeting RNF168 (siRNF168). The 
result was similar: the FOXM1 protein in RNF168 depleted cells was found to have a 
slower degradation rate than the NSC control (Figure 4.24).   
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Figure 4.23 Overexpression of RNF168 accelerates FOXM1 degradation in the 
presence of epirubicin. A. MCF-7 cells were transfected with RNF168 or empty vector 
control. Then, cells were treated with 2 h 1 μM epirubicin prior to 100 μM cycloheximide 
(CHX) treatment for several time points indicated (0, 2, 4, 6, and 8 h). Densitometry was 
used to quantify the FOXM1 level from western blot using imageJ. β-tubulin was used 
for normalising. B. Quantitative FOXM1 levels were normalised relative to 0 h CHX 
treatment. Graphs represent the mean of 3 independent experiments ±SD. Statistical 
analysis was performed using Student’s t-test compared between pcDNA3 empty vector 
and RNF168 overexpression at the same time point. (*, p ≤ 0.05 significant; **, p ≤ 0.01 
significant; ns, non-significant)  
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Figure 4.24 RNF168 knock-down has a slight but significant effect on FOXM1 
degradation in the presence of epirubicin. A. MCF- 7 cells were transfected with 
siRNF168, or NSC. The cells were then treated with 2 h of 1 μM epirubicin before 
adding 100 μM of cycloheximide (CHX). Cells were collected at several time points 
indicated (0, 2, 4, 6, and 8 h). Densitometry was used to quantify the FOXM1 levels 
from western blot using imageJ. β-tubulin was used for normalisation. B. Quantitative 
FOXM1 level was normalised relative to 0 h CHX treatment. The graphs represent the 
mean of 3 independent experiments ±SD. Statistical analysis was carried out using 
Student’s t-test comparing pcDNA3 empty vector and RNF168 overexpressed cells at 
the same time point. (*, p ≤ 0.05 significant; **, p ≤ 0.01 significant; ns, non-significant)  
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Next, the effect of epirubicin in the regulation of FOXM1 degradation by RNF168 was 
investigated. To test that, I transfected MCF-7 cells with the flag-RNF168 (RNF168) or 
pcDNA3-flag empty vector control (pcDNA3), then treated them with 100 µM CHX, 
without the presence of epirubicin.  The cells were then collected at various time points 
(0, 1, 2, 4, 6 and 8 h), without epirubicin for western blot analysis. Consistently, the 
FOXM1 protein from the flag-RNF168 transfected MCF-7 cells degraded faster when 
compared with the pcDNA3 control transfected cells (Figure 4.25). However, the 
difference was not as obvious as for the experiment performed in the presence of 
epirubicin (Figure 4.23 and 4.34). This might indicate that RNF168 promotes the 
degradation of FOXM1 specifically in the presence of epirubicin. 
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Figure 4.25 Overexpression of RNF168 slightly accelerates FOXM1 degradation in 
the absence of epirubicin. A. MCF-7 cells were transfected with RNF168 or empty 
vector control. Then, cells were treated with 2 h 1 μM epirubicin prior to adding 100 μM 
of CHX. Cells were collected at several time points (0, 2, 4, 6 and 8 h). Densitometry 
was used to quantify the FOXM1 levels from western blot using imageJ. β-tubulin was 
used for normalisation. The arrow indicates the endogenous levels of RNF168. The 
asterisk indicates the pcDNA3-flag-RNF168. B. Quantitative FOXM1 levels were 
normalised to the 0 h time point of CHX treatment.  
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4.2.14 FOXM1 interacts with RNF168 but not with RNF4 
To confirm the interactions between RNF4, RNF168 and FOXM1, I performed co-
immunoprecipitation (co-IP) experiments using MCF-7 cells treated with 1 μM epirubicin 
for 0, 6 and 24 h. Initially, antibodies against FOXM1 were used to perform the pull-
down experiment of the FOXM1-containing complexes. Input and eluent were analysed 
by western blotting. The interaction between FOXM1 and RNF4 or RNF168 was 
assessed using antibodies against RNF4, RNF168 and FOXM1 (for affinity checking).  
Only the band corresponding to RNF168, but not RNF4, was detected both before and 
after epirubicin treatment. FOXM1 was found to be degraded after 24 h of epirubicin 
treatment (Figure 4.26). Interestingly, the interaction between FOXM1 and RNF168 was 
found to increase at 24 h of epirubicin treatment as the RNF168 band was stronger at 
this time point (see the long exposure of RNF168 in Figure 4.26). This indicates that 
FOXM1 interacts with RNF168. The interaction is also increased after a longer time of 
treatment with epirubicin and this interaction might culminate with the initiation of the 
degradation of FOXM1.  
The reverse co-IP was also performed using antibodies against RNF168 to pull-down 
the RNF168 complexes after the MCF-7 cells were treated with epirubicin at indicated 
time points (0, 6, and 24 h). Input and eluent were analysed by western blotting. 
Similarly, the result revealed a stronger intensity for the FOXM1 band at the conditions 
of 0 h and 6 h of 1 μM epirubicin treatment, and a faint band at 24 h (Figure 4.27). At 24 
h treatment, there was a decrease in the intensity of the FOXM1 band. This might be 
due to cells that start undergoing cell death mediated by the epirubicin treatment 
205 
 
leading to the global protein degradation. In addition, no RNF4 band was found. This 
indicates that RNF4 does not interact with RNF168. This evidence emphasised a direct 
interaction between RNF168 and FOXM1 and also that FOXM1 is degraded after 24h of 
epirubicin treatment.  
Additionally, I carried out the co-IP experiments using RNF4 antibodies after the MCF-7 
cells were treated with epirubicin at indicated time points (0, 6, and 24 h). Input and 
eluent were analysed by western blotting. Consistently, neither FOXM1 nor RNF168 
were detected on the subsequent western blot analysis (Figure 4.28). This result further 
confirmed that RNF4 does not form complexes with neither FOXM1 nor RNF168.  
 
 
 
 
 
206 
 
            
 
 
Figure 4.26 Co-immunoprecipitation (co-IP) experiments using FOXM1 antibodies 
show an interaction of FOXM1 with RNF168 but not RNF4. MCF-7 cells were treated 
with 1 μM epirubicin for 0, 6 and 24 h. Antibodies against FOXM1 were used to perform 
co-immunoprecipitation. Proteins precipitated and inputs were analysed by western 
blotting and probed for RNF168, RNF4 and FOXM1. The asterisk indicates IgG bands. 
Arrows indicate RNF168 or RNF4. Input represents 1:10 dilution of pull down and IgG 
was used as a negative control. 
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Figure 4.27 Co-immunoprecipitation (co-IP) experiments using RNF168 antibodies 
demonstrate an interaction of RNF168 with FOXM1 but not RNF4. MCF-7 cells were 
treated with 1 μM epirubicin for 0, 6 and 24 h. Antibodies against FOXM1 were used to 
perform co-immunoprecipitation. Protein precipitated and inputs were analysed by 
western blotting and probed for RNF4, FOXM1 and RNF168 expression. The asterisk 
indicates IgG bands. Arrows indicate RNF168 or RNF4. Input represents 1:10 dilution of 
pull down and IgG was used as a negative control. 
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Figure 4.28 Co-immunoprecipitation (co-IP) using RNF4 antibodies exhibits an 
interaction of RNF4 with neither RNF168 nor FOXM1. MCF-7 cells were treated with 
1 μM epirubicin for 0, 6 and 24 h. Antibodies against FOXM1 were used to perform co-
IP.  Proteins pulled down with beads and inputs were analysed by western blotting for 
RNF168, FOXM1 and RNF4. The asterisk indicates IgG bands.  Arrows indicate 
FOXM1 or RNF168 or RNF4 specific bands. Input represents 1:10 dilution of pull down 
and IgG was used as a negative control. 
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To confirm the interaction between RNF168 and FOXM1, MCF-7 cells were transfected 
with pcDNA3-Flag-RNF168 (RNF168) or pcDNA3-Flag empty vector control (pcDNA3). 
After 24h of transfection, cells were treated with 1 μM epirubicin and harvested at 0, 6, 
and 24 h after the treatment. Immunoprecipitation was performed using ANTI-FLAG M2 
affinity gel beads to pull down the Flag-tagged protein. Input and eluent were analysed 
by western blotting and probed with various specific antibodies against FOXM1, RNF4, 
and RNF168 (for precipitation control). The result showed that only in cells 
overexpressing flag-RNF168 precipitated with FOXM1 and this was not observed in 
cells transfected with empty vector control (Figure 4.29). This result confirmed the 
interaction between FOXM1 and RNF168.  
To further validate the previous result (Figure 4.28), I also transfected MCF-7 cells with 
flag-RNF4 (RNF4) or the pcDNA3-flag empty vector control (pcDNA3). The following 
day, the transfected cells were treated with 1 μM epirubicin and harvested at 0, 6, and 
24 h after the treatment with epirubicin. Immunoprecipitation was performed using 
ANTI-FLAG M2 affinity gel beads to pull down the Flag-tagged protein. Input and eluent 
were analysed by western blotting. The western blot membrane was probed with 
antibodies against FOXM1, RNF4, and RNF168 (for precipitation control). Consistently, 
the western blot result failed to show both FOXM1 and RNF168 bands (Figure 4.30). 
The result indicates that there is no interaction between RNF4 and RNF168 or FOXM1. 
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Taken together, these data confirms that RNF168 might regulate FOXM1 by directly 
binding to FOXM1, while RNF4 does not bind to FOXM1. It can be concluded that RNF4 
does not directly regulate FOXM1 but it can affect other factors that have an impact on 
the expression and function of FOXM1. This can also lead to the changes on the 
transcription and translation levels ofFOXM1.   
         
 
 
Figure 4.29 Confirmation of the interaction between FOXM1 and RNF168. MCF-7 
cells were transfected with pcDNA3-flag-RNF168 or the pcDNA3-flag empty vector 
control. The transfected cells were treated with 1 μM epirubicin for 0, 6, 24 and 48 h 
before immunoprecipitation was performed using ANTI-FLAG M2 Affinity Gel to pull-
down the flag-tagged protein. Input and precipitates were analysed by western blotting 
and probed for FOXM1, RNF4, and RNF168. The asterisk indicates pcDNA3-flag-
RNF168. Arrows indicate endogenous RNF168 or RNF4. Input represents 1:10 dilution 
of pull down. 
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Figure 4.30 Immunoprecipitation confirms that there is no interaction between 
RNF4 and FOXM1 or RNF168. MCF-7 cells were transfected with pcDNA3-flag-
RNF168 or the pcDNA3-flag empty vector control. The transfected cells were treated 
with 1 μM epirubicin for 0, 6, 24 and 48 h before immunoprecipitation was performed 
using ANTI-FLAG M2 Affinity Gel to pull-down the flag-tagged protein. Input and 
precipitates were analysed by western blotting and probed for FOXM1, RNF168, and 
RNF4. Asterisks indicate pcDNA3-flag-RNF4. Arrows indicate endogenous RNF4 Input 
represents 1:10 dilution of pull down. 
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4.2.15 RNF168 promotes the degradation of FOXM1 wt but not the SUMOylation-
deficient FOXM1 
In previous experiments (Chapter 3), SUMOylation-deficient FOXM1 5x(K>R) plasmid 
was found to be more stable than the FOXM1 wt as SUMOylation of FOXM1 promotes 
its degradation (Myatt et al., 2014). I therefore hypothesised that RNF168 could affect 
the degradation FOXM1 wt more than the mutant FOXM1 5x(K>R). To test this, I 
performed two parallel experiments using firstly eGFP-FOXM1 wt (Figure 4.31) followed 
by eGFP-FOXM1 5x(K>R) (Figure 4.32), to study the degradation of FOXM1 after 
inhibition of protein synthesis (CHX treatment) together with overexpression of RNF168. 
Firstly, I transfected MCF-7 cells with eGFP-FOXM1 wt together with flag-RNF168 or 
empty vector control (pcDNA3). The transfected cells were treated for 2 h with 
epirubicin prior to the CHX treatment. The cells were harvested at indicated time points 
(0, 2, 4, 6 and 8 h). The protein expression levels were examined by western blotting. 
As expected, eGFP-FOXM1 wt transfected cells, overexpressing flag-RNF168, revealed 
a significantly faster degradation rate (Figure 4.31) than the cells without RNF168 
(pcDNA3 empty vector control). I also quantified the degradation rate of the 
endogenous FOXM1 which might be affected by the expression of RNF168. Western 
blot result showed that, in cells overexpressing RNF168, the endogenous FOXM1 levels 
were found to be more stable than the pcDNA3 transfected control (Figure 4.31C). This 
confirms the previous result that RNF168 promotes the degradation of FOXM1 (Figure 
4.23 and 4.24).  
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Next, to see the effect of the SUMOylation-deficiency FOXM1 mutant on the RNF168-
mediated FOXM degradation, I transfected MCF-7 cells with eGFP-FOXM1 5x(K>R) 
together with flag-RNF168 or empty vector control (pcDNA3). The transfected cells 
were treated with 2 h epirubicin prior to the CHX treatment. The cells were harvested at 
indicated time points (0, 2, 4, 6 and 8 h) for western blotting analysis. In contrast to 
eGFP-FOXM1 wt transfected cells, eGFP-FOXM1 5x(K>R) showed no significant 
difference in the degradation rate of FOXM1 in the presence of RNF168 overexpression 
compared to the pcDNA3 transfected control (Figure 4.32). This result was compared to 
the difference in the degradation rate of endogenous FOXM1, which after 
overexpression of RNF168, is faster than the pcDNA3 transfected control (Figure 
4.32C). This confirms that the overexpression of RNF168 is able to affect only the 
degradation of the SUMOylated FOXM1 protein and not the endogenous. 
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Figure 4.31 RNF168 overexpression promotes the degradation of the eGFP-
FOXM1 wt in the presence of epirubicin. A. MCF-7 cells were co-transfected with 
eGFP-FOXM1 wt and, flag-RNF168 or pcDNA3-flag empty vector control. The following 
day, the cells were treated with 2 h 1 μM epirubicin before the addition of 100 μM of 
CHX. Cells were then collected at indicated time points (0, 2, 4, 6 and 8 h) for western 
blot analysis. Densitometry was used to quantify the FOXM1 levels from western blots 
using imageJ. β-tubulin was used for normalisation. Quantitation analysis B. eGFP-
FOXM1 and C. endogenous FOXM1 levels were normalised to the 1h of CHX 
treatment. Graphs represent the mean of 3 independent experiments ±SD. Statistical 
analysis was performed using Student’s t-test comparing pcDNA3 empty vector and 
RNF168 overexpressed cells at the same time point. (*, p ≤ 0.05 significant; **, p ≤ 0.01 
significant; ***, p ≤ 0.001 significant; ns, non-significant)  
A 
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Figure 4.32 RNF168 overexpression does not significantly affect eGFP-FOXM1 
5x(K>R) degradation rate in the presence of epirubicin. A. MCF-7 cells were co-
transfected with eGFP-FOXM1 5x(K>R) and, flag-RNF168 or pcDNA3-flag empty vector 
control. The following day, the cells were treated with 1 μM epirubicin for 2 h before the 
addition of 100 μM of CHX. Cells were then harvested at several time points indicated 
(0, 2, 4, 6 and 8 h) for western blot analysis. Densitometry was used to quantify the 
FOXM1 levels from western blots using imageJ. β-tubulin was used for normalisation. 
Quantitative B. eGFP-FOXM1 5x(K>R) and C. endogenous FOXM1 levels were 
normalised relative to 1 h CHX treatment. Graphs represent the mean of 3 independent 
experiments ±SD. Statistical analysis was analysed using Student’s t-test compared 
between pcDNA3 empty vector and RNF168 overexpressed cells, at the same time 
point.  
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I also repeated the CHX experiment to compare the degradation rate of eGFP-FOXM1 
wt or eGFP-FOXM1 5x(K>R) in the presence of RNF168. According to the previous 
data (Figure 4.31, 4.32 and Chapter 3), I hypothesised that FOXM1 wt should also 
degrade faster in the presence of RNF168. To prove this, MCF-7 cells were co-
transfected with the pcDNA3-flag-RNF168 and eGFP-FOXM1 wt or eGFP-FOXM1 
5x(K>R) expression plasmids. The transfected cells were treated with epirubicin for 2 h 
prior to adding CHX at various indicated time points (0, 1, 2, 4, 6, and 8 h) and the cell 
pellets were then harvested for western blotting analysis. Predictably, eGFP-FOXM1 wt 
was found to degrade significantly faster in the presence of RNF168 and epirubicin, 
when compared with eGFP-FOXM1 5x(K>R) (Figure 4.33A and 4.33B). In contrast, the 
degradation rate of the endogenous form of FOXM1 in both conditions showed a similar 
trend to each other, comparing between eGFP-FOXM1 wt and eGFP-FOXM1 5x(K>R) 
transfected cells (Figure 4.33A and 4.33C). As the transcription process was inhibited 
by CHX treatment, the endogenous FOXM1 expression was not affected by the ectopic 
expression of FOXM1, eGFP-FOXM1 (wt) and eGFP-FOXM1 5x(K>R). As a result, the 
endogenous level of FOXM1 in the both conditions should be affected by only the 
overexpression of RNF168. Collectively, this result suggests that SUMOylation of 
FOXM1 is important for RNF168-mediated degradation of FOXM1. 
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Figure 4.33 RNF168 overexpression promotes eGFP-FOXM1 wt degradation in the 
presence of epirubicin. A. MCF- 7 cells were co-transfected with eGFP-FOXM1 wt or 
5x(K>R), and  flag-RNF168. The following day, the cells were treated with 2 h of 1 μM 
epirubicin prior to the addition of 100 μM CHX. Cells were harvested at several time 
points (0, 2, 4, 6 and 8 h). Densitometry was used to quantify the FOXM1 level from 
western blot using imageJ. β-tubulin was used for normalisation. Quantitative B. eGFP-
FOXM1 and C. endogenous FOXM1 levels were normalised relative to the 1 h 
treatment of CHX.  
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In addition, I examined the effect of RNF168 overexpression in the absence of 
epirubicin. To address this, MCF-7 cells were co-transfected with pcDNA3-flag-RNF168 
and eGFP-FOXM1-wt or 5x(K>R) expression plasmids. The following day, the 
transfected cells were treated with CHX. Western blotting was used to examine the 
degradation rate of FOXM1. The result showed a faster degradation rate of exogenous 
eGFP-FOXM1 wt transfected cells compared with the eGFP-FOXM1 5x(K>R) (Figure 
4.34). Interestingly, the difference in the degradation rate between eGFP-FOXM1 wt 
and eGFP-FOXM 5x(K>R) was smaller than in the experiment with epirubicin treatment 
(Figure 4.33).  
In conclusion, this data indicates that the SUMOylation of FOXM1 is important for its 
RNF168-mediated degradation mediated RNF168, especially in the presence of 
epirubicin treatment. 
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Figure 4.34 RNF168 overexpression has a mild effect on eGFP-FOXM1 wt 
degradation in the absence of epirubicin. A. MCF- 7 cells were co-transfected with 
eGFP-FOXM1 wt or eGFP-FOXM1 5x(K>R), and  flag-RNF168. The following day, the 
cells were treated with 100 μM (CHX). Cells were collected at several indicated time 
points (0, 2, 4, 6 and 8 h) of the treatment, without epirubicin. Densitometry was used to 
quantify the FOXM1 level from western blot using imageJ. β-tubulin was used for 
normalisation. Quantitative B. eGFP-FOXM1 and C. endogenous FOXM1 levels were 
normalised relative to the 1 h CHX treatment.  
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4.2.16 RNF168 interacts with FOXM1 wt but not with the SUMOylation-deficient 
FOXM1 
I next investigated the role of SUMOylation in the interaction between RNF168 and 
FOXM1 in response to epirubicin treatment. MCF-7 cells were transfected with either 
eGFP-FOXM1 wt or eGFP-FOXM1 5x(K>R) before being treated with 1 µM epirubicin at 
0 , 6, and 24 h. The co-IP experiment was performed using antibodies against RNF168. 
The precipitates from co-IP experiment were used for western blot analysis. The 
western blot membrane was probed with antibodies against FOXM1 and RNF168 (for 
affinity testing). The band corresponding to the eGFP-FOXM1 was found in the cells 
transfected with eGFP-FOXM1 wt at 0 h and 6 h but not at 24 h. The endogenous 
FOXM1 band was also found in this experiment, but at 24 h of treatment with epirubicin, 
the endogenous FOXM1 band appeared to be degraded (Figure 4.35A, the top panel). 
In contrast, the cells transfected with eGFP-FOXM1 5x(K>R) only showed the band 
corresponding to the endogenous FOXM1 (indicated by asterisk,*) whereas the eGFP-
FOXM1 was not present (Figure 4.35A, the bottom panel). Antibodies against RNF168 
were used to probe the membrane to confirm its ability to pull-down RNF168 (Figure 
4.35B). The IgG band was found in the IgG control and the IP conditions. This 
confirmed the importance of SUMOylation in terms of mediating the interaction between 
RNF168 and FOXM1. Moreover, this also indicates that FOXM1 can only interact with 
RNF168 when it is modified by SUMOylation.    
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Figure 4.35 Co-immunoprecipitation (IP) by RNF168 antibodies shows an 
interaction between RNF168 and the eGFP-FOXM1 wt. MCF-7 cells were transfected 
with eGPF-FOXM1 wt or eGFP-FOXM1 5x(K>R) before treatment with 1 μM epirubicin 
for 0, 6 and 24 h. Antibodies against RNF168 were used for performing co-
immunoprecipitation and the membranes were probed with antibodies targeting FOXM1 
and RNF168. Precipitates from beads and inputs were analysed using western blotting. 
Asterisks indicate eGFP-FOXM1 wt or 5x(K>R). Arrows indicate the endogenous levels 
of FOXM1. Input represents 1:10 dilution of pull down and IgG was used as a negative 
control. 
A 
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4.3 Discussion and conclusion 
It is clear my results that FOXM1 is modified by SUMOylation, which leads to its 
ubiquitination and degradation (Chapter 3). Although this degradation can occur via the 
ubiquitin-proteasome pathway through the APC/Cdh1 complex, the complex itself does 
not mediate the ubiquitination process (Myatt et al., 2014). This suggests that there 
should be another protein complex that works as a mediator between SUMOylated 
FOXM1 and leads to its ubiquitination. A number of studies have shown that various 
RING-type ubiquitin ligases play a key role in the crosstalk between SUMOylation and 
ubiquitination (Galanty et al., 2012; Galanty et al., 2009; Guzzo et al., 2012; Morris et 
al., 2009). These ubiquitin ligases have also been reported to be involved in the DNA 
damage repair pathway and chemotherapy resistance (Galanty et al., 2012; Mallette et 
al., 2012; Oestergaard et al., 2012; Wu et al., 2010; Yin et al., 2012). Moreover, some of 
the RING-type ubiquitin ligases, such as BRCA1, RNF4 (Galanty et al., 2012; Morris et 
al., 2009; Rojas-Fernandez et al., 2014) as well as RNF8 (Danielsen (Bartocci and 
Denchi, 2013; Danielsen et al., 2012; Galanty et al., 2009) have been reported to target 
SUMOylated proteins via their SUMO interacting motifs (SIMs) for ubiquitination. 
Although RNF168 has never been reported to have a SIM consensus, various studies 
reported that it works together with RNF8 in order to target SUMOylated proteins 
(Bartocci and Denchi, 2013; Danielsen et al., 2012; Galanty et al., 2009; Wrighton, 
2010). As a consequence, in this chapter, I focused mainly on studying the role of 
RNF4, RNF8 and RNF168 in the regulation of FOXM1. 
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First, I examined the protein expression levels of RNF4, RNF8 and RNF168 in response 
to epirubicin treatment. Interestingly, I observed that there is a correlation between the 
expression levels of RNF4 and FOXM1. In MCF-7 cells, both were found to be 
downregulated after epirubicin treatment. Similar to what is observed for the FOXM1 
protein levels in MCF-7 EpiR cells (Chapter 3), RNF4 appeared to be expressed at 
higher levels in comparison to MCF-7 cells. In contrast to RNF4 and FOXM1, the 
protein and mRNA levels of RNF168 were found to be significantly up-regulated after 
epirubicin treatment in MCF-7 cells but not in MCF-7 EpiR cells, although the expression 
was very low for the untreated cells. This suggests that RNF168 might have an inverse 
correlation with FOXM1 and might be modulated by DNA damage under the 
chemotherapy-induced genotoxic stress. For RNF8, the expression levels of both 
protein and mRNA did not change after the treatment and there were no differences 
between the two cell lines. However, it does not preclude RNF8 from having a role in 
FOXM1 regulation. RNF8 can still modulate FOXM1 expression in directly through an 
intermediate FOXM1 regulator or in another cell type. For example, RNF 8 has been 
shown to collaborate with RNF168 to modulate target protein expression (Danielsen et 
al., 2012; Galanty et al., 2009; Mallette et al., 2012).  
Based on these results, I reasoned that RNF4 might promote FOXM1 expression and 
its activity, while RNF168 might have the reverse effect on FOXM1. To address this, I 
performed an overexpression and a silencing study of the RNF proteins in MCF-7 cells 
to determine their effects on the expression of FOXM1. Consistently with my 
hypothesis, the result showed that FOXM1 was up-regulated by RNF4, but down-
regulated by RNF168. Interestingly, RNF8 expression was found to have a discrete 
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effect on the expression of FOXM1. Overexpression of RNF8, down-regulated the 
expression of FOXM1 while RNF8 knock-down resulted in an up-regulation on the 
expression of FOXM1. Although to a smaller extent, RNF8 had a similar effect on 
FOXM1 to RNF168. These data showed the positive regulation of FOXM1 expression 
by RNF4 and the negative regulation of FOXM1 by RNF168.  
Additionally, RNF4 and RNF168 were also found to have an effect on the 
transactivation activity of FOXM1 over its known downstream target, cyclin B1 (Leung 
(Laoukili et al., 2005; Leung et al., 2001). The RNF4 significantly increases the 
transactivation activity of cyclin B1 promoter while RNF168 noticeably suppresses it. In 
addition, the transcription activity of cyclin B1 did not show a significant change upon 
the transfection with increasing levels of RNF8 or BRCA1. Again, RNF8 may modulate 
RNF168 activity rather than expression. The result from luciferase reporter assay from 
RNF8 shows a similar yet less strong trend compared to RNF168. This emphasises the 
outstanding positive effect of RNF4 and the negative effect of RNF168 on the FOXM1 
downstream transcriptional target, cyclin B1. It is possible that RNF4 and RNF168 
regulate transcriptional activity of cyclin B1 promoter via the regulation of FOXM1. To 
further understand the apparent opposite regulation of FOXM1 by RNF4 and RNF168, 
FOXM1 expression levels were then examined by overexpression of RNF4 and 
RNF168.  
Initially, I observed the changes in FOXM1 protein levels by epirubicin under the 
condition of overexpression and depletion of RNF4, in MCF-7 cells. The levels of RNF4 
were found to affect the mRNA and protein expression levels of FOXM1 in MCF-7 cells, 
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both before and after epirubicin treatment. I also found that RNF4 affects the cell growth 
rate of MCF-7 cells in the same way as FOXM1 does, in both short-term and long-term 
cell proliferation. These data correlates with various studies showing that FOXM1 
promotes cell proliferation and tumour cell growth (Nakamura et al., 2010; Yang et al., 
2013). Unfortunately, the changes in FOXM1 levels from the effect of RNF4 expression 
did not affect the sensitivity of MCF-7 cells to epirubicin treatment. This result is in 
contrast with previous studies showing that the regulation of FOXM1 leads to 
chemotherapy resistance while the depletion of FOXM1 promotes cell sensitivity to 
epirubicin (Halasi and Gartel, 2012; Millour et al., 2011; Monteiro et al., 2013; Park et 
al., 2012). It is possible that the expression of RNF4 affects the FOXM1 expression 
level but it does not affect the FOXM1 level and posttranslational modification of 
FOXM1 under epirubicin-induced genotoxic stress condition. This presumption is in 
agreement with the result from CHX experiment. The result from the CHX study showed 
that RNF4 expression does not have a direct effect on the stability and degradation of 
FOXM1. The inhibition of protein translation by cycloheximide treatment revealed no 
difference between the overexpression or knock-down of RNF4 compared with pcDNA3 
empty vector and non-silencing control, respectively. This indicates that RNF4 might 
affect only FOXM1 transcription or translational levels indirectly but not directly through 
the proteasome degradation pathway. This might clarify that the fact that the expression 
of RNF4 affect the FOXM1 expression levels and the cell proliferation but not the 
epirubicin sensitivity of MCF-7 cells.  
As mentioned above, RNF4 is able to regulate transcriptional activity of cyclin B1 
promoter. In this Chapter, I also confirm the importance of the RING-domain of RNF4 in 
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regulating the transactivation functions of FOXM1 by the regulation of its known 
downstream target, cyclin B1. The function of RING-type E3 ligase is commonly 
specified by its RING domain that interacts with ubiquitin-E2 complex (Deshaies and 
Joazeiro, 2009). Mutations at the RING domain of RING-type E3 ligases (by point 
mutations from a zinc-coordinating cysteine residue to a serine residue - CS mutation) 
is resulted in catalytically inactive form of the ligase. The RING-type E3 ligase with this 
CS mutation is known to be lack of ability of E3 ligase to ubiquitinate its substrate 
proteins (Ahner et al., 2013; Luo et al., 2012; Tatham et al., 2008). Here, I show that a 
point mutation of zinc-coordinating cysteine residues into serine residues (CS mutation), 
leads to the loss of the function of RNF4 in promoting the transcriptional activity of cyclin 
B1 promoter. However, RNF4 only partially regulates the transcription activity of cyclin 
B1 via FOXM1. My result showed that RNF4 can transactivate both wt and mut3 cyclin 
B1 promoters, but it is more effective in activating the cyclin B1 promoter with the wild-
type forkhead binding domains. It seems therefore that RNF4 only partially regulates 
cyclin B1 transcription via FOXM1 and it also affects other transcription factor binding 
sites on the promoter.  
I also determined the regulation of FOXM1 by RNF168. The overexpression and knock-
down experiments reveal that RNF168 negatively regulates FOXM1 both in the absence 
and in the presence of epirubicin treatment. This down-regulation of FOXM1 appears to 
result in the increased sensitivity of MCF-7 cells to epirubicin. Accordingly, 
overexpression of RNF168 results in a significant increase of epirubicin sensitivity, while 
the knock-down shows the reverse effect. These data are consistent with previous 
studies demonstrating that FOXM1 promotes epirubicin resistance (Halasi and Gartel, 
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2012; Khongkow et al., 2013; Millour et al., 2011; Monteiro et al., 2013). I also found 
that RNF168 is a negative repressor of cyclin B1 transcriptional activity, a downstream 
target of FOXM1, and this repressive property is forkhead binding domain dependent. 
This confirms that RNF168 promote cyclin B1 promoter activity via the regulation of 
FOXM1 that is bound to the forkhead binding domain of cyclin B1 promoter.  
Surprisingly, the down regulation of FOXM1 by RNF168 does not affect short-term cell 
growth and the long-term cell proliferation, without the presence of epirubicin. This 
suggests that RNF168 is activated by genotoxic stress. These data indicate that 
RNF168 is not only involved in the ubiquitination of histone H2A (Morris et al., 2009; 
Nakada et al., 2010) in order to drive the DNA damage signalling (Mattiroli et al., 2012; 
Pinato et al., 2011) but also involved in chemotherapeutic sensitivity.   
As shown in my previous study (Chapter 3), SUMOylation of FOXM1 leads to its 
ubiquitination and subsequent degradation (Myatt et al., 2014). Through my studies, I 
found that RNF168 might be the modulator of FOXM1 degradation in this context. First, 
I discovered that overexpression of RNF168 accelerates the degradation rate of FOXM1 
while depletion of RNF168 promotes its stability. Furthermore, this effect is enhanced in 
the presence of epirubicin. This is supported by a study in U2OS cells which showed 
that RNF168 is capable of ubiquitinating (K48-linked chain) the transcriptional cofactor 
JMJD2A. This in turn leads to the proteasomal degradation of the targeted protein in an 
RNF8 dependent manner in response to doxorubicin (Mallette et al., 2012). This 
suggests that RNF168 might be the mediated molecule that plays a necessary role in 
the SUMOylation and ubiquitination crosstalk of FOXM1. Here, the direct interaction 
between FOXM1 and RNF168, but not RNF4, has also been confirmed using co-
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immunoprecipitation. Together these results strongly suggest that RNF168 directly 
binds to FOXM1 to promote its degradation.  
I also confirm the impact of SUMOylation in the subsequent degradation of FOXM1 
mediated by RNF168. In accordance to various studies, SUMOylation modifies and 
promotes the degradation of various Forkhead proteins, including FOXA1 (Bao et al., 
2011) and FOXC1/FOXC2 (Danciu et al., 2012). The result from the CHX treatment with 
the overexpression of RNF168 revealed a faster degradation rate of eGFP-FOXM1 wt 
compared to the degradation of eGFP-FOXM1 5x(K>R), especially in the presence of 
epirubicin. Moreover, these data highlighted that RNF168 is important for promoting the 
degradation of SUMOylated FOXM1, especially under the epirubicin-induced genotoxic 
stress. This regulation can take place by direct binding of RNF168 to SUMOylated 
FOXM1 but not to the SUMOylation-deficient FOXM1. These data strengthen the 
findings that SUMOylation of FOXM1 is important for its ubiquitination and subsequent 
degradation (Myatt et al., 2014), and this can be promoted by an overexpression of 
RNF168.  
In conclusion, my data suggest that RNF4 indirectly promotes the expression of FOXM1 
but it is not directly involve with the degradation of FOXM1 through the proteasomal 
pathway. This upregulation leads to an increase in some of the functions of FOXM1 
including promotion of cell proliferation and increasing the transcription of cyclin B1, a 
FOXM1 downstream target. However, this upregulation does not significantly alter the 
sensitivity of MCF-7 cells to epirubicin. Furthermore, this study indicates that the 
regulation by RNF4 of the transactivation activity of FOXM1 over a cyclin B1 promoter 
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occurs in RING-domain dependent manners. In contrast, RNF168 directly binds to 
SUMOylated FOXM1 to down-regulate its expression and promotes its degradation. 
Although the influence of RNF168 over FOXM1 expression and degradation does not 
affect the basal proliferation state of MCF-7 cells, this negative regulation by RNF168 
on FOXM1 significantly affects the sensitivity of MCF-7 cells to epirubicin and 
transactivation activity of cyclin B1 promoter in a forkhead binding domain-dependent 
manner. Without a forkhead binding domain RNF168 cannot repress the transcriptional 
activity of cyclin B1. This finding also emphasises the importance of SUMOylation in 
terms of the formation of the RNF168-FOXM1 complexes.  
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4.4 Future work 
According to my previous results, the mechanisms of SUMOylation and ubiquitination 
have been clarified but the deubiquitination mechanism remain unknown. Since, 
OTUB1, a Lys48-specific deubiquitinating enzyme (Wiener et al., 2013), has been 
shown to inhibit RNF168-dependent poly-ubiquitination pathway (Nakada et al., 2010) in 
future studies, I would examine the expression patterns of OTUB1 in MCF-7 and MCF-7 
EpiR cells and its role in FOXM1 expression. Then, I would study the role of OTUB1 in 
DNA damage and epirubicin sensitivity in both sensitive and resistant breast cancer cell 
lines. In addition, I would attempt to identify a potential interaction between OTUB1 and 
FOXM1 using co-immunoprecipitation experiments. 
 Furthermore, I would determine whether RNF8 has a role in RNF168 and FOXM1 
complex formation. To date, the SUMO interacting motifs (SIMs) of RNF168 have never 
been identified. Various studies have shown that RNF168 always works together with 
RNF8 in the DNA damage response pathways (Danielsen et al., 2012; Galanty et al., 
2009; Mallette et al., 2012). It is also possible that the SIMs in RNF8, a SUMO-Targeted 
Ubiquitin Ligase (STUbL), have a role in targeting SUMO residues on FOXM1 and 
recruiting RNF168 to form a complex with FOXM1.   
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CHAPTER 5 
THE INTERACTION BETWEEN OTUB1, A 
DEUBIQUITINATING ENZYME, AND FOXM1 
IN RESPONSE TO EPIRUBICIN 
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5.1 Introduction and Objectives 
OTUB1 (ovarian tumour domain-containing Ub aldehyde-binding protein 1) is a 
deubiquitinating enzyme (DUB) that belongs to the OTU (ovarian tumour) superfamily 
and has a role in inhibiting the formation of ubiquitin chains on target proteins (Nakada 
et al., 2010; Rose and Schlieker, 2010). The OTU-superfamily of proteases is 
homologous to the ovarian tumour gene product of Drosophila which was reported to 
have a role in oocyte morphogenesis (Makarova et al., 2000). OTUB1 contains an OTU 
domain, which has approximately 130 amino acids. This domain is highly conserved 
from yeast to humans (Messick et al., 2008). Some well-known members of this 
superfamily have been established as important regulators in various signalling 
cascades crucial for inflammation and cancer, such as ubiquitin-editing enzyme A20, 
OTUD family proteins, OTULIN, VCPIP and ZRANB1 (Malynn and Ma, 2009; Mevissen 
et al., 2013 ; Vereecke et al., 2009). OTUB1 is expressed ubiquitously in human tissues. 
It is the first protein in this superfamily to be confirmed with deubiquitinating properties 
(Zhang et al., 2012). OTUB1 is in a heterogeneous group of cysteine proteases as it 
contains an active cysteine thiol catalytic site. Cysteine proteases commonly work by 
cleaving proteins at the bond between the ubiquitin residue and the modified protein 
(Balakirev et al., 2003). In the proteasome degradation pathway, de-ubiquitination of 
substrate proteins by DUBs in OTU superfamily family, such as YOD1 and OTUB1, play 
a critical part in the process by allowing the unfolded protein to be transported to the 
narrow proteolytic chamber of the proteasome (Ernst et al., 2009; Pickart and Fushman, 
2004).   
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OTUB1 has been reported to disrupt RNF168-dependent ubiquitination pathway by 
binding to UBC13, a well known E2 conjugating enzyme, by impeding its binding to 
RNF168. This binding interferes with the ubiquitinating event and blocks the transfer of 
ubiquitin residues from UBC13 to the targeted protein (Nakada et al., 2010). OTUB1 
has also been shown to bind to the E2s of UBE2D and UBE2E families (Nakada et al., 
2010; Sowa et al., 2009).  In cancer, OTUB1 has been found to be upregulated and 
involved in colon cancer development and metastasis (Liu et al., 2014). Nevertheless, 
the role of OTUB1 in breast cancer has not yet been established.   
FOXM1 has been reported to plays an essential part in DNA damage repair and 
chemotherapeutic resistance (de Olano et al., 2012; Khongkow et al., 2013; Millour et 
al., 2011; Monteiro et al., 2013; Myatt et al., 2014). It is upregulated in the 
chemotherapeutic resistant breast cancer (including epirubicin resistance) when 
compared to the sensitive counterpart (Millour et al., 2011; Monteiro et al., 2013). In a 
study of MDA-MB-231, triple negative breast cancer, the knock-down of FOXM1 leads 
to an increase of cell sensitivity to epirubicin treatment (Park et al., 2012).  
In chapter 3, my study revealed that FOXM1 is ubiquitinated prior to degradation 
(Laoukili et al., 2008; Myatt et al., 2014). OTUB1 is also reported to interrupt the DNA 
repair pathway by inhibiting the ubiquitination (Rose and Schlieker, 2010). Interestingly, 
OTUB1 is also able to inhibit the ubiquitination of both K48-linked (Wiener et al., 2013) 
and K63-linked ubiquitin chains (Nakada et al., 2010). Therefore, I hypothesised that 
OTUB1 might stabilise FOXM1 by removing its ubiquitin residues and prevent its 
degradation.  
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OTUB1 has been reported to regulate various proteins, such as p53 (Li et al., 2014; Sun 
et al., 2012), oestrogen receptor alpha (ERα) (Stanisic et al., 2009), and RNF168 
(Nakada et al., 2010). Interestingly, these proteins have been shown to play a crucial 
role in tumorigenesis. For this reason, I decided to study the role of OTUB1 in the 
regulation of FOXM1. In previous studies, FOXM1 has also been showed to be 
regulated by ERα (Horimoto et al., 2011; Karadedou, 2006; Millour et al., 2011) and p53 
(Qu et al., 2013). In Chapter 4, I showed that RNF168 regulates FOXM1 by promoting 
its degradation. Together these data suggest that OTUB1 could either regulate FOXM1 
directly or indirectly via other proteins such as RNF168, p53 or ERα.  
Investigating the role of OTUB1 in the regulation of FOXM1 could prove useful for 
understanding breast cancer progression and epirubicin resistance and may lead to the 
development of novel targets for improving breast cancer therapy.    
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5.2 Results 
5.2.1 Sensitive cells express higher levels of OTUB1 compared with resistant 
cells 
In order to study the protein expression pattern of OTUB1 in sensitive and resistant 
breast cancer cell lines, MCF-7 and MCF-7 EpiR cells were treated with 1 µM epirubicin. 
The cells were then harvested at different time points (0, 4, 8, 16, 24 and 48 h) for 
western blotting analysis.  Interestingly, western blot results revealed that there were 2 
bands of OTUB1 in MCF-7 cells but in MCF-7 EpiR cells only the bottom band was 
present (figure 5.1A). In MCF-7 cells, the top band was found to be degraded after 24 h 
of epirubicin treatment. In addition, qPCR results revealed that there was more OTUB1 
mRNA expression in MCF-7 cells than in MCF-7 EpiR cells. Moreover, the expression of 
the OTUB1 mRNA in MCF-7 cells was increased after the treatment with 1 µM 
epirubicin, especially after 24 h treatment when it was significantly increased compared 
with the untreated condition. Similarly to the western blot results, at 48 h of epirubicin 
treatment OTUB1 transcript levels were dramatically decreased in MCF-7 cells. In 
contrast, OTUB1 mRNA expression in MCF-7 EpiR cells was constant after epirubicin 
treatment (Figure 5.1B).      
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Figure 5.1 Expression of OTUB1 following epirubicin treatment in MCF-7 and 
MCF-7 EpiR cells. MCF-7 and MCF-7 EpiR cells were treated with 1 μM epirubicin and 
harvested at time points indicated (0, 4, 8, 16, 24 and 48 h). A. Protein lysates were 
extracted and analysed by western blotting. B. The mRNA expression levels of OTUB1 
for each time point was analysed by qPCR. Statistical analysis was performed using 
Student’s t-test. (*, p ≤ 0.005; **, ≤ 0.001 significant; ns, non-significant)  
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According to the previous results, Foxm1-/- MEFs are sensitive to epirubicin (Chapter 
3.2.2) and display more epirubicin-induced DNA damage when compared with wt 
MEFs. In order to study the effect of FOXM1 on OTUB1 expression, I then tested 
whether the expression of OTUB1 in Foxm1-/- MEFs was different from wt MEFs. Both 
MEFs (wt and Foxm1-/-) were treated with 1 μM epirubicin and harvested after 0, 6 and 
24 h of treatment.  Protein and mRNA were extracted for western blotting analysis. The 
result revealed a thicker slower migrating band of OTUB1 in Foxm1-/- MEFs, that was 
decreased in wt MEFs (Figure 5.2A). As the FOXM1 band from western blotting in 
Foxm1-/- MEFs was unclear, qPCR analysis was used to confirm the depletion of Foxm1 
in Foxm1-/- MEFs. The result confirmed that the FOXM1 mRNA levels in Foxm1-/- MEFs 
could not to be determined (Figure 5.2B). I then investigated the OTUB1 mRNA 
expression levels. Consistently, the results showed higher OTUB1 mRNA expression in 
Foxm1-/- MEFs compared with wt MEFs (Figure 5.2C). In summary, this evidence 
indicates that OTUB1 might be involved in epirubicin sensitivity. In addition, the 
expression of FOXM1 might also be inversely correlated with that of OTUB1.  
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Figure 5.2 Protein levels of OTUB1 are higher in Foxm1-/- MEFs compared with wt 
MEFs. Foxm1-/- MEFs and wt MEFs were treated with 1 μM epirubicin and the cells 
were harvest after 0, 6, and 24 h of treatment. A. Protein lysates were extracted and 
analysed by western blotting. The mRNA expression levels of B. FOXM1 and C. 
OTUB1 for each time point were analysed by qPCR. Statistical analysis was performed 
using Student’s t-test. (*, p ≤ 0.005; **, ≤ 0.001 significant; ns, non-significant 
A 
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5.2.2 OTUB1 locates in both nuclear and cytoplasmic fractions 
In order to study the sub-cellular localisation of OTUB1, nuclear-cytoplasmic 
fractionation was performed. MCF-7 and MCF-7 EpiR cells were treated with 1μM 
epirubicin for 0, 6 and 24 h. Cytoplasmic and nuclear fractions were extracted using the 
NE-PER Nuclear and Cytoplasmic Extraction kit. The protein lysates were subjected to 
western blot analysis. The result showed that although OTUB1 can be found both in the 
nucleus and cytoplasm, with the faster migrating species localised primarily in the 
cytoplasm of both MCF-7 and MCF-7 EpiR cells, according to the bottom band pattern. It 
is possible that OTUB1 functions mainly in the cytoplasm of these cells. Interestingly, 
the higher molecular weight band of OTUB1, which is normally only found in MCF-7 
cells, was not as strong as it was previously shown in whole-cell lysates of these cells. 
This could be the result of its degradation during the experimental procedure. As 
previously shown in Chapter 3, the study of some post-translational modification forms 
of FOXM1 requires the presence of specific protease inhibitors. The loss of the top band 
could be attributed to the different composition of the lysis buffer used in this 
experiment. For whole-cell lysates, RIPA lysis buffer was used (see Materials and 
Methods). In contrast, the nuclear-cytoplasmic fractionation kit uses a lysis buffer with 
an undisclosed recipe (Thermo Scientific, UK). Similarly, FOXM1 protein was also found 
in both cytoplasm and nucleus (Figure 5.3). As mentioned in Chapter 3, FOXM1 can be 
imported-exported from the cells. OTUB1 as a deubiquitinating enzyme might 
deubiquitinate the FOXM1 protein and lead to its nuclear re-entry of FOXM1.  Lamin B 
and β-tubulin were used as loading controls for nucleus and cytoplasm, respectively.  
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Figure 5.3 OTUB1 locates in both cytoplasmic and nuclear fractions. MCF-7 and 
MCF-7 EpiR cells were treated with 1μM epirubicin for 0, 6, and 24 h. Sub-cellular 
fractionation was performed and lysates subjected to western blot analysis. Lamin B 
and β-tubulin were used as loading controls for nuclear and cytoplasmic fractions, 
respectively.  
 
 
 
 
 
241 
 
5.2.3 OTUB1 expression increases the sensitivity of MCF-7 cells to epirubicin 
To determine the importance of OTUB1 in epirubicin resistance and sensitivity in breast 
cancer cell lines, I performed SRB assays using MCF-7 cells transfected with a 
mammalian expression vector encoding OTUB1. The transfected cells were seeded in 
96-well plates before being treated with various concentrations of epirubicin (0 – 20 µM) 
24 h after transfection. Cell proliferation was measured by SRB assays in terms of 
percentage of cell survival. The result indicates that the overexpression of OTUB1 
increased the sensitivity of MCF-7 cells to epirubicin for some of the drug 
concentrations tested (Figure 5.4). The biggest significant differences can be found at 
higher concentrations (more than 0.3 µM) after 24h of epirubicin (Figure 5.4A). 
Unfortunately, at 5 µM there was no statistical significance. At 48h of epirubicin 
treatment, there was a difference for concentrations higher than 1 µM (Figure 5.4B), 
which is the optimal concentration previously determined by a PhD student in the lab 
(Millour et al., 2010; Monteiro et al., 2013). Western blot analysis confirmed that the 
overexpression of pcDNA3-flag-OTUB1 (OTUB1) was achieved (Figure 5.4C).  
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Next, the effect of OTUB1 silencing on epirubicin-sensitivity was also studied. To this 
end, MCF-7 cells were transiently transfected with siRNA pool against OTUB1 
(siOTUB1) or the non-silencing siRNA control (NSC). Following transfection, cell 
proliferation was determined by SRB assay (Figure 5.5A and B) and efficient knock-
down assessed by western blotting (Figure 5.5C). Consistently, cells with OTUB1 
silencing exhibited a significantly higher percentage of viable cells following treatment 
with epirubicin (Figure 5.5), compared with the NSC-transfected controls, with the 
exception for 2 time-points  (the 1.25 µM concentration of 24h epirubicin treatment and 
the 0.3 µM concentration of 48h epirubicin treatment). The non-significant results might 
due to the high standard deviation. Overall, these data indicate that OTUB1 could have 
a role in increasing the sensitivity of MCF-7 cells to epirubicin.  
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Figure 5.4 Overexpression of OTUB1 decreases the cell viability of MCF-7 cells 
after epirubicin treatment. MCF-7 cells were transfected with pcDNA3-OTUB1 or 
pcDNA3 empty vector control. The cells were treated with various concentrations of 
epirubicin for A. 24 h and B. 48 h. Cell proliferation was measured by SRB assay. The 
result was normalised to the untreated control (0 μM concentration). Results represent 
the average of three independent experiments including 6 replicates ± SD. Statistical 
analysis was performed using Student’s t-test. (*, p ≤ 0.05; **, p ≤ 0.01; ns, non-
significant) C. The expression levels of OTUB1 and β-tubulin were analysed by western 
blotting. Arrows indicate the specific OTUB1 bands, asterisk indicates pcDNA3-flag-
OTUB1 transfected band.  
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Figure 5.5 OTUB1 silencing in MCF-7 cells increases the rates of cell survival 
after epirubicin treatment. MCF-7 cells were transfected with siOTUB1 or NSC siRNA. 
The cells were treated with various concentrations of epirubicin for A. 24 h and B. 48 h. 
Cell proliferation was measured by SRB assay. The result was normalised to the 
untreated control (0 μM concentration). Results represent the average of three 
independent experiments including 6 replicates ± SD. Statistical analysis was performed 
using Student’s t-test. (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 significant; ns, non-
significant) C. The protein expression levels of OTUB1 and β-tubulin were analysed 
using western blotting. Arrows indicate the specific OTUB1 bands 
A 
C 
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The previous SRB results suggested that OTUB1 might have a role in increasing cell 
sensitivity to epirubicin. Therefore, I decided to investigate the role of OTUB1 in DNA 
damage in response to epirubicin treatment by using COMET assay. MCF-7 cells were 
transfected with siOTUB1, NSC or transfection reagent only (Mock). The cells were then 
treated with 1 µM epirubicin for 0, 6, and 24 h, prior to harvesting. The cell pellets were 
then resuspended in low-melting point agarose (LMA) before being subjected to 
electrophoresis. The cellular DNA was stained with DAPI, and images captured using 
40x magnification objective. The percentages of DNA in tail were quantified using 
COMET IV software and the quantified percentages of DNA in tail of each condition 
were plotted. Percentages of DNA in tails represent the length of COMET tail and the 
fraction DNA in the tail, thus the data from percentages of DNA in tail s represent the 
DNA damage amount in the cells. Analysis of the images revealed that there was a 
decrease in the percentages of DNA in tail in the OTUB1 knock-down MCF-7 cells 
treated with 1 µM epirubicin for 24 h (Figure 5.6). However, there were no significant 
differences after 6 h of treatment.  These results show that OTUB1 might have a role in 
increasing the amount of DNA damage hence decreasing the cell survival rate of MCF-7 
cells.  
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Figure 5.6 OTUB1 silencing results in less DNA damage after epirubicin 
treatment. MCF-7 cells were transfected with siOTUB1 or NSC or Mock. The cells were 
then treated with 1 µM epirubicin before the COMET assay was performed to examine 
the DNA damage.  A. Images were acquired with a Nikon Eclipse E400 Upright 
microscope (40x magnification objective). B. DNA damage was quantified using open 
COMET plug-in software to measure for the percentages of DNA in tail. Data represent 
the average of two independent experiments. (**, p ≤ 0.001; ns, non-significant)  
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5.2.4 Overexpression of OTUB1 decreases the growth rate of MCF-7 EpiR cells 
when treated with epirubicin 
Since my previous results indicated that OTUB1 was involved in sensitivity to epirubicin, 
I hypothesised that OTUB1 overexpression could re-sensitise MCF-7 EpiR cells to 
epirubicin treatment. To this end, MCF-7 EpiR cells were transfected with pcDNA3-flag-
OTUB1 (OTUB1) or pcDNA3 empty vector control (pcDNA3), before being re-seeded in 
96-well plates for SRB assays. The result showed that overexpression of pcDNA3-flag-
OTUB1 in MCF-7 EpiR cells reduced the percentage of cell growth following epirubicin 
treatment (Figure 5.7).  
In addition, the pcDNA3-flag-OTUB1 transfected MCF-7 EpiR cells were used for 
COMET assays in order to corroborate the hypothesis that OTUB1 can re-sensitise the 
epirubicin resistant cells. Surprisingly, there was no DNA damage found in neither MCF-
7 EpiR cells transfected with pcDNA3-flag-OTUB1 nor pcDNA3 empty vector (Figure 
5.8). This indicates that the transfected pcDNA3-flag-OTUB1 cannot re-sensitise MCF-7 
EpiR cells to epirubicin treatment.  
In conclusion, although SRB assays showed a significant difference in the percentage 
of the cell survival between OTUB1 overexpressed cells and the empty vector control, 
the result from COMET assay revealed no difference. This might be caused by the low 
transfection efficiencies of MCF-7 EpiR cells.  
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Figure 5.7 Overexpression of OTUB1 in MCF-7 EpiR cells reduces the growth rate 
in higher concentration of epirubicin. MCF-7 EpiR cells were transfected with 
pcDNA3-OTUB1 or pcDNA3 empty vector control. The cells were treated with various 
concentrations of epirubicin for A. 24 h and B. 48 h. Cell proliferation was measured by 
SRB assay. The result was normalised to the untreated control (0 μM concentration). 
Results represent the average of three independent experiments including 6 replicates 
± SD. Statistical analysis was performed using Student’s t-test (*, p ≤ 0.05; **, p ≤ 0.01; 
***, p ≤ 0.001 significant; ns, non-significant). C. The protein expression levels of 
OTUB1 and β-tubulin were analysed using western blotting. 
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Figure 5.8 Overexpression of OTUB1 fails to resensitise MCF-7 EpiR cells to 
epirubicin-mediated cell death. MCF-7 EpiR cells were transfected with pcDNA3 
OTUB1, or pcDNA3 empty vector. The cells were then treated with 1 µM epirubicin 
before the COMET assay was carried out to examine the amount of DNA damage. 
Images were acquired with Nikon Eclipse E400 Upright microscope (40x magnification 
objective). B. DNA damage was quantified using open COMET software to measure for 
the percentages of DNA in tail. Data represents the average of two independent 
experiments. (**, p ≤ 0.001; ns, non-significant) 
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5.2.5 An interaction of FOXM1 and OTUB1 has been found in MCF-7 cells 
 OTUB1 has been reported to regulate various proteins, such as p53 (Li et al., 2014; 
Sun et al., 2012) and ERα (Stanisic et al., 2009). Additionally, FOXM1 has also been 
reported to be regulated by ERα (Horimoto et al., 2011; Karadedou, 2006; Millour et al., 
2011) and p53 (Qu et al., 2013). Thus, OTUB1 might regulate FOXM1 indirectly through 
these proteins. Moreover, as is shown in Chapter3, FOXM1 can also be regulated by 
ubiquitination (Laoukili et al., 2008; Myatt et al., 2014). Consequently, OTUB1 might 
have a role in the regulation of FOXM1 through the deubiquitination pathway. To test 
this hypothesis, an interaction between FOXM1 and OTUB1 was investigated.  
Co-immunoprecipitation (co-IP) was used to test the interaction between FOXM1 and 
OTUB1. Co-IP was performed using antibodies against FOXM1 and OTUB1. In 
untreated MCF-7 cells, the protein interaction between FOXM1 and OTUB1 was 
confirmed. OTUB1 was co-immunoprecipitated with FOXM1 and the reverse co-IP was 
also validated (Figure 5.9A). This interaction was also found in MCF-7 EpiR cells (Figure 
5.9B). The result indicates that there is a direct interaction between FOXM1 and OTUB1 
in both MCF-7 and MCF-7 EpiR cells.  
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Figure 5.9 Co-immunoprecipitation showed an interaction between FOXM1 and 
OTUB1 in MCF-7 and MCF-7 EpiR cells. MCF-7 and MCF-7 EpiR cells lysates were 
extracted and co-IP was performed using FOXM1 and OTUB1 antibodies. Protein 
eluent from beads and input were analysed using Western blotting. Membrane was 
probed with FOXM1 and OTUB1 antibodies. Input represents 1:10 dilution of pull down 
and IgG was used as a negative control. 
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Next I investigated the effect of epirubicin treatment on the interaction between FOXM1 
and OTUB1. To this end, MCF-7 cells were treated with 1 μM epirubicin. The cells were 
harvested after 0, 6 and 24 h of treatment and co-IP assays performed. The study 
revealed no changes in the interaction of FOXM1 and OTUB1 in MCF-7 cells (Figure 
5.10A). The interaction of FOXM1 was also found in MCF-7 EpiR cells both before and 
after epirubicin treatment (Figure 5.10B). Again, the 31kDa-band OTUB1 in MCF-7 cells 
was not found in this co-IP experiment. 
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Figure 5.10 The interaction between FOXM1 and OTUB1 does not change after 
epirubicin treatment. MCF-7 and MCF-7 EpiR cells were treated with 1μM epirubicin 
before being harvest at 0, 6, and 24 h after the treatment. The cells lysates were 
extracted and co-IP was performed using FOXM1 and OTUB1 antibodies. Protein 
eluent from beads and input were analysed using Western blotting. Membrane was 
probed with A. FOXM1, and B. OTUB1 antibodies. Input represents 1:10 dilution of pull 
down and IgG was used as a negative control.  
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5.2.6 The bidirectional regulation effect of OTUB1 and FOXM1  
To determine whether OTUB1 regulates FOXM1 expression and vice versa, specific 
siRNAs were used to perform silencing experiments. Initially, MCF-7 cells were 
transfected with siRNA pool targeting OTUB1, FOXM1, NSC, or Mock. The effect of 
FOXM1 or OTUB1 silencing in the absence of epirubicin treatment was examined using 
western blotting and qPCR. The result showed that OTUB1 silencing was achieved both 
at protein and at mRNA levels. However, the depletion of OTUB1 did not have an effect 
on FOXM1 protein and mRNA expression levels (Figure 5.11). Similarly, the depletion 
of FOXM1 did not change the OTUB1 protein and mRNA expression levels, even 
though the FOXM1 silencing was successful (Figure 5.12). 
To further study the effect of drug treatment following the silencing of both OTUB1 and 
FOXM1, I depleted FOXM1 and OTUB1 in MCF-7 cells. Following the silencing, cells 
were treated with 1 µM epirubicin and harvested at 0, 6 and 24 h after the treatment. 
Western blotting was performed to analyse the protein expression and ImageJ was 
used to quantify both FOXM1 and the double bands corresponding to OTUB1 (Figure 
5.13). The densitometry revealed that when FOXM1 was silenced, OTUB1 showed a 
moderate decrease throughout the time course in the FOXM1 silenced cells compared 
with the NSC controls (Figure 5.13B). In contrast, in the OTUB1 silenced cells there was 
an increase in FOXM1 expression levels that was more obvious at 6 h. However, after 
24 h of epirubicin treatment there was a decrease in FOXM1 in the OTUB1 silenced 
cells (Figure 5.13C). This result suggests that the silencing of FOXM1 does not have a 
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significant effect over OTUB1 expression levels, while OTUB1 might promote the 
decrease of FOXM1 protein levels after 24 h of epirubicin treatment.   
Additionally, MCF-7 cells were transfected with pcDNA3 empty vector control (pcDNA3), 
pcDNA3-flag-FOXM1 (FOXM1) or pcDNA3-flag-OTUB1 (OTUB1). The transfected cells 
were then treated with 1µM epirubicin and harvested at 0, 6 and 24 h after the treatment 
(Figure 5.14). Unfortunately, the overexpression of FOXM1 revealed only small 
differences between the overexpressing cells and the pcDNA3 transfected control ones. 
The overexpression of OTUB1 also showed a small effect on FOXM1 protein 
expression levels. This result suggests that FOXM1 expression does not affect the 
OTUB1 expression levels and vice versa.  
In summary, the results from overexpression and silencing experiments were 
inconclusive. This indicates that FOXM1 might not be an upstream regulator of OTUB1 
and it might not control OTUB1 expression. However, OTUB1 might have an effect on 
FOXM1 protein expression, especially after epirubicin treatment.  
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Figure 5.11 OTUB1 silencing does not affect FOXM1 expression at basal levels. A. 
MCF-7 cells were transfected with siOTUB1, NSC or Mock. The mRNA expressions of 
B. OTUB1 and C. FOXM1 were analysed by qPCR. The levels of OTUB1 and FOXM1 
mRNA were normalised to L19 mRNA.  Statistical analysis was performed using 
Student’s t-test. (**, p ≤ 0.01; ns, non-significant) 
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Figure 5.12 FOXM1 silencing does not affect OTUB1 expression at basal level. A. 
MCF- 7 cells were transfected with siFOXM1, NSC or Mock. The mRNA expressions of 
B. FOXM1 and C. OTUB1 were extracted and analysed using qPCR. The levels of 
OTUB1 and FOXM1 mRNA were normalised with L19 mRNA.  Statistical analysis was 
performed using Student’s t-test. (**, p ≤ 0.01; ns, non-significant) 
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Figure 5.13 FOXM1 silencing has no significant impact on OTUB1 expression and 
vice versa. A. MCF-7 cells were transfected with siOTUB1, siFOXM1 or NSC, before 
being subjected to 1 µM epirubicin. The cells were harvested after 0, 6 or 24 h of the 
treatment. The cell lysates were analysed by western blotting. Densitometry of B. 
OTUB1 and C. FOXM1 levels were quantified by ImageJ and normalised with β-tubulin. 
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Figure 5.14 FOXM1 overexpression has no significant impact on OTUB1 
expression and vice versa. A. MCF-7 cells were transfected with pcDNA3-FOXM1, 
pcDNA3-OTUB1 or pcDNA3 empty vector control, before being subjected to epirubicin 
treatment for 0, 6 or 24 h. Whole cell lysates were analysed by western blotting. Arrows 
indicate endogenous OTUB1. Asterisk indicates the pcDNA3-flag-OTUB1 band. 
Densitometry of B. OTUB1 and C. FOXM1 levels were quantified by Image J and 
normalised with β-tubulin.   
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5.2.7 Stably overexpression of flag-OTUB1 was generated in MCF-7 EpiR cells 
In order to overcome the low transfection efficiency of MCF-7 EpiR cells, I generated 
MCF-7 EpiR cells stably transfected with pcDNA3-flag-OTUB1 expression vector 
(pcDNA3-flag-OTUB1). Firstly, MCF-7 EpiR cells were transfected with pcDNA3-flag-
OTUB1 vector containing a geneticin (G418) resistance gene. The next day, the 
transfected cells were treated with 200 µg/ml geneticin and the medium changed until 
no cell death was observed. This would mean that only the positive pcDNA3-flag-
OTUB1 transfected cells had been selected. The amount of geneticin ideal for selection 
was initially optimised using SRB assay and a killing curve obtained for MCF-7 EpiR 
cells. From this result, 200 µg/ml of geneticin was chosen as the optimal concentration 
since it was the lowest amount of drug that could kill the maximum number of cells 
(Figure 5.15). When growth was achieved, single cell clones were seeded and 
expanded for 3 - 4 weeks in 96-well plates through serial dilutions (Figure 5.16A). 
Afterwards, to confirm the successful stable transfection of pcDNA3-flag-OTUB1, cells 
were harvested and analysed by western blot (Figure 5.16B).  From the eight clones 
assessed, only clone number 8 was found to overexpress pcDNA3-flag-OTUB1.  
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Figure 5.15 Geneticin killing curve of MCF-7 EpiR cells MCF-7 EpiR cells were 
seeded in 96-well plates and treated with various concentrations of geneticin (0-1000 
µg/ml). The percentage of cell survival was determined using SRB assay. According to 
the graph, 200 µg/ml of geneticin was the optimal concentration for cell selection as it is 
the lowest concentration that can kill the highest number of cells. 
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Figure 5.16 Screening of single cell clones of the pcDNA3-flag-OTUB1 stably 
transfected MCF-7 EpiR cell line A. The diagram shows the seeding and the serial 
dilutions performed (Adapted from “Cell cloning by serial dilution in 96 well plates 
protocol” (corning) by John A Ryan).  B. Single cell clones were selected and grown in 
the presence of 200 μg/ml of geneticin. Western blot was used to screen for the 
overexpression of pcDNA3-flag-OTUB1. Total ERK was used as a loading control. 
Arrow indicates endogenous OTUB1. Asterisk indicates the transfected pcDNA3-flag-
OTUB1 band.  
A 
B 
263 
 
5.2.8 Characterisation of OTUB1 single cell clones stably transfected MCF-7 EpiR 
cells 
In order to study the effect of overexpressing flag-OTUB1 on FOXM1 expression and 
epirubicin sensitivity in MCF-7 EpiR cells, the pcDNA3-flag-OTUB1 stably transfected 
MCF-7 EpiR cells (clone8) were analysed by western blotting, qPCR and SRB assays. 
Clone number 1 was included as a negative control.  
Clone1 and clone 8 were treated with 1 μM epirubicin and harvested after 0, 6 and 24 h 
of treatment. The levels of FOXM1 and OTUB1 were determined by western blotting 
(Figure 5.17A).  The comparison of clone1 and clone 8 by densitometry quantification 
revealed no significant differences in the protein levels of FOXM1; however, OTUB1 
overexpression was again confirmed for clone number 8 (Figure 5.17B). Because of this 
result, clone 8 cells were then treated with 1 μM of epirubicin and harvested at 0, 4, 8, 
16, 24, and 48 h of a time course for western blotting analysis. 
Since I hypothesised that OTUB1 would contribute to the degradation of FOXM1, I 
would expect the FOXM1 levels to decline over the time course with epirubicin 
treatment. Instead, the expression of FOXM1 was relatively constant and was even 
increased after 48 h of epirubicin treatment (Figure 5.18A). The densitometry 
quantification also showed no significant changes on the FOXM1 levels after the 
treatment (Figure 5.18B). The mRNA expression levels of FOXM1 and OTUB1 were 
also examined by qPCR. Surprisingly, there were no significant differences for the 
transcript levels of OTUB1 and FOXM1 mRNA levels after 8 h of epirubicin treatment 
(Figure 5.19A). However, at 0 h and 4 h of epirubicin treatment, the mRNA expression 
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levels of FOXM1 and OTUB1 in clone number 8 was unexpectedly higher compared to 
clone number 1 (Figure 5.19B). 
After examining the transcript and protein levels of FOXM1 and OTUB1, the sensitivity 
of both clones number 1 and 8 to epirubicin was assessed by SRB assay. Cells were 
treated with increasing amounts of epirubicin for 24 h. The result showed no differences 
in the growth rate between clone 1 and clone 8, even though the concentration of 
epirubicin was increased to 100 μM. This result indicates that the pcDNA3-flag-OTUB1 
stable transfection failed to re-sensitise MCF-7 EpiR cells to epirubicin. 
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Figure 5.17 Protein analysis of MCF-7 EpiR stably transfected with pcDNA3-flag-
OTUB1. A. Single cell clones number 1 (Flag-OTUB1 negative) and number 8 (flag-
OTUB1 positive) were treated with 1 μM epirubicin and harvested after 0, 6 and 24 h of 
epirubicin treatment. Total protein lysates were analysed by western blotting. Arrow 
indicates endogenous OTUB1. Asterisk indicates the transfected pcDNA3-flag-OTUB1 
band. B. Densitometry analysis of FOXM1 levels were quantified by Image J and 
normalised with the bottom band of total ERK. 
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Figure 5.18 Time course treatment analysis of MCF-7 EpiR clone number 8 stably 
transfected with pcDNA3-flag-OTUB1 A. Single cell clone number 8 (flag-OTUB1 
positive) was treated with 1 μM epirubicin and harvested at different time points (0, 4, 8, 
16, 24 and 48 h). Total protein lysates were analysed using western blotting. Arrow 
indicates endogenous OTUB1. Asterisk indicates the transfected pcDNA3-flag-OTUB1 
band. B. Densitometry of FOXM1 levels were quantified by ImageJ and normalised to 
the bottom band of total ERK. 
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Figure 5.19 Transcript levels of MCF-7 EpiR cells stably transfected with pcDNA3-
flag-OTUB1. The mRNA expression levels of A. OTUB1 and B. FOXM1 from clones 
number 1 and 8 after treatment with 1 µM of epirubicin. The cells were harvest at 
various time points (0, 4, 8, 16, and 24 h) and were analysed using qPCR. The mRNA 
expression levels of OTUB1 and FOXM1 were normalised with L19. Statistical analysis 
was performed using Student’s t-test (*, p ≤ 0.05; **, ≤ 0.01 significant; ns, non-
significant). 
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Figure 5.20 Percentage of cell growth of OTUB1 transfected clones number 1 and 
8 in MCF-7 EpiR cells.  Single cell clones number 1 and 8 were treated with various 
concentrations of epirubicin for 24 h. Cell proliferation was measured by SRB assay. 
The result was normalised to the untreated control. Results represent the average of 
three independent experiments including 6 replicates ± SD. Statistical analysis was 
performed using Student’s t-test (ns, non-significant).  
 
 
 
 
 
 
 
269 
 
5.3 Discussion and conclusion 
Many studies have shown that FOXM1 plays a crucial role in DNA damage repair and 
has a role in chemotherapeutic agent resistance (de Olano et al., 2012; Khongkow et 
al., 2013; Millour et al., 2011; Monteiro et al., 2013; Myatt et al., 2014). Previous work 
done in our lab, has shown that ectopic expression of FOXM1 in MCF-7 cells results in 
increased cell viability, enhancement of DNA damage repair mechanisms and 
decreased DNA damage γH2Ax foci in response to genotoxic stress (Monteiro et al., 
2013). FOXM1 has also been found to be overexpressed in chemotherapy resistant cell 
lines, further supporting a role for FOXM1 in DNA damage-induced resistance (Millour 
et al., 2011; Monteiro et al., 2013). Moreover, depletion of FOXM1 in chemotherapy 
resistant cells, such as MDA-MB-231 cells (triple negative breast cancer), was able to 
re-sensitise these cells to epirubicin-mediated cell death (Park et al., 2012). It is well 
established that FOXM1 can be regulated by PTMs, specifically via phosphorylation 
(Koo et al., 2012). However, the role of FOXM1 SUMOylation and ubiquitination 
remains unclear.  
In Chapters 3 and 4, I have shown that FOXM1 is regulated by SUMOylation and 
ubiquitination. It is also well known that OTUB1 inhibits the ubiquitin pathway by 
separating E2 ubiquitin conjugating enzyme from the ubiquitin residues (Rose and 
Schlieker, 2010). Moreover, OTUB1 has been found to suppress RNF168-dependent 
ubiquitination pathway by impeding the bound of UBC13 (E2) to RNF168 and 
preventing it to work as an ubiquitin ligase (Nakada et al., 2010). In the context of 
cancer development and progression, OTUB1 has been reported to be involved in the 
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development of metastasis in colon cancer (Liu et al., 2014). OTUB1 has also been 
found to de-ubiquitinate ERα leading to its stabilisation (Stanisic et al., 2009). However, 
the role of OTUB1 in breast cancer and epirubicin resistance remains unclear. In fact, 
OTUB1 is a recently newly discovered protein found to be involved in DNA damage 
(Nakada et al., 2010). I have previously demonstrated in Chapter 4, that RNF168 has a 
role in promoting the degradation of FOXM1. Since OTUB1 has been shown to regulate 
RNF168, I hypothesised that OTUB1 could also play a role in the regulation of FOXM1. 
Moreover, as a deubiquitinating enzyme, it is possible that OTUB1 is involved in the 
deubiquitination of FOXM1. The regulation of FOXM1 by OTUB1 will provide a clearer 
understanding of how FOXM1 is regulated. In this chapter, I have studied the 
relationship between OTUB1 and FOXM1 and the role of OTUB1 in epirubicin 
resistance in breast cancer cell lines.      
I found that the protein and mRNA levels of OTUB1 were deregulated in MCF-7 cells 
and MCF-7 EpiR cells. Accordingly, OTUB1 mRNA levels in MCF-7 EpiR cells were 
down-regulated in comparison with MCF-7 cells. Interestingly, western blot analysis 
showed a double band pattern for OTUB1 protein (31 kDa and 35 kDa) in MCF-7 cells 
(Figure 5.1).  In contrast, the higher molecular weight band (35 kDa) was absent in the 
MCF-7 EpiR cells. This higher molecular band of OTUB1 could represent a modified 
form of OTUB1 in MCF-7 cells. In fact, to date, there are not many known PTMs 
targeting OTUB1. Yet, one study in U2OS cells showed that OTUB1 can be modified by 
mono-ubiquitination. The ubiquitinated-deficient OTUB1 mutant leads to the loss of its 
function as a deubiquitinating enzyme (Li et al., 2014).   
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Similarly to MCF-7 EpiR cells, Foxm1-/- MEFs also expressed lower levels of OTUB1 
than wt MEFs. A previous study in our lab showed Foxm-/- MEFs were found to be more 
sensitive to epirubicin than wt MEFs (Monteiro et al., 2013). Similarly to what was 
observed for MCF-7 cells, Foxm1-/-  MEFs also showed increased levels of the higher 
molecular band of OTUB1 (35kDa) than the wt MEFs. The fact that putative bands of 
similar pattern as FOXM1 are found in Foxm1-/- MEFs was surprising. However, the 
absence of FOXM1 was confirmed by qPCR results in Foxm1-/- MEFs. In addition, 
nuclear-cytoplasmic fractionation was performed to determine the sub-cellular 
localisation of OTUB1 and FOXM1. The western blot revealed that despite the fact that 
OTUB1 was found in both the cytoplasmic and nuclear fractions, it was preferentially 
located in the cytoplasm.  In agreement, a previous study in U2OS cells shows that 
OTUB1 regulates p53 stability in the cytoplasm. This study also claims that OTUB1 is a 
cytoplasmic deubiquitinating enzyme (Sun et al., 2012; Sun and Dai, 2014). It is 
possible that OTUB1 might work in the cytoplasm to de-ubiquitinate FOXM1, which was 
also found in the cytoplasm after being SUMOylated and ubiquitinated (Chapter 3).  The 
loss of the top band of OTUB1 in the sub-cellular fractionation experiment might due to 
the difference in composition of the lysis buffer used in this experiment, as mentioned 
above.  
It is widely known that ubiquitination is associated with DNA double strand break (DSB) 
repair (Bohgaki et al., 2013; Li et al., 2011; Nakada et al., 2010; Zhao et al., 2014) and 
this repair is widely known to have a key role in chemotherapy resistance. As a result, 
deubiquitinating enzymes such as OTUB1 might be involved in chemotherapy 
resistance. In order to examine the role of OTUB1 in epirubicin resistance, MCF-7 cells 
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were transfected with pcDNA3-flag-OTUB1 or pcDNA3 empty vector control and cell 
survival determined by SRB assays. The transfected cells were treated with various 
concentrations of epirubicin. The results showed that OTUB1 overexpressing cells were 
more sensitive to epirubicin, especially at high concentrations compared to the empty 
vector control cells. In addition, I examined the effect of OTUB1 silencing on epirubicin 
sensitivity in MCF-7 cells. The MCF-7 cells were then transfected with siRNA against 
OTUB1 (siOTUB1) or NSC, or mock transfected, before the cell viability determined by 
SRB assays. The cell survival results showed that OTUB1 depleted cells were more 
resistance to epirubicin compared with the NSC siRNA-transfected cells. This suggests 
that OTUB1 might have an important role in mediating epirubicin resistance in MCF-7 
cells. In accordance, OTUB1 has been found to play a part in the DNA damage 
response pathway (Nakada et al., 2010). In this chapter, I studied the role of OTUB1 in 
DNA damage and epirubicin resistance. COMET assay was used to determine the 
amount of DNA damage in OTUB1 silenced MCF-7 cells. According to the SRB results, 
the OTUB1 knock-down cells showed significant differences at lower concentrations 
(0.1 µM) of epirubicin. As a result, the COMET assay was performed using the OTUB1 
silenced cells. The result showed that in OTUB1 depleted cells treated with epirubicin 
for 24 h, there was less DNA damage than in the NSC control. Collectively, these data 
suggest that silencing of OTUB1 promotes epirubicin resistance in MCF-7 cells, 
confirming that OTUB1 has a role in DNA damage response pathway. This is further 
supported by a previous study which shows that the ubiquitin-deficient mutant OTUB1 
leads to an inhibition of DNA-damage induced apoptosis (Li et al., 2014). 
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So far these results show that OTUB1 has a role in promoting sensitivity of MCF-7 cells 
to epirubicin. Next, in order to prove that OTUB1 plays a part in sensitising cells to 
epirubicin-mediated cell death, I overexpressed OTUB1 in MCF-7 EpiR cells. To this 
end, MCF-7 EpiR cells were transiently transfected with pcDNA3-flag-OTUB1. SRB and 
COMET assays were then performed to assess the effects on cell survival and DNA 
damage. The SRB assay result shows that the pcDNA3-flag-OTUB1 transfected MCF-7 
EpiR cells have a lower cell growth compared to the control pcDNA3 empty vector 
transfected cells. Although the percentage of cell growth diminishes, the pcDNA3-flag-
OTUB1 transfected MCF-7 EpiR cells do not die following the treatment with epirubicin. 
Similarly, COMET assays show no differences in the amount of DNA damage after 
treatment with epirubicin. These results suggest that OTUB1 is unable to re-sensitise 
MCF-7 EpiR cells to epirubicin, but maintains the growth rate of these cells constant. In 
addition, it is possible that the MCF-7 EpiR cells overexpressing OTUB1 represent a 
selectively enriched MCF-7 EpiR cell population that can withstand and adapt to the 
expression of OTUB1. One possibility is that these cells can deregulate or alter existing 
signalling pathways crucial to maintaining the epirubicin resistant phenotype.  
Although the pcDNA3-flag-OTUB1 overexpression cannot re-sensitise MCF-7 EpiR cells 
to epirubicin, it promotes DNA damage and epirubicin sensitivity in MCF-7 cells. In 
addition, the OTUB1 expression levels show a negative correlation with FOXM1 
expression levels (i.e. MCF-7 cells expressed higher levels of OTUB1 and lower levels 
of FOXM1) in comparison with MCF-7 EpiR cells. This led me to investigate whether 
FOXM1 and OTUB1 can regulate each other. Based on previous studies it has been 
shown that FOXM1 is regulated by ERα (Millour et al., 2010) and that ERα is regulated 
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by OTUB1 (Stanisic et al., 2009). It is therefore possible that OTUB1 regulates FOXM1 
indirectly via the regulation of other upstream FOXM1 regulators, such as ERα or 
RNF168. To test whether OTUB1 directly regulates FOXM1, the interaction between 
FOXM1 and OTUB1 needs to be identified. Using co-immunoprecipitation, I found an 
interaction of FOXM1 and OTUB1 in both MCF-7 and MCF-7 EpiR cells. In addition, the 
interaction increased after 6 h of epirubicin treatment in both cell lines. Interestingly, in 
MCF-7 cells this interaction decreased after 24 h treatment while the interaction in MCF-
7 EpiR cells remained through the 24 h of treatment. As I mentioned above, the OTUB1 
35kDa band was found only in MCF-7 but not in MCF-7 EpiR cells. This higher 
molecular weight band might be a modified form of OTUB1 that impairs disassociation 
of OTUB1 from FOXM1. To further elucidate the regulation of FOXM1 by OTUB1 and 
vice versa, I then knocked down and overexpressed OTUB1 to investigate whether 
there was an effect on FOXM1 expression. Both in the absence or presence of 
epirubicin treatment, there were no differences in either protein or mRNA levels. 
Conversely, I also depleted and overexpressed FOXM1 to study the effect on OTUB1 
levels. Similarly, there were no differences in either the protein or mRNA levels of 
OTUB1. This data showed that OTUB1 has no effect on FOXM1 expression, and 
FOXM1 does not regulate OTUB1 expression. However, this does not exclude the 
hypothesis that OTUB1 regulates FOXM1 indirectly. It is already known that upon DNA 
damage FOXM1 might be recruited to damage sites to initiate repair together with other 
cofactor proteins (Monteiro et al., 2013; Tan et al., 2007). One could hypothesise that 
OTUB1 de-ubiquitinates one of these FOXM1-repair-cofactors that will affect the 
function of FOXM1. This is supported by the study of Nakada et al. (2010), in which 
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OTUB1 is shown to act as an inhibitor of DSB-induced chromatin ubiquitination (Nakada 
et al., 2010). The ubiquitination of chromatin serves as a signal for recruiting other 
repair proteins (Doil et al., 2009) to the damaged site. In this way, it is possible that 
OTUB1 removes these ubiquitin signals to mark the end of the DNA damage repair 
process. In addition, it is also possible that OTUB1 de-ubiquitinates a FOXM1 regulator 
protein, such as E2F1. In fact, E2F1 has been reported to be able to be modified by 
ubiquitination (Putzer and Engelmann, 2013). E2F1 has been found to function together 
with FOXM1 as co-factors (Sullivan et al., 2012) as well as to be a key regulator of 
FOXM1 (Millour et al., 2011).   
Finally, in order to understand the role of OTUB1 in epirubicin resistance, I generated a 
MCF-7 EpiR single-cell clone stably overexpressing OTUB1 to ensure that the entire cell 
population contained pcDNA3-flag-OTUB1. Unfortunately, the stable OTUB1 
transfected cells show no differences in FOXM1 levels, neither before nor after 
epirubicin treatment. When the cells were assayed for SRB, the result also showed that 
the stable OTUB1 transfection could not re-sensitise MCF-7 EpiR cells to epirubicin. 
However, this can be due to the fact that the OTUB1 expressing cells have adapted to 
the tumour suppressing function of OTUB1. In summary, although the levels of OTUB1 
in sensitive and resistant cells appear to be differentially regulated, OTUB1 expression 
levels increase the sensitivity of MCF-7 cells. However, OTUB1 fails to re-sensitise 
MCF-7 EpiR cells to epirubicin.  
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5.4 Future work 
From the results obtained in this chapter, the role of OTUB1 in terms of FOXM1 
regulation and epirubicin resistance remains unclear. To further explore the role of 
OTUB1 in DNA damage and repair, more experiments should be done. For example, to 
clarify the role of OTUB1 in DNA damage, one could use repair assays specific for 
homologous recombination (HR) and non-homologous end joining (NHEJ) (Khongkow 
et al., 2013). Although my results did not show a direct regulation of FOXM1 by OTUB1, 
it is still possible that there could be an indirect regulation of FOXM1 by OTUB1. As a 
deubiquitination enzyme, OTUB1 might have a role in deubiquitinating FOXM1 or its 
upstream regulators. In order to study that, the ubiquitination of FOXM1 should be 
examined in cells in which OTUB1 is overexpressed and silenced.  In addition, the 
OTUB1 35kDa-band that was found in MCF-7 but not in MCF-7 EpiR cells, could 
represent a modified form of OTUB1 (Chapter 5). This putative modified form should be 
identified and characterised. Immunofluorescent and FILM-FRET experiments (Myatt et 
al., 2014) using confocal microscopy could be useful techniques to confirm the sub-
cellular co-localisation of FOXM1 and OTUB1 in response to epirubicin treatment. This 
will provide a better understanding of how these two proteins interact and are regulated, 
and what is the role of OTUB1 de-ubiquitination activity in regards to the FOXM1-
mediated DNA damage response. In fact, if OTUB1 has a role in the regulation of 
FOXM1 and epirubicin resistance, it could represent a potential interesting target for 
overcoming chemotherapy resistance. 
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CHAPTER 6 
FINAL DISCUSSION  
AND CONCLUSION 
 
 
 
 
 
278 
 
Data from Cancer Research UK and World Health Organization (WHO) have shown 
that cancer is the major cause of death worldwide. In 2012, there were 14.1 million 
patients diagnosed with cancer and more than 8 million people died from the disease 
(WHO, 2012). Breast cancer is the most common cancer in women, with over 1 million 
people getting diagnosed every year and the rate increasing annually (Ferlay et al., 
2010; Kamangar et al., 2006). Conventional chemotherapy is the most common 
treatment strategy for breast cancer. Chemotherapy resistance is the main cause of 
treatment failure (>90%) in patients with metastasis (Longley and Johnston, 2005).  
The Forkhead box protein M1 (FOXM1) has been found to be upregulated in many 
types of cancer, including breast cancer (Koo et al., 2012). In addition, FOXM1 
upregulation has been found to be related to resistance to various cancer treatments, 
including endocrine therapy (Millour et al., 2010), cisplatin (Kwok, 2010), Trastuzumab 
(also known as Herceptin), paclitaxel (Carr et al., 2010), and also anthracyclines (Halasi 
and Gartel, 2012; Millour et al., 2011; Monteiro et al., 2013; Park et al., 2012). I have 
confirmed in Chapter 3 that FOXM1 plays an important role in preventing DNA damage 
and promoting epirubicin resistance. As shown in a previous study, the lack of FOXM1 
leads to increase level of DNA damage and loss of the DNA repair ability (Monteiro et 
al., 2013). In agreement, depletion of FOXM1 can re-sensitise the epirubicin resistant 
triple negative MDA-MB-231 breast cancer cells to epirubicin (Park et al., 2012) and the 
highly resistant MCF-7 EpiR cells to undergo cellular senescence (Khongkow et al., 
2013). Moreover, FOXM1 has been shown to promote the DSB repair (Millour et al., 
2011; Monteiro et al., 2013) and target some genes, including EXO1, PLK4 and RFC4, 
that are necessary for the DSB repair mechanism (Park et al., 2012). In accordance, 
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FOXM1 has become an attractive target for breast cancer therapy and for reversing of 
the chemotherapy resistance. For example, a small molecule FOXM1 inhibitor, 
thiostrepton, can specifically induce cell death in breast cancer cells. This drug has also 
been shown to have a minimal toxicity against non-cancerous cells (Kwok et al., 2008).  
There is accumulating evidence that FOXM1 is regulated at the transcriptional and post-
translational levels in response to conventional chemotherapeutic drug treatments (Lam 
et al., 2013). Thus, an understanding of the PTMs of FOXM1 might help to reveal how 
FOXM1 is regulated and lead to the development of drugs, which can improve the 
breast cancer therapy and overcome the FOXM1-mediated chemotherapy resistance. 
SUMOylation and ubiquitination has been reported to be important for regulating the 
transcription and degradation of targeted proteins. Although SUMOylation has various 
effects on target proteins, most of the SUMOylation events have been found to result in 
transcriptional repression (Ouyang et al., 2009). Here, I establish that FOXM1 can be 
modified by SUMO1 in response to cytotoxic anticancer agents, including epirubicin and 
paclitaxel treatment (Myatt et al., 2014). In my study, interaction of FOXM1 and 
SUMO2/3 could not be found in these breast cancer cell lines. However, it is still 
possible the FOXM1 can interact with SUMO2/3 in response to other stress stimuli or in 
other cell types. 
It has previously been shown that SUMOylation of FOXM1 leads to its ubiquitination 
and subsequent nuclear export. Once FOXM1 has been exported out of the nucleus, 
FOXM1 is targeted by the proteasome system and degraded (Figure 6.1). This is in 
agreement with studies on other Forkhead transcription proteins, such as FOXA (Bao et 
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al., 2011), FOXL2 (Georges et al., 2011; Marongiu et al., 2010), and FOXC1/C2 (Danciu 
et al., 2012), showing that SUMOylation leads to their degradation. I have also shown in 
Chapter 3 that the SUMOylation-deficient FOXM1 (FOXM1 5x(K>R)) cannot be 
ubiquitinated and accumulates in the nucleus, as confirmed by Leptomycin B treatment 
(Jang et al., 2003; Wolff et al., 1997). Interestingly, this finding is in agreement with a 
study performed by Dr. Stephen Myatt, in which mutations in SUMO1 specific-sites on 
FOXM1 leads to an upregulation of the function of FOXM1 and delays its mitotic exit 
(Myatt et al., 2014). These data emphasise that SUMOylation could be a novel 
switchable regulator that controls the transactivation activity of many important 
transcription factors, including FOXA, FOXL2, FOXC1/2 and FOXM1.  
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Figure 6.1 Model summarising the impact of SUMOylation on FOXM1 function and 
degradation. In normal cells, FOXM1 is SUMOylated at the mitotic exit or after 
undergoing genotoxic stress. This leads to the ubiquitination and nuclear export of 
FOXM1. Subsequently, FOXM1 degradation is mediated via the APC/C-Cdh1 complex. 
FOXM1 degradation is required for the initiation of the mitotic exit from the cell cycle 
and the down regulation of its downstream target, such as Cyclin B1 and Aurora B 
kinase. In contrast, FOXM1 5x(K>R) which contains 5 point mutations of SUMO 
specific-motifs cannot be SUMOylated. This SUMOylation-deficient FOXM1 also leads 
to a defect in the ubiquitination and, thus this results in the accumulation of FOXM1 in 
the nucleus. Consequently, the cells with SUMOylation-deficient FOXM1 are delayed in 
the mitotic exit.      
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In addition, I also show in Chapter 3 that the APC/C-Cdh1, a complex responsible for 
targeting cell cycle proteins for ubiquitination and subsequent degradation, is associated 
with the regulation of FOXM1 degradation. This association has been shown to target 
FOXM1 to degradation and therefore resulting in mitotic exit (Laoukili et al., 2008; Park 
et al., 2008). This APC/C-Cdh1 complex has been reported to bind directly to D- and 
KEN-box motifs at the N-terminus of FOXM1 (Laoukili et al., 2008). I also found that 
increasing concentrations of Cdh1 protein could promote and target exclusively the wild-
type, but not the SUMOylation-deficient, FOXM1 for degradation. This can explain why 
the mutations to SUMO specific-motifs on FOXM1 can lead to an increase in the ability 
of FOXM1 to transactivate the cyclin B1 promoter, a transcriptional downstream target 
of FOXM1 (Laoukili et al., 2005; Leung et al., 2001), in a forkhead binding element-
dependent manner. Accordingly, this SUMOylation-deficient FOXM1 has also been 
found to effectively promote epirubicin resistance (Halasi and Gartel, 2012; Millour et 
al., 2011; Monteiro et al., 2013; Park et al., 2012).  
Although the study in Chapter3 shows that Cdh1 is important for the binding of the 
APC/C complex to FOXM1 (Laoukili et al., 2008; Park et al., 2008), its degradation is 
not entirely dependent on the APC/C complex as ubiquitination of SUMOylated FOXM1 
will depend on other SUMOylation and/or substrate-specific ubiquitination.  This 
suggests that other ubiquitin ligases such as RNF4, RNF8 and RNF168, could act as 
the mediators of the crosstalk between SUMOylation and ubiquitination of FOXM1. 
Importantly, these ligases have been reported to be involved with the DNA damage 
response (Munoz et al., 2012; Nakada et al., 2010). I investigated this by exploring the 
possibility that some of these potential RING-type E3 ligases (eg. RNF4, RNF168 and 
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RNF8) can act as upstream regulators of FOXM1 and prime its ubiquitination. I found 
that the expression of FOXM1 correlates with RNF4 expression, which is inversely 
related to RNF168, while RNF8 does not show much difference after epirubicin 
treatment. The result from RNF4 indicates that it has a role in promoting the FOXM1 
expression at both mRNA and protein levels. As RNF4 is known to be one of the 
STUbLs, SUMO-targeted ubiquitin E3 ligases (Fryrear et al., 2012; Hu et al., 2010; Yin 
et al., 2012), I then hypothesised that RNF4 might target FOXM1 to regulate its 
expression. At odds with my prediction, RNF4 did not form a direct interaction with 
FOXM1 or RNF168. Furthermore, RNF4 did not have an effect on the degradation of 
FOXM1 via the ubiquitin-proteasome pathway. A possible explanation could be that 
RNF4 normally targets the poly-SUMO2/3 chains (Hu et al., 2010; Tatham et al., 2008; 
Yin et al., 2012), and my results from chapter 1 show that FOXM1 is not modified by 
SUMO2/3. In addition, unlike SUMO2/3, SUMO1 cannot form poly-SUMOylation chains, 
which are crucial for binding by RING-finger proteins, such as RNF4 and RNF8. 
(Bergink and Jentsch, 2009). This could explain why RNF4 does not target FOXM1 and 
regulate its expression in MCF-7 cells. Nevertheless, the modification of FOXM1 by 
SUMO1 happens at 5 sites which are closed located (Myatt et al., 2014), and this might 
function in a similar manner as the SUMO2/3 chains. The fact that that RNF4 does not 
regulate the degradation of FOXM1 in a response to epirubicin treatment might clarify 
the reason why RNF4 only affects the FOXM1 protein and mRNA expression levels and 
the cell proliferation, but not the epirubicin sensitivity of MCF-7 cells. 
However, I have confirmed the importance of the RING-domain of RNF4 by showing 
that it indirectly regulates the transcriptional activity of cyclin B1.  The CS RNF4 mutant 
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contains a mutation in the RING finger domain, resulting in a change from cysteine to 
serine (Ahner et al., 2013; Luo et al., 2012; Tatham et al., 2008), which abolishes the 
ability of RNF4 to ubiquitinate targeted proteins (Ahner et al., 2013; Luo et al., 2012; 
Pero et al., 2001). This mutation resulted in the lost of the regulation of the 
transcriptional activity of cyclin B1 by RNF4, indicating that ability of RNF4 to promote 
ubiquitination is required for it to regulate the activity of FOX proteins, including FOXM1. 
In contrast to RNF4, RNF168 suppresses the expression of FOXM1, especially after 
epirubicin treatment. Although RNF168 expression did not affect the growth of MCF-7 
cells, it sensitised the cells to epirubicin treatment. This might be because the regulation 
of FOXM1 expression by RNF168 is modulated by the epirubicin-induced genotoxic 
stress signals. This is consistent with previous reports, which suggest a role for FOXM1 
in the promotion of epirubicin resistance (Halasi and Gartel, 2012; Millour et al., 2011; 
Monteiro et al., 2013; Park et al., 2012). By repressing FOXM1 expression, RNF168 
promotes MCF-7 cells sensitivity to epirubicin. Moreover, RNF168 has also been 
reported to be involved in the ubiquitination of histone H2A and DDR signalling (Mattiroli 
et al., 2012; Pinato et al., 2011). Interestingly, RNF168 can also promote the 
transcriptional activity of the cyclin B1 promoter in a forkhead binding element-
dependent manner, further suggesting RNF168 regulates FOXM1 expression and 
activity. Importantly, my data show that RNF168 forms complexes with FOXM1 and 
therefore suggest that RNF168 may bind FOXM1 directly to promote its degradation. 
Notably, the result from the co-immunoprecipitation experiment showed that RNF168 
can interact only with the SUMOylated form of FOXM1, but not with the SUMOylation-
deficient FOXM1. Moreover, in the presence of epirubicin, RNF168 can only promote 
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the degradation of the wild type FOXM1, but not of the SUMOylation-deficient FOXM1. 
Together these results suggest that RNF168 mediates the degradation of FOXM1 and 
this process requires FOXM1 SUMOylation. Interestingly, RNF168 does not have an 
obvious SUMO-interacting motif (SIM) yet it has been clearly shown to target 
SUMOylated FOXM1. SIMs are motifs that other RING-domain E3 ligases use to 
interact with their SUMOylated substrates. However, it is possible that RNF168 targets 
SUMOylated FOXM1 via a mediator protein such as RNF8 or some other STUbLs. 
RNF8 has also been reported to have SIMs that recognise SUMOylated proteins 
(Bartocci and Denchi, 2013; Danielsen et al., 2012; Galanty et al., 2012) and it has also 
been found to function together with RNF168 (Danielsen et al., 2012; Galanty et al., 
2009; Mallette et al., 2012). In line with this, a study performed in U2OS cells showed 
the interaction between RNF168 and RNF8. This interaction was capable of generating 
k48 linked ubiquitin chains to JMJD2A, a transcriptional co-factor, thus helping in its 
degradation (Mallette et al., 2012). Consistently, the expression of RNF8 also affected 
FOXM1 in a similar way as RNF168 but its impact was less noticeable. Taken together, 
I demonstrate that SUMOylation leads to the ubiquitin-proteasome degradation of 
FOXM1 and this is at least in part mediated by RNF168, which might occur with the help 
of Ring-domain proteins, such as RNF8 (Figure 6.2). The fact that FOXM1 expression is 
modulated by SUMOylation and ubiquitination led me to ask if deubiquitinating enzymes 
might also have a role in FOXM1 regulation. In the last chapter of this thesis, I then 
investigated the importance of a deubiquitinating enzyme, OTUB1, in regulating FOXM1 
expression. 
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OTUB1 (Ovarian Tumour domain-containing Ubiquitin aldehyde-Binding protein 1) is a 
deubiquitination enzyme (DUB) that has been reported to inhibit DSB-induced 
ubiquitination (Nakada et al., 2010; Rose and Schlieker, 2010). In cancer, OTUB1 was 
found to be upregulated and involved in colon cancer development and metastasis (Liu 
et al., 2014). In addition, OTUB1 has also been found to be a repressor for RNF168-
dependent poly-ubiquitination (Nakada et al., 2010). Furthermore, OTUB1 has also 
been reported to regulate various proteins, such as p53 (Li2014, Sun2012), oestrogen 
receptor alpha (ERα) (Stanisic2009). Interestingly, these proteins have been shown to 
play a crucial role in carcinogenesis and epirubicin resistance (Horimoto et al., 2011; 
Millour et al., 2010; Millour et al., 2011). In line with this, I hypothesised that OTUB1 
might have a role in stabilising FOXM1, by inhibiting its ubiquitination by RNF168. Thus, 
in chapter 5, I intended to explore the importance of OTUB1 in regulating FOXM1 and 
epirubicin sensitivity. However, my results suggested that OTUB1 does not promote 
FOXM1 stability. I also found an inverse correlation between OTUB1 and FOXM1 
expression. This can be seen in both MCF-7 cells and MEFs. MCF-7 cells were 
observed to have higher levels of OTUB1 compared with MCF-7 EpiR cells. In 
agreement, Foxm1-/- MEFs also showed a higher OTUB1 expression than wt MEFs. It is 
also noticeable that OTUB1 is upregulated in sensitive cells (MCF-7 cells), but not in 
their resistant counterparts. In fact, OTUB1 has been reported to promote apoptosis and 
inhibit cell proliferation in a p53-dependent manner (Sun et al., 2012). In agreement, my 
experiments also indicated that an overexpression of OTUB1 in sensitive cells might 
lead to an increase in the sensitivity of the cells to epirubicin-induced DNA damage and  
cell death.  
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Figure 6.2 Model summarising the regulation of FOXM1 at post-translational 
levels. During transcriptional activation, FOXM1 is phosphorylated by some cell cycle 
specific cyclins and cdks, complexes and some other kinases such as ATM. Once 
phosphorylated, FOXM1 is translocated to the nucleus initiating the transactivation of 
downstream target genes. Then, when FOXM1 becomes inactive, at the mitotic exit, 
FOXM1 is removed from its binding on target genes, and becomes SUMOylated in a 
UBC9-dependent manner. This SUMOylation leads to its ubiquitination, which results in 
the nuclear export of FOXM1 and RNF168-mediated degradation, via the APC/C-Cdh1 
complex.           
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The OTUB1 protein in MCF-7 cells exists as a doublet (31kDa and 35kDa). 
Interestingly, the higher molecular weight band (35kDa) is absent in MCF-7 EpiR cells. 
This higher molecular band of OTUB1 could represent a modified form of OTUB1 in 
MCF-7 cells. In fact, to date, not many known PTMs have been shown to be targeting 
OTUB1. Yet, one study in U2OS cells showed that OTUB1 can be modified by mono-
ubiquitination. The ubiquitinated-deficient OTUB1 mutant loses its function as a 
deubiquitinating enzyme (Li et al., 2014).   
Previous work showed that FOXM1 is regulated by ERα (Cicatiello et al., 2004; 
Horimoto et al., 2011; Karadedou, 2006; Madureira et al., 2006; Millour et al., 2010). A 
study in breast cancer cell lines by our lab also demonstrated that ERα activates 
FOXM1 expression by directly binding to the FOXM1 promoter through an oestrogen-
response element (ERE) (Horimoto et al., 2011; Millour et al., 2010). At the same time, 
ERα has also been found to be regulated by OTUB1 (Stanisic et al., 2009). OTUB1 can 
de-ubiquitinate ERα, leading to its stabilisation (Stanisic et al., 2009). In addition, 
OTUB1 has also been shown to promote the stability and enhance the activity of p53 
(Sun et al., 2012). Interestingly, p53 has also been shown to downregulate FOXM1 and 
promote cell sensitivity to DNA damage (Millour et al., 2011). Hence, I firstly examined 
the effect of OTUB1 on epirubicin sensitivity, and found that OTUB1 overexpression 
increases the sensitivity of MCF-7 cells to epirubicin while a knockdown reduces the 
sensitivity of these cells. Moreover, in OTUB1 depleted cells there was a lower amount 
of DNA damage compared with the control, as revealed by COMET assays. These data 
suggest the possibility that OTUB1 might downregulate FOXM1 through an intermediate 
protein, such as ERα (Stanisic et al., 2009) or p53 (Sun et al., 2012). They also indicate 
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that OTUB1 overexpression in the resistant MCF-7 EpiR cells should re-sensitise these 
cells to epirubicin. However, the results showed otherwise, and there was a slight 
reduction in their growth rates. These results are consistent with a recent study showing 
that OTUB1 suppresses cell growth through stabilising p53 (Li et al., 2014). However, 
my results from the COMET assay showed that the overexpression of OTUB1 could not 
re-sensitise the MCF-7 EpiR cells from their resistant phenotype.  
All together, these data led me to hypothesise that OTUB1 might have a subtle role in 
suppressing FOXM1 expression. 
Although the co-IP in Chapter 5 showed a direct binding between OTUB1 and FOXM1 
in both MCF-7 and EpiR cells, OTUB1 expression did not have an effect over FOXM1 
expression, at both mRNA and protein levels. Conversely, FOXM1 expression also did 
not affect the expression of OTUB1. It is possible that FOXM1 and OTUB1 might form a 
complex, as OTUB1 can also bind to RNF168 (Nakada et al., 2010) and p53 (Sun et al., 
2012), but this does not appear to be regulating the expression of FOXM1. This 
complex might, however, play a role in other pathways, such as the ubiquitination of 
histone-H2Ax (Nakada et al., 2010) in response to DNA damage (Wiener et al., 2012). 
Moreover, in MCF-7 cells OTUB1 affected their cell growth and epirubicin sensitivity yet 
it fail to re-sensitise MCF-7 EpiR cells to the drug. This also suggests that there might be 
other DUBs playing a role in the stabilisation of FOXM1. In future, deubiquitinase 
profiling assays need to be performed (Ye et al., 2011) in order to unravel potential new 
DUBs. It is possible that OTUB2, another deubiquitinating enzyme, might compensate 
for the loss of OTUB1 in FOXM1 regulation. As a consequence, further work has to be 
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done to define the role of OTUB1/2 in the de-ubiquitination of FOXM1 and drug 
sentivity.   
Although OTUB1 has been found to form a complex with FOXM1, it might not regulate 
FOXM1 expression. It is possible that OTUB1 de-ubiquitinates a FOXM1 regulator 
protein, such as E2F1. In fact, E2F1 has been reported to be able to be modified by 
ubiquitination (Putzer and Engelmann, 2013). E2F1 has previously been found to 
cooperate with FOXM1 to regulate target gene expression (Millour et al., 2011; Sullivan 
et al., 2012).   
The role of FOXM1 in tumorigenesis and in promoting drug resistance renders it a 
target for therapeutic intervention. Indeed, thiazole antibiotics, including thiostreption 
and Sianomycin A, have been shown to inhibit FOXM1 expression specifically at the 
mRNA and protein levels. Thiostrepton has been shown to bind directly to the DNA-
binding domain of FOXM1 and thereby preventing it from activating the transcription of 
target genes and hastening it degradation. Interestingly, thiostrepton appears to target 
cancer cells specifically and has minimal effects on the proliferation of non-cancerous 
cells (Kwok et al., 2008).  The reason for this is unclear but it could be due to the fact 
that cancer cells express high levels of FOXM1 and have become addicted to the 
elevated levels of FOXM1 for its continuous survival. Indeed, while silencing FOXM1 in 
breast cancer cells can sensitise them to DNA damaging agents (Khongkow et al., 
2013), FOXM1 depletion efficiently induces drug resistant breast cancer cells, which 
express high levels of FOXM1, to undergo senescence. The finding that FOXM1 
expression is modulated by SUMOylation and ubiquitination also suggests the idea that 
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small molecules or natural compounds that enhance SUMOylation and ubiquitination 
may enhance the efficacy of conventional chemotherapeutic drugs. In the same way, it 
is also important to unveil the mechanism that regulates FOXM1 SUMOylation and 
ubiquitination, as this may open up further avenues for pharmacological intervention to 
inhibit FOXM1 activity and expression. 
In summary, my work has established that FOXM1 is regulated by post-translational 
modifications (PTMs), such as SUMOylation and ubiquitination. This suggests that 
SUMOylation of FOXM1 by SUMO1 leads to its ubiquitination and subsequently 
RNF168-mediated degradation, via the APC/C-Cdh1 dependent proteasome pathway. I 
have also confirmed the importance of FOXM1 in DNA damage signalling and in 
promoting epirubicin resistance (Monteiro et al., 2013). Through SUMOylation FOXM1 
can be down regulated. This reduction in FOXM1 expression promotes the sensitivity to 
epirubicin in MCF-7 cells (Khasraw et al., 2012; Minotti et al., 2004). This study provides 
valuable information about the regulation of FOXM1 protein, an oncoprotein that plays 
an important role in breast cancer chemotherapy resistance. Crucially, this could 
represent the start-point for the development of targeted therapies that will promote the 
degradation of FOXM1 in order to reduce its activity in breast cancer and help prolong 
breast cancer patient life.  
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